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                  ”There are some remedies worse than the disease”  
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ACBS Anticholinergic Cognitive Burden Scale 
ADE  Adverse drug events 
ADL Activities of daily living 
ADR Adverse drug reactions 
ADS Anticholinergic Drug Scale 
AUC Area under the curve 
CCI Charlson Comorbidity Index 
CDI Clostridium difficile infections 
CDR Clinical Dementia Rating 
ChEIs Acetylcholinesterase inhibitors 
CNS  Central nervous system  
COPD Chronic obstructive pulmonary disease 
DAPs Drugs with anticholinergic properties 
DDIs Drug-drug interactions 
DDDI D-class drug-drug interactions 
HR Hazard ratio 
IADL Instrumental activities of daily living 
MMSE Mini Mental State Examination 
MNA Mini Nutritional Assessment 
NSAID Non-steroidal anti-inflammatory drug 
OR Odds ratio 
PIDs Potentially inappropriate drugs 
PPI Proton-pump inhibitors 
SAA Serum anticholinergic activity 
SD Standard deviation 
 SFINX Swedish, Finnish, Interaction X-referencing database 






Residential care  Long-term care given to older people who stay in a residential setting 
rather than in their own home. Room and board and varying degrees of 
assistance. Various options available depending on the needs of the 
individual with disabilities, mental health problems, or dementia. This term 
is often used interchangeably with assisted living facility. 
Assisted living facility Room and board and varying degrees of assistance with management of 
medical conditions and with activities of daily living (ADL) in physically or 
cognitively impaired patients. In Finland, often similar to nursing homes in 
their level of care. 
Nursing home Facility providing 24-hour care for people requiring assistance with 
ADL/Instumental activities of daily living (IADL) and having identified health 
needs.   
Group home Small group homes available, e.g., for patients with dementia. They may 
specialize in people with mental health problems, patients with 
neuropsychiatric symptoms, or certain ethnic groups. 
Long-term care ward, long-
term care hospital 
Facility providing room and board, management of chronic medical 
conditions, and assistance with ADLs in physically and/or cognitively 
impaired patients. More hospital-like setting than traditional nursing 
homes. 
Acute geriatric ward Provides subacute and acute care, management, and rehabilitation for 
multimorbid, older patients by a multidisciplinary geriatric team. 
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Background: Frail older people in institutional settings are known to suffer from comorbidities and 
are often administered a high number of concomitant drugs. They are therefore prone to 
polypharmacy, adverse drug effects, and drug-drug interactions (DDIs). Older people living in 
assisted living represent a particularly frail segment of the elderly population, and a large proportion 
of them suffer from cognitive impairment. During the last decade knowledge has accumulated on 
the adverse effects of drugs with anticholinergic properties (DAPs) and long-term use of proton-
pump inhibitors (PPIs) among older people. Less is known about the extent and prevalence of these 
effects among the frailest older people in institutional settings. Residents in assisted living facilities 
are often taken care of by consulting primary care physicians. Therefore, they may have rare 
opportunities for a thorough reassessment of their medication after admission to institutional care. 
Thus, their use of drugs intended to be taken over a limited period is often extended.  
Aims: This study explores the associations of DAPs and PPIs with adverse effects and investigates 
potentially severe DDIs among older residents in institutional settings.  Of particular interest were 
adverse effects and mortality associated with the use of PPIs (Studies 1 and 2). In addition, 
concomitant use of DAPs and acetylcholinesterase inhibitors (ChEIs) and their association with 
psychological well-being (PWB) were investigated (Study 3). Finally, the prevalence of potentially 
severe D-class drug-drug interactions  (DDDIs) and their association with mortality were clarified 
(Study 4). 
Methods: This study consists of four substudies. Study 1 includes 1987 residents (mean age 83.7 
years, 80.7% women) from a project investigating the nutrition of nursing homes in Helsinki in 
2003. Study 2 consists of three samples from various institutional settings: 1389 residents in 69 
assisted living facilities in 2007 (first cohort; mean age 82.7 years, 78.9% women), 1004 residents 
of long-term care hospitals in 2003 (second cohort; mean age 81.3 years, 75.3% women), and 425 
residents in acute geriatric wards or in nursing homes in 1999-2000 (third cohort; mean age 86.1 
years, 81.6% women) in Helsinki. Study 3 investigates 1475 residents (mean age 82.8 years, 77.7% 
women) from a project assessing nutrition in assisted living facilities in the metropolitan area of 
Finland. In Study 4, these same residents were followed up for mortality for 3 years. Those 1327 
residents having complete follow-up data available were included (mean-age 82.7 years, 78.3% 
women). In all studies participants were interviewed by trained nurses. Demographics were 
retrieved from medical records. Drug use and medical diagnoses were confirmed from medical 
records, and drugs were coded with the WHO Anatomical Therapeutic Chemical Classification 
 System. All DAPs were classified according to the Anticholinergic Risk Scale (Study 3). Mini 
Nutritional Assessment (MNA) was used for evaluating nutritional status, Clinical Dementia Rating 
(CDR) for assessing dementia and disability, PWB scale for exploring residents’ well-being, and 
Charlson comorbidity index  (CCI) for assessing the severity and burden of diseases. Swedish, 
Finnish, Interaction X-referencing database (SFINX) was used to detect DDDIs (Study 4). 
Mortality data were retrieved from central records in Studies 2 and 4. 
Results: Of nursing home residents in Study 1, 22% were administered proton-pump inhibitors 
(PPIs) on a daily basis. Regular PPI use was associated with diarrhoea, prior hip fracture, coronary 
heart disease, and lactose intolerance, indicating possible side effects or use for an inappropriate 
therapeutic intent. 
In Study 2, the prevalence of the use of PPIs varied from 21.4% (geriatric wards and nursing 
homes) to 26.4% (assisted living facilities). The use of PPIs was not associated with mortality 
among residents in assisted living facilities. However, their use was associated with increased 
mortality in settings where residents experienced higher levels of disability and comorbidities 
(long-term hospitals, geriatric wards, and nursing homes), and thus, possible higher vulnerability to 
adverse drug events (ADEs) of PPIs. In the acute geriatric hospital and nursing home cohort, the 
risk for mortality was HR 1.90 (95% CI 1.23 to 2.94) even after adjustment for age, gender, 
comorbidities, delirium, and use of aspirin and selective serotonin reuptake inhibitors.  
In Study 3, 41.6% of residents were administered DAPs. Of residents in assisted living facilities, 
10.7% were administered ChEIs and DAPs concomitantly. DAP use was associated with use of a 
higher number of drugs, more severe disability, depression, psychiatric disorders, and Parkinson´s  
disease. DAP use was associated with low psychological wellbeing even after adjustment for age, 
gender, education, comorbidities, and use of ChEIs. 
In Study 4, 5.9% of residents in assisted living facilities were susceptible to severe DDDIs. The 
most common DDDIs were related to use of potassium- sparing diuretics, carbamazepine and 
methotrexate. Residents exposed to severe DDIs were more often exposed to polypharmacy than 
residents not exposed to DDIs. No significant difference in mortality emerged between residents 
with and without DDDIs.  
 Conclusions: The PPIs are common in institutionalized settings and they may expose to 
unexpected adverse effects such as diarrhoea and higher mortality among frail older people. 




use was associated with poorer psychological well-being. Potentially severe DDIs are relatively 
uncommon in these populations even with a high prevalence of polypharmacy.  
  
 Tiivistelmä 
Tausta: Laitoksissa asuvien hauraiden vanhusten tiedetään olevan monisairaita ja usein käyttävän 
paljon samanaikaisia lääkkeitä. Monilääkityksen takia he ovat alttiita haittavaikutuksille ja 
lääkkeiden haitallisille yhteisvaikutuksille. He ovat haurainta osaa vanhusväestöä ja suurin osa 
heistä kärsii muistisairaudesta. Viimeisen kymmenen vuoden aikana tutkimustieto antikolinergisten 
lääkkeiden and pitkäaikaisen protonipumppuinhibiittoreiden (PPI) käytön haitoista on lisääntynyt. 
Vähemmän tiedetään miten nämä haitat ilmenevät kaikkein hauraimmilla laitoshoidossa asuvilla 
vanhuksilla. Pitkäaikaishoidossa asuvat vanhukset ovat usein yleislääkäreiden hoidossa. He 
pääsevät harvoin perusteelliseen lääkehoidon arviointiin sen jälkeen kun he ovat muuttaneet 
pitkäaikaishoitoon. Siten sama lääkitys jatkuu usein pitkään, vaikka lääkitys olisi tarkoitettu 
käytettäväksi vain väliaikaisesti. 
Tutkimuksen tavoitteet: Tämän tutkimuksen tarkoituksena oli arvioida antikolinergisten ja PPI 
lääkkeiden yhteyttä niiden mahdollisiin haittavaikutuksiin sekä lääkkeiden yhteisvaikutuksia 
laitoshoidossa olevilla vanhuksilla. Erityisesti arvioitiin PPI lääkkeiden haittavaikutuksia 
(osatutkimus 1) ja PPI käytön yhteyttä kuolemanvaaraan (osatutkimus 2). Lisäksi selvitettiin 
antikolinergisesti vaikuttavien lääkkeiden samanaikaista käyttöä asetyylikoliiniesteraasi-estäjien 
(AKE) kanssa ja niiden vaikutusta psyykkiseen hyvinvointiin (osatutkimus 3) sekä potentiaalisesti 
vakavien D-luokan yhteisvaikutusten yleisyyttä sekä niiden yhteyttä kuolemanvaaraan (osatutkimus 
4). 
Menetelmät: Väitöskirja koostuu neljästä osatutkimuksesta. Osatutkimuksen 1 aineistossa oli 1987 
helsinkiläistä vanhainkotiasukasta (keski-ikä 83.7 vuotta, 80.7%  naisia), joiden lääkitys tutkittiin 
osana asukkaiden ravitsemustilan kehittämisprojektia.  Osatutkimus 2 koostui kolmesta otoksesta: 
1389 asukkaasta 69 Helsingin palvelutaloista vuodelta 2007 (ensimmäinen kohortti; keski-ikä 82.7 
vuotta, naisia 78.9%), 1004 asukkaasta pitkäaikaissairaaloista vuodelta 2003 (toinen kohortti; keski-
ikä 81.3 vuotta, naisia 75.3%), ja 425 asukkaasta geriatrisen akuuttihoidon osastoilta tai Helsingin 
kaupungin vanhuskodeista vuosilta 1999-2000 (kolmas kohortti; keski-ikä 86.1 vuotta, 81.6% 
naisia). Osatutkimuksessa 3 aineistona oli 1475 Helsingin metropolialueen palvelutalojen asukasta 
(keski-ikä 82.8 vuotta, 77.7% naisia) projektissa, joka selvitti heidän ravitsemustilaansa vuonna 
2007. Osatutkimus 4:ssa seurattiin näiden samojen asukkaiden kuolleisuutta kolmen vuoden ajan. 
Ne 1327 asukasta, joilla oli täydelliset seurantatiedot käytettävissä lääkehoidon ja ravitsemustilan 




Kaikissa tutkimuksissa koulutetut hoitajat tekivät haastattelun osallistujille. Demografiset tiedot, 
lääkkeiden käyttö ja sairausdiagnoosit vahvistettiin sairauskertomustiedoista. Lääkkeet koodattiin 
käyttämällä WHO:n ATC koodeja (Anatomical Therapeutic Chemical Classification System). 
Kaikki antikolinergisesti vaikuttavat lääkkeet luokiteltiin Anticholinergic Risk Scale luokituksen 
mukaan (osatutkimus 3). Ravitsemustila määriteltiin Mini Nutritional Assessment (MNA) 
mittarilla, dementian vaikeusaste ja toiminnanvajeet Clinical Dementia Rating (CDR) luokituksella, 
asukkaiden hyvinvointi Psychological Well-being mittarilla. Charlson comorbidity indeksin  avulla 
arvioitiin sairauksien vakavuutta ja kuormitusta. Swedish-Finnish Interaction X-referencing - 
tietokantaa (SFINX) käytettiin arvioitaessa lääkkeiden mahdollisia vakavia, D-luokan 
yhteisvaikutuksia (osatutkimus 4). Tiedot kuolleisuudesta kerättiin keskusrekistereistä 
(osatutkimukset 2 ja 4).  
Tulokset: Osatutkimuksessa 1 vanhainkodin asukkaista 22 % sai päivittäin PPI lääkkeitä. 
Säännölliseen PPI käyttöön liittyviä oireita ja piirteitä olivat ripuli, aikaisempi lonkkamurtuma, 
sepelvaltimotauti ja laktoosi-intoleranssi viitaten PPI lääkkeiden mahdollisiin sivuvaikutuksiin tai 
niiden käyttöön väärällä hoitoindikaatiolla. 
Osatutkimuksessa 2:ssa PPI lääkkeiden käytön yleisyys vaihteli 21.4 %:sta (geriatriset osastot ja 
vanhainkodit) 26.4 %:iin (palvelutalot). PPI lääkkeet eivät liittyneet kuolleisuuteen palvelutalojen 
asukkaiden kohdalla. Sen sijaan ne liittyivät kohonneeseen kuolleisuuteen laitoksissa, joissa 
asukkailla oli enemmän toiminnanvajeita ja jossa he olivat monisairaita. Pitkäaikaissairaaloiden, 
geriatristen osastojen ja vanhainkotien asukkaat olivat alttiita PPI-lääkkeiden haittavaikutuksille. 
Geriatrisen akuuttihoidon osaston ja vanhainkodin kohortissa kuolleisuuden vaara oli HR 1.90 (95 
% CI 1.23 - 2.94) jopa vakioitaessa ikä, sukupuoli, liitännäissairaudet, delirium, sekä ASA ja SSRI 
lääkkeiden käyttö. 
Osatutkimuksessa 3, 41.6 % asukkaista käytti antikolinergisesti vaikuttavia lääkkeitä.  Tutkittavista 
10.7% käytti AKE-lääkkeitä ja antikolinergisesti vaikuttavia lääkkeitä samanaikaisesti. 
Antikolinergisesti vaikuttavien lääkkeiden käyttöön liittyi suurempi lääkkeiden lukumäärä, 
toiminnanvajaus, depressio, psykiatriset sairaudet ja Parkinsonin tauti.  Antikolinergisesti 
vaikuttavien lääkkeiden käyttö oli yhteydessä heikompaan psyykkiseen hyvinvointiin kun ikä, 
sukupuoli, koulutus, monisairaus ja AKE-lääkkeiden käyttö vakioitiin. 
Osatutkimuksessa 4 laitosten asukkaista 5.9 % altistui lääkkeiden vakaville D-luokan 
yhteisvaikutuksille. Tavallisimmat lääkkeiden yhteisvaikutukset liittyivät kaliumia säästävien 
diureettien, karbamatsepiinin ja metotreksaatin käyttöön. Asukkaat, jotka altistuivat lääkkeiden 
 vakaville yhteisvaikutuksille, käyttivät enemmän lääkkeitä ja heillä esiintyi enemmän 
nivelsairauksia. Ryhmien välisessä kuolleisuudessa ei ollut merkitsevää eroa.  
Johtopäätökset: PPI lääkkeiden käyttö on tavallista laitoshoidossa ja niiden käyttöön mahdollisesti 
liittyy mahdollisesti haittavaikutuksia kuten ripulia ja lisääntynyttä kuolleisuutta laitoshoidossa 
olevilla kaikkein hauraimmilla vanhuksilla. Antikolinergisesti vaikuttavien lääkkeiden ja AKE-
lääkkeiden yhteiskäyttö on yleistä laitoshoidossa. Antikolinergisesti vaikuttavien lääkkeiden 
käyttöön liittyy heikentynyt psyykkinen hyvinvointi. Lääkkeiden vakavat yhteisvaikutukset ovat 























Older people living in institutional care represent the frailest segment of the older population, and 
they suffer from multiple co-morbidities and cognitive decline and are dependent in their activities 
of daily living (ADL) (Elseviers et al. 2010, Onder et al. 2012). They are often administered a high 
number of concomitant drugs (Ramage-Morin 2009, Elseviers et al. 2010, Onder et al. 2012, 
Beloosesky et al. 2013). Thus, they are prone to polypharmacy, DDIs and various adverse events 
(Johnell and Klarin 2007, Hosia-Randell et al. 2008, Vetrano et al. 2013).  
Many commonly prescribed drugs predispose patients to adverse effects, which may in fact 
outweigh any benefits (AGS 2012, Socialstyrelsen 2012). Several experts have defined 
inappropriate drugs for older people (Beers et al. 1991, Beers 1997, Fick et al. 2003, Gallagher et al. 
2008, O’Mahony and Gallagher 2008, AGS 2012, Socialstyrelsen 2012, O'Mahony et al. 2015). 
These drug lists include, for example, psychotropic drugs, drugs with anticholinergic properties 
(DAPs), non-steroidal anti-inflammatory drugs (NSAIDs), and generally drugs that lack efficacy or 
ones that have more harms than benefits. Older people in institutional settings suffer from dementia, 
malnutrition, risk of falls, and frailty, which predispose them to the adverse effects of many 
medications. If a medication is prescribed to treat the side effect of a previous medication, a 
“prescribing cascade” may result. Health care personnell need to be alert to this, especially among 
frail older people, who are particularly susceptible to DDIs and adverse reactions (ADRs) (Resnick 
1995, Rochon and Gurwitz 1997, Seymour and Routledge 1998, Delafuente 2003, Gill et al. 2005, 
Spinewine et al. 2007, Bell et al. 2012).  
Although inappropriate drugs have been investigated for several decades, the studies have been 
mainly descriptive and have explored prevalence. Less is known about the side effects or prognostic 
validity associated with these drugs (Jano and Aparasu 2007).  Furthermore, the benefits and harms 
of many commonly prescribed drugs have not been explored and weighted in frail older populations 
(Vetrano et al. 2013). For example, long-term use of PPIs has been suggested to predispose older 
people to Clostridium difficile infections (Leonard et al. 2007, Yearsley et al. 2006), community-
acquired pneumonia (Laheij et al. 2004) and hip fractures (Moayyedi and Cranney 2008). However, 
it is not known whether the benefits of these drugs overcome these adverse effects in frail, 
institutionalized older people.  
DAPs have been found to worsen cognitive decline among frail older people (Uusvaara et al. 2009). 
In institutional settings, their use is even more complicated since dementia is common and residents 
may concomitantly use ChEIs.   
                                                                                                                                                                                            
In Finland, older residents in institutional care are often taken care of  by primary care physicians 
(Hosia-Randell et al. 2008, Rummukainen et al. 2012, Pitkälä et al. 2014). These physicians act 
merely as visiting consultants in institutional settings. In addition, few patients in nursing homes 
have opportunities for a thorough review of their medication after admission to a nursing home 
(Pitkälä et al. 2014). Thus, their use of those drugs intended to be taken over a limited period may 
often be extended. 
This study focuses on risks and adverse effects, such as diarrhoea, poor psychological well-being, 
and mortality, related to the use of PPIs and DAPs among frail older people living in institutional 
settings. It also explores the prevalence and risks related to DDDIs among older people living in 








2. Review of the literature 
 
2.1. Ageing and changes in pharmacokinetics and pharmacodynamics 
 
Ageing is known to be associated with an increased prevalence of multiple diseases, which often 
exposes older people to polypharmacy (Corsonello et al. 2010). The ageing process is characterized 
by significant changes in physiological reserve, pharmacokinetics, and pharmacodynamic 
responses. Age-related changes in pharmacokinetics and pharmacodynamics in conjunction with 
comorbidity and polypharmacy expose frail older people to higher risk of adverse drug reactions 
(ADRs), which in turn contribute to rising health burden and costs (Corsonello et al. 2010, 
Hovstadius et al. 2010). 
2.1.1.Pharmacokinetics 
 
Gastric emptying and colonic transit are usually slower in the elderly, but absorption in the 
intestine, particularly passive absorption, is less affected (Boparai and Korc-Grodzicki 2011, 
Hubbard et al. 2013). However, one in three older people suffer from atrophic gastritis and inability 
to secrete gastric acid, which may lead to intestinal bacterial overgrowth and decline in absorption 
of iron, folate, calcium, vitamin K, and vitamin B12 (Saltzman and Russell 1998). This is especially 
relevant among older adults administered drug therapies that affect gastric acid secretion (Ito and 
Jensen 2010).  Medicines absorbed through the skin may undergo alterations with ageing. Drug 
absorption may be decreased due to reduced tissue blood perfusion related to skin atrophy in older 
persons (Trautinger 2001).   
With ageing, loss of water content and increase of body fat content may lead to modification of the 
distribution of drugs, with an increased circulating concentration of water-soluble drugs and a 
prolonged elimination of lipid-soluble drugs (Cusack 2004, Turnheim 2004, Boparai and Korc-
Grodzicki 2011, Hubbard et al. 2013). For example, the long half-life of the benzodiazepine 
diazepam has been considered inappropriate because of its extremely prolonged elimination in older 
adults (Beers 1997). This may be especially relevant among frail older people – such as the 
institutionalized elderly– among whom body fat is increased and lean body mass is decreased 
(Hubbard et al. 2013). 
With frailty and ageing serum albumin level diminishes ( Boparai and Korc-Grodzicki 2011, 
Hubbard et al. 2013). Decreased serum albumin levels, together with impaired nutritional state and 
 comorbidities, may predispose to increased response to drugs bound to albumin, as a consequence 
of an increase in the active percentage of these drugs that are highly bound to protein (Boparai and 
Korc-Grodzicki 2011).  
There is wide inter-individual variation in hepatic drug metabolism (Cusack 2004). Age-related 
decline in elimination of metabolized drugs is common in older individuals with serious diseases. 
This particularly applies to drugs eliminated by the cytochrome enzyme system (Cusack 2004, 
Boparai and Korc-Grodzicki 2011). There may be a decline in liver size and liver blood flow that 
may influence the rate of hepatic metabolism (Boparai and Korc-Grodzicki 2011). Inhibition of 
drug metabolism is not altered with ageing, but induction has been shown to be reduced in some 
studies (Cusack 2004). Among older people, first-pass metabolism may be reduced, leading to 
increased bioavailability of some drugs metabolized by cytochrome P450 enzymes (Boparai and 
Korc-Grodzicki 2011).  
With ageing diminished glomerular filtration rate, tubular secretion, and renal blood flow leads to a 
reduction in renal elimination of drugs, constituting the most significant pharmacokinetic change in 
older people that results in a decreased clearance of many drugs (Mangoni and Jackson 2004, 
Turnheim 2004, Boparai and Korc-Grodzicki 2011). Because of reduced muscle mass there may be 
normal serum creatinine levels despite a reduced glomerular filtration rate. Therefore, Cockcroft-
Gault or other equations are often used to estimate the glomerular filtration rate (Boparai and Korc-
Grodzicki 2011). This method has been criticized and alternative methods such as use of cystatin C 
levels in serum as estimates of renal function are under investigation (Hubbard et al. 2013). 
Renal impairment and decreased clearance of drugs may especially be aggravated in older people 
with chronic medical conditions  such as diabetes and heart failure (Khalil et al. 2016). 
Other comorbidites may also alter pharmacokinetics. Diabetic gastroparesis, atrophic gastritis, 
obesity surgery or other gastrointestinal disorders may hinder drug absorption (Gubbins and Bertch 
1991, Horowitz et al.. 2002, Stein et al. 2014). 
2.1.2.Pharmacodynamics 
 
Old age may lead to increased drug sensitivity as a consequence of altered pharmacodynamics 
(Turnheim 2004). Age-related changes in pharmacodynamics may occur, for example, at the 
receptor level or they may be due to altered homeostatic mechanisms (Turnheim 2004). 
Pharmacodynamic changes in ageing tend to be more complex than pharmacokinetic changes, and 




exaggerated response to benzodiazepines due to loss of neuronal substance, decreased synaptic 
activity, impaired glucose metabolism in the brain, and higher penetration of drugs in the central 
nervous system (CNS) (Turnheim 2004, Boparai and Korc-Grodzicki 2011). Similarly, the use of 
anticholinergic drugs, may be related to adverse effects in the CNS such as cognitive impairment 
and confusion (Turnheim 2004, Boparai and Korc-Grodzicki 2011). 
 
2.1.3. Risks in older people for adverse drug reactions 
Among older people, common ADRs are often due to alterations in renal, gastrointestinal, 
cardiovascular, endocrine, and neurological systems. In addition, the toxicity of drug combinations 
may be synergistic and greater than the sum of the risk of toxicity of each agent used alone. Non-
steroidal anti-inflammatory drugs (NSAIDs) can increase the risk of peptic ulcer by 4-fold in older 
patients, and this risk is 15-fold with concomintant use of NSAIDs and corticosteroids (Boparai and 
Korc-Grodzicki 2011) (Table 1) 
 
Table 1. Examples of drugs causing common adverse effects in older people (adapted by Boparai 
and Korc-Grodzicki 2011) 
Anticoagulants Bleeding, increased risk for drug interactions 
Drugs with anticholinergic properties  Dry mouth, constipation, urinary retention, 
delirium 
Tricyclic antidepressants Dry mouth, constipation, urinary retention, 
tachycardia, hypotension, sedation, cognitive 
impairment 
Antihistamines Sedation, dry mouth, cognitive impairment 
Antihypertensives Hypotension, sexual dysfunction, altered mental 
status 
Antipsychotics Orthostatic hypotension, confusion, sedation, 
weight gain, drug-induced movement disorders, 
changes in thermal regulation 
Benzodiazepines Sedation, impaired motor function, depression, 
altered mental status 
Digoxin Intoxication with nausea, vomiting, cardiac 
arrythmias, altered mental status 
H2-receptor antagonists Altered mental status, depression, confusion 
Narcotic analgesics Constipation, sedation, altered mental status, 
falls 
Non-steroidal anti-inflammatory drugs Gastric irritation, gastrointestinal bleeding, 
constipation, renal dysfunction, fluid retention, 
altered mental status 
Sedatives/hypnotics Excessive sedation, gait disturbances, delirium, 
depression 
 2.2. Polypharmacy  
 
Polypharmacy can be defined as the concurrent use of many different drugs. It can also be defined 
as the excessive use of not clinically indicated or inappropriate drugs (WHO 1997). These drugs 
may be prescribed as chronic, required, or short-term medication. Also over-the-counter drugs 
(OTC) drugs, complementary and alternative medicines, and dietary supplements need to be taken 
into account. 
Polypharmacy is most commonly defined quantitatively by a specific number of drugs in use, but 
also qualitative definitions, in reference to the quality of drug treatment, are used especially in the 
USA. (Larsen and Martin 1999, Maher et al. 2014). In studies applying a quantitative definition, 
five or more different prescribed drugs is the most frequently used cutoff (Bjerrrum et al. 1998, 
Viktil et al. 2007, Haider et al. 2008, Onder et al. 2012). Excessive polypharmacy is most 
commonly defined as the use of ten or more drugs (Chan et al. 2009, Haider et al.2009, Jyrkkä et al. 
2011, Onder et al. 2012). However, there is no consensus regarding the number of medications at 
which polypharmacy begins (Fried et al. 2014). 
Older people are prone to polypharmacy due to comorbidities, lack of follow-up of evidence-based 
clinical practice guidelines, and multiple prescribers (Barat et al. 2000, Bergman et al.2007, Chan et 
al. 2009, Sergi et al. 2011, Blanco-Reina et al. 2015). The development of drugs for old age 
diseases such as dementia and osteoporosis has increased the number of drugs that old people are 
administered (Jyrkkä et al. 2006). More than 90% of older people use prescribed medications 
(Jyrkkä et al. 2006, Fried et al. 2014). Home-dwelling older people use on average four to seven 
drugs per person (Barat et al. 2000, Jyrkkä et al. 2006, Haasum et al. 2012). Older people in 
institutional settings constitute the frailest group, with a higher number of prescribed drugs, on 
average seven to ten drugs (Jyrkka et al. 2006, Hosia-Randell et al.2008, Haasum et al. 2012, Onder 
et al. 2012). 
Several studies have suggested that advanced age, living in institutions, female sex, and lower 
education are associated with polypharmacy (Jyrkkä et al. 2006, Haider et al. 2009). Multimorbidity 
(Chan et al. 2009) and use of cardiovascular drugs, analgesics, asthma drugs, psychotropics, and 
anti-ulcer medications have been proposed to be associated with polypharmacy (Bjerrum et al. 
1998, Jyrkkä et al. 2006). Table 2 lists factors that have been associated with polypharmacy 




Table 2. Factors associated with polypharmacy (adapted from Barat et al. 2000, Jyrkkä et al. 2006, 
Bergman et al. 2007, Chan et al. 2009, Haider et al. 2009, Jyrkkä et al. 2009, Hovstadius et al.2010, 
Boparai and Koro-Grodzicki 2011, Sergi et al. 2011) 
Factors related to population, health care system and physicians 
 
Enhanced life expectancy, increasing older population 
Development of new therapies and technologies 
Increased use of preventive strategies 
Development of drugs for old age diseases 
Single disease oriented treatment guidelines 
Prescribing habits, multiple prescribers, physician’s work load, lack of time 
Factors related to patients 
Age 
Female gender 
Low socioeconomic status 
Low education  
Impaired self-reported health status 
Single diseases (cardiovascular disease, asthma/chronic obstructive pulmonary disease, 
chronic pain, diabetes, depression)  
Multimorbidity 
Impaired nutritional status 
Impaired functional status 
Impaired cognitive function  
Non-adherence to drug treatment  
Living in institution 
 
The benefits of a medication should always outweigh potential harms for the patient. The use of 
multiple medications may be associated with risk of negative consequences such as ADRs, drug-
drug interactions (DDIs), non-adherence to drug threrapy, inappropriate prescribing, and underuse 
of a beneficial medication (Spinewine et al. 2007). A systematic review showed that polypharmacy 
is associated with falls, hospitalizations, decline in cognitive and physical functioning, and 
mortality (Fried et al. 2014). From the point of view of society, polypharmacy also increases 
healthcare costs (Masoudi et al. 2005). 
Several studies have suggested an association between polypharmacy, risk of hospital admissions 
and mortality among older people (Alarcón et al. 1999, Espino et al. 2006, Iwata et al. 2006, Ruiz et 
al. 2008, Jyrkkä et al. 2009 , Fried et al. 2014).  However, the independent role of polypharmacy in 
mortality is difficult to show, as drugs may instead be markers of underlying diseases causing 
deaths in elderly persons. This confounding by indication has rarely been taken into account in 
these studies. Most studies are merely descriptive, lacking the possibility for assessment of 
causality.   
 2.2.1. Polypharmacy among older people in institutional care 
Several factors may increase the use of medications among older residents in institutional care. 
Older people in these settings suffer from multiple comorbidities and symptoms requiring treatment 
(Hosia-Randell et al. 2008). In addition, strict use of evidence-based clinical practice guidelines 
may lead to polypharmacy and very complicated drug treatments (Boyd et al. 2005). Besides 
polypharmacy, underuse of necessary drugs is also common (Löppönen et al. 2006).  
Many international studies have reported that institutionalization is associated with a higher number 
of prescribed drugs (Jyrkkä et al. 2006, Finkers et al. 2007, Hosia-Randell et al. 2008, Olsson et 
al.2010, Bronskill et al. 2012, Onder et al. 2012). In a five-year follow-up study conducted in 
Finland, the mean number of drugs among older people who moved from home to institutional care 
increased from 7.8 to 11.5 (p<0.001) (Jyrkkä et al. 2006). In this Finnish study, older people in 
assisted living received on average more cardiovascular drugs and less drugs taken when needed 
than community-dwelling older people (Jyrkkä et al. 2006). Poor self-reported health, female 
gender, high age, and specific diseases and symptoms (asthma/chronic obstructive pulmonary 
disease (COPD), heart disease, diabetes, depression and pain) were associated with a higher number 
of administered drugs. Poor health has been associated with the use of more than ten drugs, 
malnutrition, and functional and cognitive impairments (Jyrkkä et al. 2011).  An association was 
present between excessive polypharmacy and mortality (Jyrkkä et al. 2009). 
In the SHELTER study conducted in nursing homes in eight European countries, nearly half of the 
residents (N= 4023) used 5-9 drugs and a further 24% ten or more drugs (Onder et al. 2012).  An 
association existed between excessive polypharmacy (>10 drugs) and chronic diseases, depression, 
pain, dyspnea and gastrointestinal symptoms. An inverse association was observed between 
excessive polypharmacy and age, decreased functional ability, and cognitive impairment (Onder et 
al. 2012). 
Some studies suggest that elderly persons with dementia take on average more drugs than those 
without dementia (Lau et al. 2010). In addition, some studies have shown that specific drug 
categories considered inappropriate for older people, most commonly anticholinergics and sedative 
drugs, are prescribed more often to the elderly with poorer cognitive performance (Hanlon et 
al.1998).  
However, one US study reported cognitive impairments to be associated with reduced prescription 




Nursing home residents with impaired cognitive status are often prescribed drugs to treat chronic 
conditions rather than to manage symptoms with questionable benefits to the patients (Tjia et al. 
2010). Use of drugs in older adults with cognitive impairment raises several potential concerns. 
There is a need to avoid drugs that may affect cognition when treating patients with co-existing 
cognitive impairment (Huey et al. 2006). In nursing homes, an association has emerged between 
drugs considered potentially inappropriate (PIDs) and polypharmacy (Rancourt et al. 2004, Hosia-
Randell et al. 2008, Stafford et al. 2011). 
2.3. Potentially inappropriate drugs (PIDs) 
PIDs can be defined as drugs in which the risk of adverse events exceeds the clinical benefits, or 
drugs used when there is a safer and more effective choice of treatment (Beers et al. 1997, 
O`Mahony and Gallagher 2008).  PID lists were developed to prevent prescribing high-risk 
medications for older adults. Use of PIDs has been suggested to be associated with increased risk of 
adverse events involving increased risk of hospitalization or mortality among older people 
(Gallagher et al. 2008, Gallagher and O`Mahony 2008, Ruggiero et al. 2010, Gallagher et al. 2011). 
However, the use of an inappropriate drug according to the former Beers’ list was not associated 
with other health care use or mortality among community-dwelling older people (Jano and Aparasu 
2007). One study exploring nursing home patients suggested an increased risk of hospitalizations 
and mortality among those using any Beers’ inappropriate medications compared with those not 
using any of these (Lau et al. 2005).  
2.3.1. Criteria for PIDs  
Criteria for PIDs can be divided into explicit (criterion-based) and implicit (judgement-based) 
criteria (O’Connor et al. 2012, Kaufmann et al. 2014). Explicit criteria are usually based on 
literature review or expert consensus methods (O’Connor et al. 2012).  Moreover, explicit criteria 
are usually drug- or disease-oriented and can be applied with little or no clinical judgment 
(Spinewine et al. 2007). Thus, they are highly reproducible and are well suited for large-scale 
studies. They have been developed in various countries (USA, Canada, Asutralia, Ireland, France, 
Germany, Sweden, Norway, Italy, Austria, Thailand, and Taiwan) (Morin et al. 2015). Implicit 
tools are, by contrast, based on a clinician´s assessment and are patient-specific. The focus is 
usually on the patient rather than on drugs or diseases. These approaches are potentially the most 
sensitive in finding  patients’ drug problems and can account for  individual preferences of a patient 
(Spinewine et al. 2007). However, they are often time-consuming, are dependent on the user’s 
knowledge and attitudes, and may have low reliability (Kaufmann et al. 2014).      
 The most widely used explicit criteria for PIDs have been Beers’ criteria, which were originally 
developed for nursing home residents (Beers et al. 1991) and were later expanded to include all 
people of advanced age (Beers 1997). The criteria have been updated twice (Fick et al. 2003, AGS 
2012). Although the Beers' criteria have been widely used and studied, the criteria before 2012 
update (AGS 2012) had a low prognostic validity (Jano and Aparasu 2007). Furthermore, they 
included  a large number of drugs unavailable in countries other than USA, thus differing from 
criteria that take into account local health policies, drug regimens, and clinical guidelines (Pitkälä et 
al. 2002). The updated version of Beers’ criteria (AGS 2012) is more comprehensive than the 
previous ones (Beers et al. 1991, Beers et al. 1997, Fick et al. 2003).  The updated version also 
includes, for example, antipsychotics and NSAIDs (AGS 2012). Although these criteria may be 
used in clinical practice, evaluation and decisions should be evaluated on a personal basis (PID use 
for a short period, with low dosages following patient`s symptoms) (Hartikainen and Ahonen 
2011).   
The drugs available in different countries vary markedly (Pitkälä et al. 2002).  Accordingly, many 
countries have developed their own PID lists to take into account, country-specific approved drugs 
and specific prescribing and therapeutic culture and guidelines (Table 3). It is important to consider 
and weigh benefits and harms of drugs in clinical assessment of an older patient. Alternative safer 
treatments should be chosen when available. In some cases, a limited use of PIDs may be justified 
(sometimes a single dose, for a short period, with low dosages or close response follow-up).  It has 
been argued that PID lists should be used to flag older people with potential risks rather than 
explicitly discontinuing these drugs (Pitkälä et al. 2002). The STOPP/START criteria have been 
widely adopted by European experts (Gallagher et al. 2011). It has also been argued that these 
criteria have better prognostic validity than the Beers’ criteria (O’Mahony et al. 2015).  
Gallagher and colleagues (2011) developed a new screening tool for older persons' prescriptions 
that incorporates the criteria for PID known as STOPP (Screening Tool of Older Persons' 
Prescriptions) and the criteria for potentially appropriate, indicated drugs known as START 
(Screening Tool to Alert doctors to Right, i.e. appropriate, indicated Treatment) validated by 
Delphi`s consensus technique. STOPP criteria includes, among others, drug–drug and drug–disease 
interactions, drugs that adversely affect older patients at risk of falls, and duplicate drug class 
prescriptions. START consists of 22 evidence-based prescribing indicators for commonly 




Table 3. Criteria for potentially inappropriate drugs for older people (adapted from Ahonen 2011, 
O’Connor et al. 2012). 
Study Name of criteria, 
year, country 
Characteristics of criteria and target population 
Beers et al. 1991 Beers’ criteria, 1991,  
USA 
Explicit criteria, list based on a study among nursing home 
older residents (30 PIDs) 
Beers 1997 Beers’ criteria, 1997, 
USA 
Explicit criteria, expanded list from Beers et al.1991, based on 
a population study of people ≥65 years (66 PIDs) 




Explicit consensus criteria, drugs associated with clinically 
significant ADRs in older people, availability of at least one 
drug that has been shown to be a safer alternative (38 PIDs)  
Zhan et al. 2001 Zhan’s criteria,  2001, 
USA 
Explicit criteria (11 drugs that should always be avoided in 
older patients, 8 drugs that are rarely appropriate, 14 drugs 
that have some indications, but are often misused; total 33 
PIDs)   
Fick et al. 2003 
 
Beers’ criteria, 2003, 
USA 
 
Explicit criteria, updating of the Beers criteria, medications 
that should generally be avoided due to possible lack of 
efficacy or risk for ADRs when a safer alternative drug is 
available, drugs to be avoided in certain medical conditions 
(49 PIDs) 
Laroche et al. 2007 
 
French criteria, 2007, 
France 
Explicit consensus criteria (29 medications or medications 
classes that should be avoided due to possible lack of efficacy, 
risk for ADRs when a safer alternative drug is available, 5 
drugs to be avoided in certain medical conditions; total 34 
PIDs) 




Explicit consensus criteria based on indication of drug or 
symptoms, duration of treatment, drug interactions, dosage, 
duplicate drugs, including  65 PIDs (STOPP) and  22 
evidence-based prescribing indicators for commonly 
encountered diseases in older people (START)   
Basger et al. 2008 
 
Australian Prescribing 
Indicators Tool, 2008, 
Australia 
Explicit and implicit criteria based on treatment guidelines, 
drug-disease interactions, laboratory trackings, general 
warnings 
Rognstad et al. 2009 NORGEP, 2008, 
Norway 
Explicit consensus criteria, drugs, drug dosages, and drug 
combinations that should be avoided for older people (21 
PIDs, 14 drug combinations) 
Socialstyrelsen 2010 
 
”Indikatorer för god 
läkemedelsterapi hos 
äldre” 2010, Sweden 
Explicit criteria, long-term use of benzodiazepines, drugs with 
strong anticholinergic properties, concomitant use of at least 3 
psychotropic drugs, potentially severe drug-drug interactions 






Explicit criteria based on consensus (A=drugs that can be 
used, B=low evidence, experience, efficacy, C=with caution, 
D=should be avoided) 
American Geriatrics Society 
2012 (Beers´ Criteria 
Update Expert Panel) 
Beers’ criteria, 2012, 
USA 
Explicit consensus criteria,update of the previous 
Beers`criteria, drugs to be generally avoided, in certain 
diseases, drugs to be used with caution in older patients (53 
PIDs) 




(MAI), 1992, USA 
 
Implicit criteria based on indication, efficacy, adequate 
dosage, sufficient instructions, clinically significant drug 
interactions, feasibility of drug treatment, availability of less 
expensive alternative drugs, absence of duplicate medications, 
adequacy of  drug treatment 
PID = Potentially inappropriate drug, ADR=adverse drug reaction 
PID criteria in different countries have similarities but also differences (Chang and Chan 2010, 
O’Connor et al. 2012). Most criteria include various sedative drugs, psychotropic drugs, and 
anticholinergic drugs in their lists. Many also include drugs (e.g. digoxin, NSAIDs) that are harmful 
 for renal function (Gallagher et al. 2008, Gallagher and O’Mahony 2008, AGS 2012).  Drug-disease 
interactions are taken into account (e.g. the use of certain calcium channel blockers in patients with 
chronic constipation or heart failure, theophylline as monotherapy or beta-blockers in patients with 
asthma or chronic obstructive pulmonary disease, long-term neuroleptics in patients with 
Parkinsonism) (Fick et al. 2003, Basger et al. 2008, Gallagher and O’Mahony 2008).  
 
2.3.2. Prevalence and outcomes of PID use 
Prevalence of PIDs and their associated factors have varied depending on the patient population and 
the criteria used (Guaraldo et al. 2011). In community settings, the prevalence of PIDs according to 
Beers´ criteria has been in the range of  6-41% (Pitkälä et al. 2002, Fialova et al. 2005, Leikola et al. 
2011), whereas the respective figure among older nursing home residents is 16-83% (Lau et al. 
2005, Raivio et al. 2006, Hosia-Randell et al. 2008, Ruggiero et al. 2010, Chang and Chan 2010, 
Vieira de Lima et al. 2013). Even studies using the same criteria may have different findings if 
some drugs from the PID list are ignored (Pitkälä et al. 2002). Few studies have compared how 
different criteria identify PID users. In an inter-European study, STOPP/START criteria found a 
higher prevalence of PID users (51.3%) than the Beers’ criteria (30.4%) (Gallagher et al. 2011). 
However, in a Malaysian study the Beers´ criteria seemed to identify more PID users than the 
STOPP criteria (Chen et al. 2012). In a Spanish study,  both Australian criteria (Basger et al. 2008) 
and STOPP/START criteria (Gallagher and O’Mahony 2008) found a high number of drug 
problems among nursing home residents (García-Gollarte et al. 2012).  
PID use has been associated with higher age, female gender, and higher number of drugs (Guaraldo 
et al. 2011). A review argued that the use of inappropriate drugs according to the former Beers' 
criteria was not associated with the amount of health care use or mortality (Jano and Aparasu 2007). 
In a nursing home study using Beers’ criteria in Finland, there was no association between PIDs 
and mortality or hospital admissions (Raivio et al. 2006), whereas an American study did show an 
association between the number of PIDs and hospitalizations and mortality (Lau et al. 2005). A 
Spanish study revealed that modification of medications on the basis of STOPP/START criteria 
may decrease falls, delirium, and use of health care services among nursing home patients (García-







2.4.  Proton-pump inhibitors (PPIs) 
 
Proton pump inhibitors (PPIs) are one of the most widely used drug classes (Masclee et al. 2014). 
In Finland, their consumption has increased almost exponentially; there is more than a 5-fold 
increase since their entry into the market in the early 1990s. In 2015, the Finnish Social Insurance 
Institution reported a defined daily dose (DDD) of 67.75 per 1000 inhabitants (Kela 2015).  
The availability of PPIs has changed the treatment of upper gastrointestinal disorders, and, in 
general, they are effective and well-tolerated drugs (Arkkila 2015). PPIs are highly effective for 
treating gastric acid–related diseases such as gastro-oesophageal reflux, oesophagitis, and gastric 
and duodenal ulcers (Wolfe et al. 2000). They are also used to reduce the risk of gastrointestinal 
bleeding related to NSAIDs and low-dose aspirin (Pilotto et al. 2004, AGS 2012). Although there 
are critical indications for long-term use (e.g. Barrett’s oesophagus), chronic PPI use is often not 
indicated (Choudhry et al. 2008). The STOPP/START criteria recommended that full dosage of PPI 
use should be limited to eight weeks (Gallagher and O’Mahony 2008). It has been stated that PPIs 
are overutilized among hospital inpatients (Heidelbaugh et al. 2006, Pham et al. 2006, Hamzat et al. 
2012). Hospital patients are commonly discharged with a PPI prescription (Heidelbaugh et al. 2006, 
Pham et al. 2006).  
The use of PPIs has increased rapidly during the past decades, especially in older people and 
accounts for a significant amount of drug expenses (Heidelbaugh et al. 2006, Hamzat et al. 2012). 
Accordingly, PPIs are the most common drugs prescribed to community-dwelling older people 
(Onder et al. 2016) and one of the mostly prescribed drugs for long-term care residents (de Souto 
Barreto et al. 2013, Vetrano et al. 2013), even without an indicated diagnosis (Patterson Burdsall et 
al. 2013).  
PPIs are generally safe to use, and they are usually not included as PIDs for older people. For 
example, the Beers’ criteria 2012 recommend their use when an older person with a history of 
gastric or duodenal ulcer is using NSAIDs or low-dose aspirin (AGS 2012). However, in recent 
years some unexpected adverse effects have been described in association with PPI use. Therefore, 
long-term use of PPIs at full dosages is considered inappropriate for older people according to 
STOPP & START criteria (Gallagher and O’Mahony 2008). Clinical guidelines for PPI use have 
been developed in some countries such as in the UK (NICE 2014) and USA (Bhatt et al. 2008, 
NICE 2014). 
 2.4.1.Pharmacokinetics of PPIs 
All classes of PPIs share the same mode of action (inhibition of gastric proton pump). There are 
only minor pharmacokinetic differences between various PPIs. They have a half-life of about one 
hour and are thus unlikely to accumulate even when clearance is reduced - with increasing age. 
They also have similar time to achieve maximum concentration (Klotz 2000). 
PPIs are exclusively metabolized by the hepatic route, by the cytochrome P450 isoform CYP2C19, 
for which they have a greater affinity, and by the isoform CYP3A4, which functions as an overflow 
pathway. CYP2C19 has two genotypes with a slow metabolizer and an extensive metabolizer 
phenotype. Approximately 3% of Caucasians are slow metabolizers. The effects of the genotypes 
vary among the PPIs, with omeprazole being most affected and rabeprazole the least since it is 
predominantly metabolied non-enzymatically and only minimally by CYP. The polymorphically 
expressed CYP2C19 contributes to a variable but significant extent to rapid hepatic elimination. 
Renal impairment does not affect PPI metabolism. Nevertheless, lower dosages are advisable for 
older people (Klotz 2000). 
 
2.4.2. Drug-drug interactions involving PPIs 
PPIs impair the absorption of many drugs since they decrease gastric acidity (Robinson and Horn 
2003).  Because older people are often administered a wide range of other drugs concomitantly with 
PPIs , there is an increased risk for DDIs (Robinson and Horn 2003). DDIs are common for drugs 
whose clearance involves CYP-mediated oxidative metabolism (CYP2C19 and CYP3A4) in the 
liver, with possible associations with the CYP phenotype of the patient. The potential for significant 
DDIs varies according to the class of PPIs. Special attention is warranted when PPIs are co-
administered with narrow therapeutic index drugs such as phenytoin, warfarin, and theophylline. In 
addition, PPIs may alter the absorption of some drugs, such as digoxin and ketoconazole, by 











Table 4. DDIs between PPIs and other drugs (adapted from Klotz 2000). 
 Drug used 
 




increased AUC1 ? NA2 NO3 increased AUC1 
Ketoconazole Absorption 
(intragastric pH) 
decreased AUC1 NA2 NA2 decreased AUC1 
Theofylline 5CYP1A2 NO3 NO3 NO3 NO3 
Phenytoin 5CYP2C9 decreased CL4 NO3 NO3 NO3 
Warfarin 5CYP2C9 NO3 NO3 NO3 NO3 
Metoprolol 5CYP2D6 NO3 NA2 NO3 NA2 
Cyclosporin 5CYP3A4 NO3 NA2 NO3 NA2 
Carbamazepine 5CYP3A4 decreased CL4 NA2 NO3 NA2 
Nifedipine 5CYP3A4 decreased CL4 NA2 NO3 NA2 
Diazepam  5CYP2C19 decreased CL4 NO2 NO3 NO3 
1AUC = area under the concentration-time curve; 4CL = systemic clearance; 5CYP = cytochrome P450; 2NA = 
data not available; 3NO = no significant interaction;  ? = maybe involved. 
2.4.3. Adverse effects associated with PPI use 
Short-term use of PPIs may be associated with infrequent mild side-effects such as headache, 
diarrhoea, constipation, nausea and rash (Masclee et al. 2014). PPIs increase the gastric pH, 
impairing the absorption of many drugs (Robinson and Horn 2003). In addition, PPIs have some 
DDIs (Robinson and Horn 2003). In older people, long-term PPI use may be associated with risks 
and ADEs such as infections (Masclee et al. 2014).   
Gastrointestinal infections 
As a major defense mechanism against ingested pathogens, gastric acidity prevents colonization of 
the normally sterile upper gastrointestinal tract (Dial et al. 2005). Accordingly, PPI use and 
achlorhydria are associated with small bowel bacterial overgrowth (Masclee et al. 2014). Long-term 
PPI use may also be related to risk of Clostridium difficile infection (CDI) (Dial et al. 2005, Kwok 
et al. 2012, Masclee et al. 2014). In meta-analyses of cohort and case-control studies of >300 000 
patients, the risk estimates have varied between 1.7 and 2.3 among users of PPIs compared with 
non-users (Janarthanan et al. 2012, Kwok et al. 2012). Compared with histamine-2-receptor 
antagonist users, PPI users may have a higher risk of CDI (Kwok et al. 2012). In a meta-analysis, 
concomitant use of PPIs and antibiotics seemed to confer a greater risk (OR 1.96) than PPI use 
alone (Kwok et al. 2012). Possible mechanisms may be related to increased conversion of the spore-
form of C. difficile to its more virulent vegetative form, which is able to survive in the enteric 
lumen and, easily spreads between patients, especially in hospitals and nursing homes. The 
vegetative spores may return to a toxin-producing strain causing acute infection (Masclee et al. 
2014).   
 Continuous PPI use also causes an elevated risk of CDI recurrence (Linsky et al. 2010, McDonald 
et al. 2015).  Few studies have investigated the prevalence and risk factors of CDI in nursing 
homes, where residents are often admitted from acute care settings. Nursing home residents are 
predisposed to CDI due to comorbidities, decreased immune response, medications, and generally 
increased risk of infection. A majority of nursing home residents acquire CDI prior to entering the 
nursing home after a recent hospital discharge (Zarowitz et al. 2015). They are more likely to have 
severe underlying comorbidities and be readmitted to the hospital compared with patients with 
nursing home-acquired CDI (Zarowitz et al. 2015).  
Decreased gastric acidity may also be related to increased risk of other bacterial enteric infections, 
such as Salmonella and Campylobacter infections (Leonard et al. 2007).  
Pneumonia 
PPIs may be associated with increased colonization of the upper gastrointestinal tract with 
potentially pathogenic organisms, which may increase the risk of community-acquired pneumonia 
in older people (Laheij et al. 2004, Sarkar et al. 2008). The risk may be especially relevant among 
hospitalized older patients at risk of aspiration (Masclee et al. 2014). A meta-analysis of 31 
observational  studies suggested a slightly increased risk of pneumonia among PPI users (OR 1.27) 
(Eom et al. 2011). However, a recent meta-analysis including cohort studies on new users of 
NSAIDs with or without PPIs suggested no risk of PPIs upon hospitalization for community -
acquired pneumonia (Filion et al. 2014).  
Malabsorption 
B12 vitamin. While a normal diet usually contains substantially more vitamin B12 than is needed, 
the functional reserve is diminished in older people due to a decline in vitamin B12 absorption. A 
large proportion of vitamin B12 in food is bound to protein, from which it is released with the aid of 
acid and pepsin in the stomach, and, furthermore, bound to the intrinsic factor in order to be 
absorbed at the end of the small intestine (Arkkila 2015).  PPIs reduce the levels of acid, which 
impairs the release of protein-bound vitamin B12 to its unbound state, thus leading to impaired 
absorption of vitamin B12 and its deficiency. Other factors, such as Helicobacter pylori infection 
(Valuck and Ruscin 2004) or bacterial overgrowth of small intestine (Masclee et al. 2014) may 
enhance this process. Long-term PPI treatment may also be associated with B12 vitamin deficiency 
by decreasing the release of intrinsic factor (Sagar et al. 1999, Masclee et al. 2014). Prolonged 
vitamin B12 deficiency may lead to reversible megaloblastic anaemia and demyelinating neurologic 
disease resulting in gait disorders and muscle weakness, and it has been linked to other aspects of 




studies have investigated the association between PPI use and B12 vitamin deficiency with 
controversial findings (Valuck and Ruscin 2004, den Elzen et al. 2008, Dharmarajan et al. 2008). 
However, it has been concluded that long-term use of PPIs may lead to a decline in B12 
concentration and in vulnerable older people also to deficiency (Arkkila 2015). 
Calcium. PPIs may decrease calcium absorption by inhibiting solubilization of calcium salts and 
release of ionized calcium (Ito and Jensen 2010, Arkkila et al. 2015).  Since calcium solubility 
absorption is dependent on the pH of the solution, calcium absorption has likewise been speculated 
to depend on the gastric pH (Hansen et al. 2010).  
Magnesium. PPI treatment may be associated with hypomagnesaemia, which may lead to severe 
symptoms such as fatigue, tetany, cardiac arrhythmia, and concomitant secondary electrolytic 
disturbances (e.g. hypocalcaemia). The mechanism is seen to be a class-drug effect, possibly 
involving magnesium absorption (Arkkila 2015). The time of onset has varied widely (2 weeks to 
14 years, mean 5.3years). Hypomagnesaemia may be resolved with withdrawal of PPI and may 
recur with PPI restart. Associated risk factors were comorbidity and concomitant use of diuretics 
(Ito and Jensen 2010, Hess et al. 2012, Arkkila 2015).      
Risk of fractures 
Several large-scale studies have shown an association between long-term PPI use and bone 
fractures (Yang et al. 2006, Roux et al. 2009, Corley et al. 2010, Ngamruengphong et al. 2011, 
Maggio et al. 2013b). This relationship has not been observed consistently in all studies (Targownik 
et al. 2008, Gray et al. 2010, Ito and Jensen 2010). According to the literature review by Masclee et 
al. (2014), there still seems to be inconsistent evidence concerning the association between PPIs and 
fractures.  
Possible mechanisms have been suggested to be related to mineral density loss since PPIs may 
decrease intestinal calcium absorption, and this may lead to risk of fractures (Hansen et al. 2010, 
Ngamruengphong et al. 2011, Masclee et al. 2014). It has also been argued that PPIs may affect 
bone resorption,  resulting in decreased bone turnover (Masclee et al. 2014). Furthermore, profound 
acid suppression by PPIs may indirectly cause hypergastrinaemia, stimulating parathyroid glands to 
increase parathyroid hormone levels (Masclee et al. 2014, Arkkila 2015).  
One study suggested that the highest risk of fractures occurred among those with the highest PPI 
adherence, an intermediate risk among those with intermediate adherence, and the lowest risk 
among those with lowest adherence (Ding et al.2014). 
 Cardiovascular outcomes  
It has been argued that certain class of PPIs (omeprazole and esomeprazole) may attenuate the 
effect of aspirin on platelet aggregation and, in addition, impair conversion of clopidogrel to its 
active metabolite, thereby affecting platelet inhibition function (Masclee et al. 2014). Thus, PPIs 
may increase the risk for cardiovascular events (Wurtz et al. 2010). Several studies have explored 
this issue, but inconsistent evidence has emerged of an association between long-term PPI use and 
risk of adverse cardiovascular events (Masclee et al. 2014).   
Other risks 
It has been hypothesized that PPIs may increase the risk for gastrointestinal malignancies (Song et 
al. 2014). Long-term PPIs may lead to hypergastrinaemia (Yang et al. 2007). Gastrin has growth-
promoting effects on a number of epithelial cell types, including cells located in the pancreatic, 
gastric, and colonic mucosa. It is possible that the trophic effects of gastrin may increase the chance 
of sporadic mutations in normal cells and/or enhance the proliferation and progression of neoplastic 
tissues or their precursors (Yang et al. 2007). However, PPIs have not been documented to increase 
the risk for adenocarcinomas of the stomach or colon (Williams and McColl 2006, Song et al. 2014, 
Arkkila 2015). 
Recent studies have also suggested that PPIs may increase the risk of dementia (Haenisch et al. 
2015, Gomm et al. 2016). The German Study on Ageing, Cognition, and Dementia followed up 
73 679 participants free of dementia at baseline in 2004 until 2011 (Gomm et al. 2016). The patients 
receiving regularly PPIs (N=2950) had an increased risk of dementia during follow-up (HR 1.44; 
95%CI 1.36 to 1.52). However, this study has been criticized for several reasons. The risk 
associated with dementia may arise from residual confounding. Furthermore, dementia diagnoses 
were not rigorously defined in the study (Nguien and Hur 2016).   
In summary, risks related to PPI use have been found in epidemiological studies. The original 
randomized, controlled trials did not reveal these ADEs. Whereas most of the ADEs related to PPIs 
have a theoretical basis, these longitudinal studies cannot rule out user bias or residual confounding. 
Furthermore, some of the ADEs seems to carry fairly small risks (e.g. pneumonia) while others may 
include high risks (e.g. gastrointestinal infection). This emphasizes the fact that the clinician should 





























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































2.4.4. PPI use and mortality  
In a large UK population-based study based on general practice records, mortality of long-term 
users of omeprazole (N=17489, mean age 60 years, median follow-up 26 months) was compared 
with that of the general population. Use of omeprazol was associated with increased mortality 
(Bateman et al. 2003). Mortality risk was considered to be due to pre-existing illness such as pre-
existing severe oesophageal disease. In this study, a significant mortality increase was seen in the 
first year, but it fell to population levels by the fourth year. The main mortality causes were 
attributed to neoplasms and circulatory, digestive, and respiratory diseases (Bateman et al. 2003). 
According to a follow-up study of older people discharged from hospitals  (N=441, mean age 80 
years, follow-up one year) in Italy, the use of high dose PPIs was independently associated with 
one-year mortality even after adjustment for age, sex, cognitive impairment, depression, disability, 
nutrition, several comorbidities, number of drugs, and use of NSAIDs or antithrombotics (Maggio 
et al. 2013a). In this study, PPI users (N=174) were more often cognitively impaired, received a 
higher number of drugs and anti-thrombotic treatment and presented more comorbidity, 
cardiovascular diseases, peptic ulcer, and diarrhoea compared with non-users (N=317) (Maggio et 
al.2013a). In an Australian study (N=602, mean age 86 years, one year follow-up), use of PPIs was 
not associated with mortality among residents in intermediate level residential aged-care facilities 
(Wilson et al. 2011). The participants were assessed in a fall prevention study. The mortality rate 
among PPI users was 11.0%, compared with 9.8% among patients without PPIs (HR 1.08; 95% CI 
0.63-1.86).  
Scant studies exist concerning the association of PPIs and mortality. None of the randomized 
studies of PPIs has explored mortality as an outcome. The prospective cohort studies (Wilson et al. 
2011, Maggio et al. 2013a) may not take into account all confounding factors. Thus, mortality in 
these studies may be due to confounding by indication. The retrospective study concerning general 
practice records may include even more confounders since the background general population may 
be healthier than the one using general practice consultations.   
2.5.  Drugs with anticholinergic properties (DAPs) 
Drugs with anticholinergic properties (DAPs) refer to medications having antagonistic effects on 
the cholinergic neurotransmitter system. DAPs are commonly used, for example, to treat peripheral 
symptoms such as overactive bladder, COPD, gastrointestinal symptoms, or muscle spasms, but 
 they also have a number of CNS effects (Uusvaara et al. 2011, Salahudeen et al. 2014, Salahudeen 
et al. 2016).     
2.5.1. Physiology of DAPs blockade 
Cholinergic neurotransmission occurs through the binding of the neurotransmitter acetylcholine to 
either muscarinic or nicotinic receptors (Uusvaara et al. 2011, Lampela 2013). Acetylcholine is a 
neurotransmitter with brain-mediating effects on cognitive functions as well as on the 
parasympathetic nervous system, which has physiological functions in many organs of the body, 
including the eye, heart, lungs, blood vessels, gastrointestinal tract, and urinary bladder (Samuels 
2009). The term anticholinergic activity of a drug usually refers to the antagonistic effects on 
muscarinic receptors (Kay et al. 2005).  
The DAPs blockade on the various muscarinic receptors in the peripheral parasympathetic nervous 
system is taken advantage of when bronchodilatation is needed in COPD, and to treat symptoms of 
irritable bowel or diarrhoea as well as urinary incontinence due to overactive bladder or inactive 
detrusor muscle (Uusvaara 2013, Salahudeen et al. 2014).  The muscarinic receptor (M-receptor) 
subtype distribution in various organs and the potential side-effects of their blockade are presented 
in Table 6.  
Table 6. Distribution of M-receptors in the central nervous system (CNS) and other organs and 
adverse reactions (ADRs) related to DAPs (adapted from Tune 2001, Kay et al. 2005, DeMaagd 




Distribution in (CNS) Distribution in other 
locations than CNS 
Potential ADRs of blockade of M-receptor 
M1 high levels in central 
cortex, hippocampus and 
neostriatum (about 40-
50% of total 
acetylcholine receptors) 
gastrointestinal tract, 
skin, salivary glands, 
sympathetic ganglia 
- CNS ADRs1 (cognitive decline, mood 
disorders, confusion, delirium, hallucinations, 
slowing of psychomotor speed, ADL 
impairment, sleep disturbance) 
- Peripheral ADRs (e.g. constipation, dry 
mouth) 
M2 high levels 
throughout brain 
cardiac tissue, smooth 
muscle  
- CNS ADRs1 (cognitive deficits) 
- Peripheral ADE (tachycardia, palpitation, 
angina pectoris) 
M3 low levels throughout 
brain 
smooth muscle, salivary 
glands, eyes, blood 
vessels, lungs 
- CNS effects? 
- Peripheral ADRs (bronchus dilation, 
vasoconstriction, dry mouth) 
M4 high levels in 
neostriatum, cortex, and 
hippocampus 
salivary glands - CNS effects? 
- Peripheral ADRs (dry mouth, dental caries) 
M5 substantia nigra and 
hippocampus 
eye (ciliary muscle, iris) - CNS effects? 
- Peripheral ADRs (blurred vision, increased 
risk for glaucoma) 





However, precise distribution and functions of muscarinic receptors are not well-known (Lampela 
2013). Previous studies have suggested that the effects of acetylcholine, a neurotransmitter in the 
brain involved in cognition, are mediated by all muscarinic (M1-M5) receptors, which are 
distributed in varying amounts in different parts of the brain, especially in the hippocampus and 
cortex. Cholinergic transmission is important in the CNS in processing of memory, language, and 
visuospatial and perceptual functions (Kay et al. 2005, Lampela 2013) as well as orientation, 
concentration, attention, and psychomotor speed (Lieberman 2004, Uusvaara et al. 2011, Lampela 
et al. 2013). DAPs act as blockers of these receptors and if they can enter the CNS, they can cause a 
decreased cholinergic activity in the brain, which may be associated with cognitive decline, 
memory impairment, sleeping problems, attention deficit, confusion, hallucinations, and delirium 
(Lieberman 2004, Uusvaara et al. 2011, Lampela et al. 2013, Leaderbrand et al. 2016). The 
activities of M3, M4, and M5 in the brain are not completely understood. The blocking of these 
receptors may lead to, for example, hallucinations, sedation, and delirium (DeMaagd and Geibig 
2006).  These adverse effects may go unrecognized in older people, among whom memory is not 
re-evaluated on a routine basis (Kay et al. 2005). 
The muscarinic receptors M1-M3 are found in the gastrointestinal tract, and therefore  
anticholinergic drugs may cause constipation and even impaired nutrition (DeMaagd and Geibig 
2006, Uusvaara et al. 2011).  M2 and M3 receptors are located in the bladder, and thus, their 
blockade may cause decreased contraction and urinary retention (DeMaagd and Geibig 2006, 
Samuels 2009).  M1, M3, and M4 participate in glandular secretion in bronchi, gastrointestinal 
tract, and skin, whereas M3 and M5 work in ciliary muscles and in the iris during accommodation 
(Uusvaara et al. 2011).   
DAPs can be either lipid-soluble or lipid-insoluble compounds. Lipid-soluble anticholinergics (e.g. 
atropine, scopolamine) may have more CNS adverse effects than lipid-insoluble anticholinergics 
(e.g. glycopyrrolate) (Lampela et al. 2013). Anticholinergic adverse effects are divided into 
peripheral and central adverse effects. Central anticholinergic adverse effects occur when an 
anticholinergic drug penetrates through the blood-brain barrier into the CNS. Increasing age, 
comorbidities, and neurological conditions (Alzheimer´s disease, Parkinson´s disease, cerebral 
stroke, head injuries) common in older people predispose to an increase in blood-brain permeability 
(Kay et al. 2005, Weiss et al. 2009). Individuals with apolipoprotein E4 allele, which represents a 
 major risk factor for Alzheimer´s disease with cognitive decline, may be more susceptible to 
cognitive effects of DAPs (Uusvaara et al. 2009). 
It has been argued that the use of several DAPs and the strength of anticholinergic activity of a 
DAP, i.e. anticholinergic burden,  has importance when assessing the ADEs of DAPs among older 
patients (Carnahan et al. 2006, Rudolph et al. 2008, Lampela et al. 2013). There are several ways to 
measure anticholinergic activity or burden in the elderly.  
Serum anticholinergic activity (SAA) assay, as measured by radioreceptor assay, reflects the 
cumulative binding of all drugs and their metabolites to all muscarinic receptors (M1-M5) (Tune et 
al. 1992). SAA has been correlated to serum levels of DAPs, anticholinergic activity in cerebral 
spinal fluid, and impaired cognition (Chew et al. 2008). However, there are also contradictory 
findings (Lampela et al. 2013). In a Finnish study, SAA was not associated with the number of 
DAPs used or cognition, vision, or ADL (Lampela et al. 2013). The meta-analysis suggested that 
RCTs using SAA had no association between use of DAPs and cognition, whereas pooled analysis 
of observational studies showed that elevated SAA was associated with cognitive decline 
(Salahudeen et al. 2016).  Problems with reliability of SAA measurement has limited its clinical 
use. Therefore, several definitions of DAPs and drug lists have been introduced to measure 
anticholinergic burden.  
2.5.2. Criteria to define DAPs 
The serum anticholinergic activity (SAA) assay, originally developed by Tune and Coyle, has been 
considered the ‘gold standard’ for quantification of anticholinergic effect of drugs in vivo. 
However, this test has not been readily available in clinical practice, and its performance and 
interpretation have not been standardized. Therefore, lists that rank drugs on the basis of their 
anticholinergic potency have been developed from SAA measurements, the published literature, and 
expert opinion. In addition, several different in vivo methods (e.g. saliva or sweat secretion, 
papillary reflex, or heart rate variability) have been applied to measure anticholinergic effects. 
However, none of these methods are specific to cholinergic neurotransmission, and it has been 
recommended that they should be used together with subjective assessments of anticholinergic 
effects.There is no widely accepted simple, reliable, and fast method to assess anticholinergic 
burden in clinical practice (Lampela et al. 2013). 
Over 600 drugs have been recognized to have anticholinergic activity (Durán et al. 2013). There are 




2006, Carnahan et al. 2006, Boustani et al. 2008, Chew et al. 2008, Han et al. 2008, Rudolph et al. 
2008, Carrière et al. 2009, Uusvaara et al. 2009, Ehrt et al. 2010, Sittironnarit et al. 2011).  The drug 
lists have many drugs in common, but there is also considerable variation in defining these drugs 
(Durán et al. 2013). The development of some of these lists has depended on the patient population 
assessed. Thus, those (potentially anticholinergic) drugs not used or not available in a particular 
patient population were omitted from the criteria (Uusvaara et al. 2011, Durán et al. 2013) (Table 
7). 
Many drugs on the Beers´ list, which is based on expert opinion, were considered inappropriate 
because of their anticholinergic side effects (Beers 1997). Tune (2001) showed that anticholinergic 
burden is associated with delirium. Ancelin et al. (2006) showed that DAPs have measurable effects 
on various cognitive functions of older people.  
Carnahan et al. (2006) developed the Anticholinergic Drug Scale (ADS), in which scores vary 
between 0 and - 3 based on the drug´s anticholinergic activity. They showed that ADS is associated 
with SAA activity (Carnahan et al. 2006). Lampela et al. (2013) further showed that 117 drugs on 
Carnahan´s list that had anticholinergic activity were only moderately associated with cognitive 
function measured by the Mini Mental State Examination (MMSE) test.  
The Anticholinergic Cognitive Burden Scale (ACBS) developed by Boustani et al. (2008)  is a tool 
based on a systematic literature review by an expert panel of clinicians focusing on central rather 
than peripheral anticholinergic effects for categorizing drugs according to the severity of their 
cognitive effects.  He suggested his ACBS scale for clinical use to evaluate the anticholinergic 
burden on cognition among vulnerable older people (Boustani et al. 2008). 
Chew et al. (2008) measured in vitro the anticholinergic activity of 107 medications commonly 
used by older persons, by using pharmacokinetic data to translate the relationship between the dose 
and anticholinergic activity. Chew`s list showed only a moderate association with cognition among 
older people (Lampela et al. 2013). Ehrt et al. (2010) developed the Anticholinergic Activity Scale 
(AAS) based on Chew`s list and a previous literature review based on SAA and expert opinion in 
an eight-year cohort study (Ehrt et al. 2010). 
Carrière et al. (2009) further developed Ancelin’s list of DAPs. Their findings suggested that the 
continuous use of DAPs was associated with risk of incident dementia. Han et al. (2008)  developed 
his list of DAPs by clinician-rated scores quantifying potential anticholinergic effects. Uusvaara et 
al. (2009) combined several expert lists of DAPs.  
 The Anticholinergic Risk Scale (ARS) was developed by an expert panel (Rudolph et al. 2008). It 
has shown the association of adverse effects with DAPs in two cohort studies. Drugs were scored 
from 0 to 3 according to their potential anticholinergic effects.  
Hilmer and colleagues (2007) developed the Drug Burden Index (DBI), a method of evaluation of 
effect of overall exposure to medications with anticholinergic and sedative properties. It has been 
shown to be associated with poorer function among community dwelling older people. The DBI 
also has an electronic calculator available on the internet (Kouladjian et al. 2016). 
 
SFINX-PHARAO is a Finnish-Swedish database presenting both DDIs and adverse effects of 1400 
drugs (SFINX 2015). The adverse effects are reported in PHARAO with respect to nine central 
drug effects, including anticholinergic effects. With the aid of PHARAO, it is possible to analyze 
the adverse effect profile of a particular drug, e.g. when adding a new drug to a previous 
medication, or to analyse the adverse effect risks of all drugs together (medication overall 
assessment).  
A systematic review by Salahudeen et al. (2015a) evaluated the association between anticholinergic 
burden, based on previous anticholinergic scales and expert opinion, with adverse outcomes in older 
people. Sittironmarit and colleagues (2011) measured the Anticholinergic Loading Scale (ACL) 
based on previous anticholinergic scales and expert opinion and evaluated the association between 
ACL with psychomotor speed and executive function.  
These criteria differ in many ways (Uusvaara et al. 2011, Durán et al. 2013). The development of 
some of these lists has depended on the patient population assessed. Table 7 gives examples of 

























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































2.5.3. Prevalence of use of DAPs 
Older people in long-term institutional settings are often treated with DAPs (Chatterjee et al. 2010, 
Haasum et al. 2012, García-Gollarte et al. 2012, Pitkälä et al. 2014). The use of anticholinergic 
drugs differs according to applied criteria, setting, availability of drugs, and country. Previous 
studies have shown that 8-26% of community dwelling older persons use DAPs (Roe et al. 2002, 
Lechevallier-Michel et al. 2005, Ancelin et al. 2006, Hilmer et al. 2007, Carrière et al. 2009).  
Table 8.  Prevalence of DAP use in institutional settings.  
 
Study Country, study 
population, n 
Age, years Method to detect 
DAP use 
Users of DAPs 
Bergman et al. 
2007 
Sweden, residents of 
nursing homes; 
(n=7904) 
65 or older List based on quality 
indicators by Swedish 
National Board of 




USA; residents with 
dementia in nursing 
homes (n=87) 
65 or older ACB1 At least one DAP 82%, two or more DAPs 
56%. At least one drug with severe 
properties (ACB1 score 3) 37% 
Chatterjee et 
al. 2010 
USA, residents with 
dementia in nursing 
homes (n=509 931) 
65 or older ADS2 Any DAPs 73.8%.  
DAPs with “marked anticholinergic 
activity” 21.3% 
Olsson et al. 
2010 
Sweden; residents of 
nursing homes and 
special care units for 
dementia (n=3705) 
65 or older List based on quality 
indicators by Swedish 
National Board of 
Health and Welfare 
20% 
Kumpula et al. 
2011 












65 or older List based on quality 
indicators by Swedish 
National Board of 
Health and Welfare 
12.1% 
Wawruch et al. 
2012 
Slovakia; patients in 
long-term care 
hospitals; (n=1636)  
65 or older List based on 
literature and ARS3 
14.2% 
Kersten et al. 
2013b 
Norway; residents in 
nursing homes 
(n=1101) 
73 or older ADS2≥3 21% 
Pylkkänen 
2013 
Finland; residents in 
assisted living and 
nursing homes in 
Helsinki and Kouvola 
(N=326) 
65 or older Combined Beers, 
ARS3 
68% 
Landi et al. 
2014 
Italy; nursing home 
residents (n=1490) 
65 or older ARS3 48% 
Pitkälä et al. 
2014 
Finland; residents in 
assisted living facilities 
(N=227) 
65 or older Combined Beers, 
ARS3 
71% 
Palmer et al. 
2015 
USA; residents with 
dementia in nursing 
homes (n=69877)  
65 or older ACB1 77% 
  1ACB = Anticholinergic Cognitive Burden Scale (Boustani et al. 2008); 2ADS = anticholinergic drug scale (Carnahan 
et al. 2006); 3ARS = anticholinergic risk scale (Rudolph et al. 2008) 
 Among institutionalized older people, the variations in prevalence are even higher. In this 
population, 12-82 % have been treated with anticholinergic drugs, with the highest amounts being 
reported among those with dementia (Table 8). The wide variations in prevalences depend on 
population characteristics and the tool used to detect DAPs. In Sweden, the prevalence of residents 
who were administered DAPs was lower than in other countries (12.1% to 20%), due to the use of a 
restricted criteria, including only a potent class of DAPs (antihistamines, urinary and 
gastrointestinal antispasmodics, cyclic antidepressants, low-potency antipsychotics, anticholinergic 
antiparkinson drugs, class la antiarrhythmics, anticholinergic antiemetics). Clinical conditions such 
as neuropsychiatric symptoms associated with dementia, incontinence and sleep problems – which 
are often managed with DAPs are common in frail nursing home residents (Kolanowski et al. 
2009). DAPs with high anticholinergic activities often prescribed to institutionalized residents 
include psychotropics and incontinence drugs (Pitkälä et al. 2014).   
2.5.4. Adverse effects related to DAP use 
DAPs are often used to treat psychiatric or neurological disorders or symptoms such as 
incontinence, diarrhea, or pain. However, DAPs also have side effects that can accumulate if a 
person uses several DAPs simultaneously (anticholinergic burden) (Tune 2001). Even medicines 
with minor anticholinergic properties may contribute to unwanted central and peripheral adverse 
events if used in combination with other agents having anticholinergic properties. Determination of 
anticholinergic adverse effects is difficult (Lampela et al. 2015). Older people are thought to be 
particularly vulnerable to central ADEs of anticholinergic drugs, possibly because of a decrease in 
the number of muscarinic receptors and an increase in the permeability of the blood-brain barrier 
due to comorbidities (diabetes, Alzheimer’s disease, Parkinson’s disease, cerebral stroke, head 
injuries) (Weiss et al. 2009). Individuals with apolipoprotein E4 allele, which represents a major 
risk factor for Alzheimer´s disease with cognitive decline, may be more susceptible to cognitive 
effects of DAPs (Uusvaara et al. 2009). Clinically significant adverse events related to DAPs range 
from dry mouth, blurred vision, and constipation to more severe events such as urinary retention, 
arrhythmias, cognitive decline, and even delirium (Tune 2001).  
The adverse effects associated with DAPs may often be treated with another drug (“prescribing 







DAP use is associated with impairment of cognitive function in older people ( Lechevallier-Michel 
et al. 2005, Ancelin et al. 2006, Cao et al. 2008, Han et al. 2008, Carriere et al. 2009, Gray et al. 
2010, Uusvaara et al. 2013). In some studies, the association of DAPs and cognitive decline has 
been dose- or burden-dependent (Hilmer et al. 2007, Lampela et al. 2013, Fox et al. 2014), whereas 
other studies have not found this association (Kersten et al. 2013b). While earlier studies stated that 
DAPs may not lead to dementia, the latest report suggests that there may be irreversible cognitive 
effects of strong DAPs (Gray et al. 2010). A Norwegian trial also proposed that reducing DAPs in 
nursing home residents may not improve their cognition (Kersten et al. 2013a). Both centrally and 
peripherally acting anticholinergic drugs have been associated with a decrease in cognition in older 
patients (Fox et al. 2011, Ruxton et al. 2015). Patients with dementia and frail residents in nursing 
homes are especially vulnerable to further cognitive decline (Bell et al. 2012). Cognitive 
impairment due to drugs in these patients may be misattributed to the disease process itself (Bell et 
al. 2012). 
Use of medicines with anticholinergic or sedative properties may result in adverse events by 
increasing the overall anticholinergic or sedative load. The likelihood that medicines may produce 
unwanted central anticholinergic effects depends in part on age-related and individual variability in 
pharmacokinetic parameters, blood-brain barrier permeability, degree of cholinergic neuronal 
degeneration, and a patient’s baseline cognitive status (Wawruth et al. 2012). 
Use of DAPs among nursing home residents may also be associated with delirium, which implies a  
poor prognosis (Luukkanen et al. 2011, Landi et al. 2014). However, a systematic review found no 








 Table 9. Association between DAP use and delirium (adapted from Fox et al. 2014). 
Study, country Design, setting N Mean age, 
females (F, %) 
Participant characteristics Findings  






Patients admitted due to cerebral infarct or 
haemorrhage 
DAPs were associated 
with delirium  
Gaudreau et al. 
2005, Canada 
Cohort study, hospital 261 60 years; 
F=44% 
Patients with previous cancer diagnosis, no 
association between DAPs and delirium 
No association 
between DAPs and 
delirium  
Pandharipande et 
al. 2006, USA 
 
Cohort study, hospital 198 56 years; 
F=48% 
 
Patients admitted to intensive care units, no 
association between DAPs and delirium 
No association 
between DAPs and 
delirium 
Campbell et al. 
2011, USA 
Cohort study, hospital 147 77 years;  
F=63% 
Patients  with previous cognitive impairment  No association 
between DAPs and 
delirium 
Luukkanen et al. 
2011, Finland 
Cohort study, hospital 
and nursing home 
425 86.1y; 
F=81.6% 




DAPs and delirium 
 
Falls, functional impairments, and quality of life  
Anticholinergic drugs may increase the risk of falls (Tune 2001, Landi et al. 2007, Berdot et al. 
2009), with the risk associated with specific DAPs such as olanzapine and trazodone (Ruxton et al. 
2015). It has been argued that acetylcholine is critical in communication between neurons and 
muscles for modulating posture and movement (Ruxton et al. 2015). DAPs may also have central 
side effects, such as dizziness, weakness, and lightheadedness, which may predispose to falls (Landi 
et al. 2007). The adverse effects of anticholinergic drugs also include impairments in physical 
performance (Hilmer et al. 2007) and physical functioning (Landi et al. 2007, Lampela et al. 2013, 
Fox et al. 2014).  
 
Hospital admissions and mortality risk 
Although there are many studies investigating the relationship between inappropriate drugs and 
hospitalizations (Jano and Aparasu 2007), less is known about how DAPs predict hospitalizations. 
In a few studies conducted on this topic, use of anticholinergic drugs has been associated with 
increased risk of hospital admissions (Uusvaara et al. 2011, Lönnroos et al. 2012, Salahudeen et al. 
2015a).  The first two Finnish studies were conducted among home-dwelling older people, whereas 
the last one was a large-scale register-based study (N=537387) from New Zealand exploring how 




and physical impairments, delirium, falls, and other adverse effects (Uusvaara et al. 2011, Lönnroos 
et al. 2012, Salahudeen et al. 2015a). None of these studies have specifically explored the causes 
underlying hospitalizations. One study found no significant difference in nursing home admissions 
among users and non-users of DAPs (Narbey et al. 2013).  
Studies investigating the association of DAPs with mortality have reported mixed results. Some 
have suggested an increased risk for mortality (Panula et al. 2009, Fox et al. 2011, Lowry et al. 
2011, Mangoni et al. 2013), whereas others have not shown an association (Kumpula et al. 2011, 
Luukkanen et al. 2011, Uusvaara et al. 2011, Wilson et al. 2011, Narbey et al. 2013, Kidd et al. 
2014). The discrepancy in the findings may arise from the anticholinergic drug scales used in the 
studies or differences in the characteristics of study populations  or follow-up times (Fox et al. 
2014, Ruxton et al. 2015). Table 10 gives a summary of the studies investigating the associations of 




























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































2.6.  Drug-drug interactions (DDIs)  
The effect of medication may be influenced by other medications that an individual is taking. One 
drug may have an effect on another in two ways: pharmacokinetically or pharmacodynamically. 
DDIs may lead to increased toxicity or decreased efficacy of the drug, which may result in a 
prescribing cascade, further increasing the risk of adverse drug reactions (ADRs) (Mallet et al. 
2007). The risk for DDIs increases exponentially with the number of ingested drugs (Johnell and 
Klarin 2007).  
Older people are at high risk for DDIs due to physiological changes with ageing, polypharmacy, 
comorbidities, and decreased nutritional status (Mallet et al 2007). In older patients, DDIs are a 
common reason for preventable ADR, hospitalizations related to drug toxicity, higher health care 
costs, and increased risk of mortality (Juurlink et al. 2003, Moura et al. 2009).   
On the other hand, some DDIs may be beneficial. DDIs can been used in clinical practice in the 
treatment of hypertension, for example, concomitant use of diuretics with ACE-inhibitors has a 
synergistic effect in lowering blood pressure (Carnasos and Stewart 1985).   
The drugs most commonly involved in serious potential interactions are those used in daily clinical 
management of elderly patients with chronic diseases (e.g. cardiovascular and neurological 
disorders, chronic pain, dementia and related neuropsychiatric symptoms). Clinically relevant DDIs 
are more likely with drugs having a narrow therapeutic index (e.g. digoxin, phenytoin, 
carbamazepine, methotrexate, theophylline, and warfarin) since even small changes in the 
concentration of these drugs may result in significant clinical symptoms including intoxication 
(Delafuente 2003, Malone et al. 2005, Gagne et al. 2008) (Table 11).  
In Finland, the most common potential DDIs in older patients were associated with the use of 
potassium-sparing diuretics, carbamazepine, and codeine (Hosia-Randell et al. 2008). In a study 
conducted by Aparasu et al. (2007) in the USA, the four most common DDIs accounted for 97% of 
all DDIs: anticoagulants/thyroxine (44%), warfarin/NSAID (40%), warfarin/fibrates (8%), and 
warfarin/trimethoprim (5%). In an Italian study, the four most common DDIs were the following: 
warfarin/NSAIDs, theophylline/ciprofloxacin or fluvoxamine, warfarin/barbiturates, and 




 Table 11. Examples of clinically important DDIs in the elderly (adapted from Seymour and 
Routledge 1998, SFINX 2015) 
 
Drug A Drug B Effect of interaction Mechanism of interaction 




Antihypertensives Vasodilators, antipsychotics  Postural hypotension Combined hypotensive effects 
Beta-blockers verapamil, diltiazem Atrioventricular block, 
bradycardia and severe 
hypotension 
Drug A can interact pharmaco-
dynamically with drug B, exerting an 
additive cardiodepressive effect 
Low-dose Aspirin NSAIDs1 Peptic ulceration Increases risk of gastrointestinal 
bleeding 
Carbamazepine Enzyme inhibitors2, verapamil Increased effect of drug A Reduced clearance of A or increased 
clearance of B 




Decreased effect of drug 
A 
Codeine is a prodrug and the 
formation of morphine by CYP2D6 
enzyme is essential for analgesia. 
Drug B are inhibitors of this CYP 
isoenzyme  
Corticosteroids (oral) NSAIDs1  Peptic ulceration Gastrointestinal irritation and 
inhibition of ulcer healing 
Donepezil SSRIs Increased risk for 
arrhythmia 
Additive effects prolonging QT-time, 
increasing risk of Torsades de Points 
Digoxin Amiodarone, diltiazem, 
verapamil, clarithromycin 
Diuretics (loop and thiazides) 
Increased effect of drug A 
 
Increased effect of drug A 
















Risk for serotonin 
effects/syndrome is 
increased 
Unknown, possible additive 
inhibitory effect on serotonin re-
uptake. Changes of pharmacokinetics 
of drug B in some cases 
Lithium NSAIDs, thiazide diuretics Increased effect of drug A Reduced clearance of A 
SSRIs NSAIDs Increased risk of bleeding Both NSAIDs and SSRIs impair 
platelet aggregation. SSRIs reduce 
the amount of serotonin in platelets 
and NSAIDs inhibit the synthesis of 
thromboxane A2. NSAIDs also 
impair the protective effect of 
prostaglandins in gastric mucosa by 
inhibiting COX-1 enzyme. 
Theophylline Enzyme inhibitors3  Increased effect of drug A Reduced clearance of A 
Warfarin NSAIDs, low-dose Aspirin 
Metronidazole, fibrates 











Additive effects on coagulation and 
haemostasis 
Inhibition of warfarin metabolism  
 
Impaired absorption and increased 





Decreased effect of drugB  
Increased effect of drug B 
Increased effect of drug B 
Impaired effect of drug B 
Impaired absorption of drug B 
Possible CYP450 inhibition 
Impaired elimination of drug B 
Impaired absorption of drug B 
1NSAIDs = non-steroidal anti-inflammatory drugs; SSRI=Selective serotonin reuptake inhibitor; 2e.g. quetiapine, 
risperidone, amlodipine, many antifungal medications, oxycodone, buprenorphine, tamsulosin, tamoxifen (among many 




Identifying DDIs in older people and their management may be challenging. Physicians are often 
unaware of all of the drugs that their patients are taking (Langdorf et al. 2000, Mallet et al. 2007). 
Atypical presentation of symptoms, such as confusion, falls, and weakness, may confuse the 
detection of DDIs. Older patients might receive prescriptions from several physicians. This may 
increase the risk of polypharmacy and DDIs (Seymour and Routledge 1998).  
It is likely that only a small proportion of potential interactions result in clinically significant events 
(Mallet et al. 2007),  and, while death or serious clinical consequences are rare, mild, clinically 
insignificant ADRs among the elderly may be more common (Seymour and Routledge 1998). Only 
a few studies have examined clinical outcomes of DDIs in older populations (Juurlink et al. 2003).   
 
2.6.1.Pharmacokinetic interactions 
DDIs may be pharmacokinetic or pharmacodynamic (Mallet et al. 2007). In recent years, advanced 
databases have enabled clinical evaluation of pharmacokinetic interactions. Pharmacokinetic 
interactions result in changes in the drug concentrations involved, increasing or decreasing the 
pharmacological effect of these drugs (Delafuente 2003). 
With pharmacokinetic DDIs, one drug affects the absorption, distribution, metabolism, or excretion 
of another drug (Mallet et al. 2007). Decreased liver and renal functions related to ageing may 
exaggerate the DDIs affecting drug metabolism and elimination, resulting in an increased risk of 
drug toxicity (Delafuente 2003). 
The precipitant drug may alter the absorption of the object drug in different ways. Changes in 
gastric acidity and gastrointestinal motility may affect the absorption of certain drugs (e.g. PPIs vs. 
calcium, iron, vitamin B12). Absorbant drugs (e.g. cholestyramine) may inhibit absorption of 
certain drugs (e.g. digoxin, warfarin, levothyroxine). Drugs with anticholinergic properties and 
opioids will slow gastrointestinal motility, while such drugs, as metoclopramide will increase 
motility. Because of slowing of the gastrointestinal tract, the absorption of a drug may be delayed. 
However, the full extent of drug absorption is achieved and the area under the blood 
concentration–time curve (AUC) is unchanged . This may be important to consider when using an 
analgesic. Another consequence of one drug slowing the gastrointestinal transit time could be a 
decrease in the amount absorbed of another drug. This could potentially cause peak serum 
concentrations of the drug to be below the needed threshold for effect (Delafuente 2003). 
 
 A common DDI affecting drug distribution is alteration in protein binding by competitive inhibition 
of protein binding sites. It is clinically important only for drugs that are highly protein bound and 
with a narrow therapeutic index, for which even small increases in drug serum concentrations may 
be associated with severe drug toxicity (e.g. warfarin and aspirin interaction) (Delafuente 2003). 
For drugs that do not have significant toxicity associated with small increases in drug serum 
concentrations, DDIs involving protein binding inhibition mechanisms are less important. Although 
competitive inhibition will increase the free fraction of the drug, the serum concentration may not 
become toxic. More importantly, however, as the free fraction increases there is more unbound drug 
available for renal elimination or liver metabolism, keeping serum drug concentrations below a 
toxic level (Delafuente 2003). 
The most clinically important types of pharmacokinetic DDIs are those altering a drug’s 
metabolism. Drugs that are substrates, inhibitors, or inducers of CYP isoenzymes may inhibit or 
induce the pharmacokinetics of other drugs, particularly those that are extensively metabolized by 
the hepatic cytochrome P450 system (Delafuente 2003). With ageing, more common and 
potentially more significant are DDIs that affect renal function due to a decrease in glomerular 
filtration rates (Delafuente 2003). 
2.6.2. Pharmacodynamic interactions 
When pharmacodynamic DDIs occur, two drugs have additive (synergistic) or antagonistic 
pharmacological effects, which may result in increased toxicity or decreased efficacy of the 
involved drugs (Delafuente 2003). When two or more drugs with similar pharmacodynamic effects 
are taken, the additive effects may result in excessive response and toxicity (e.g. combination of 
NSAIDs and corticosteroids) (Seymour and Routledge 1998). Drugs with opposing 
pharmacodynamic effects may reduce the response to one or both drugs (e.g. combination of ChEIs 
and anticholinergic drugs) (Delafuente 2003). 
Pharmacodynamic interactions are common in older people, who are often sensitive to these due to 
reduced homeostatic mechanisms (Seymour and Routledge 1998, Delafuente 2003). The additive 
effects of DDIs may be particularly important when they compromise the already impaired 
physiological functions among older patients. Combinations of drugs causing additive sedative 
effects, anticholinergic effects, and hypotension and use of drugs with a narrow therapeutic index 





Software database systems have been developed and implemented in clinical practice for detection 
and prevention of adverse drug events related to DDIs. A study comparing a summary of DDI 
information with several interaction databases revealed that information is neither complete nor 
consistent among various software database systems (Böttiger et al. 2009). Many programes have 
not been updated with the evolving knowledge of these interactions and do not take into 
consideration important factors needed to optimize drug treatment in older patients (Mallet et al. 
2007). Methods such as computerized physician order entry (CPOE), computerized drug interaction 
software, and computerized decision support systems (CDSS) that detect and alert the physician and 
pharmacist to potentially serious outcomes can decrease the risk of drug errors. Systems that 
proactively screen for interactions at the time of electronic prescribing should be developed to 
prevent adverse drug events related to DDIs (Mallet et al. 2007). 
Databases for DDIs do not usually include information concerning pharmacodynamic interactions 
in older patients.  For example, antipsychotics that block alpha1-adrenergic receptors augment the 
effects of antihypertensives, causing orthostatic hypotension and increasing the risk of falls 
(Delafuente 2003). The load of several sedatives or DAPs may be considered as examples of 
pharmacodynamic interactions that have additive adverse effects among older people. 
 
2.6.3.Prevalence of DDIs according to study populations 
Prevalence rates of DDIs have varied greatly between populations, settings, countries, and methods 
used in studies. The prevalence especially depends on the DDIs included by the researchers. Some 
have included only potentially serious drug interactions (DDDIs) (Hosia-Randell et al. 2008), 
whereas others have included also potentially mild or moderate DDIs (Johnell and Klarin 2007, 
Becker et al. 2008, Teixeira et al. 2012). Potential DDIs should be distinguished from proven DDIs 
(Mallet et al. 2007). 
Prevalence of DDDIs has varied according to the study populations: 5-12%  in nursing home 
settings (Bergman et al. 2007,  Hosia-Randell et al. 2008), 3-16%  in register-based studies (Johnell 
and Klarin 2007, Becker et al. 2008, Nobili et al. 2009), and 3-12% in community settings  




 Table 12. Prevalence of DDIs in older patients in different settings. 
Study Country, study 
population, n 
Age, years Method to detect DDIs Results 
Population based studies 




≥60 Hansten et al1 (USA 2002) 
Any type of DDIs (major, 
moderate, minor)   
25% DDIs (60-79 years) 
36% DDIs (≥80 years) 
Johnell and Klarin 
2007 
Sweden, register study 
(n=630743) 
≥75 FASS2 
Type C: clinically relevant 
DDIs and type D: 
potentially serious DDDIs 
26% DDIs  
5% DDDIs 
Becker et al. 2008 Netherlands, population 
study (n=3728) 
≥70 Royal Dutch Association 
for the Advancement of 
Pharmacy3  
Any DDI or potentially life-
threatening DDDI 
11% DDIs, 2% DDDIs 
(1992) 
19% DDIs, 3% DDDIs 
(2005) 
Nobili et al. 2009 Italy, register study 
(n=58800) 
≥65 Italian drug interaction 
database4 
16% DDDIs 
Secoli et al. 2010 Brazil, community-
dwelling residents 
(n=2143) 
≥60 Micromedex5  
Any DDIs  
27% DDIs 
Home-dwelling older people 
Björkman et al. 2002 Six European countries, 
home-dwelling 
residents (n=1601) 
≥65 FASS2 46% DDIs 
10% DDDIs 
Jokinen et al. 2009 Finland, home care 
residents (n=389) 
≥75 SFINX6 
C-class clinically relevant 
DDI; D-class DDDIs 
72% DDIs 
3% DDDIs 





Any DDI (contraindicated, 





Nursing home residents 
Bergman et al. 2007 Sweden, residents of 
nursing homes (n=7904) 
≥65 FASS1 45% DDIs  
12% DDDIs  
Hosia-Randell et al. 
2008 
Finland, residents of 
nursing homes (n=1987) 
≥65 SFINX6 5% DDDIs 
Liao et al. 2008 Taiwan, residents of 
nursing homes (n=323) 
Mean age 
75 
DDIs Database Information 
System7 
25% DDIs 
Notes: 1 Hansten, Horn: Drugs interactions & Updates, USA 2002; 2 FASS: Drug Interactions developed by Sjöqvist. 
Potential DDIs are categorized A to D (A and B minor, C and D clinically significant; 3 The Royal Dutch Association 
for the Advancement of Pharmacy categorizes both evidence and the potential clinical relevance of DDIs; 4  Italian 
interaction database classifies clinical relevance (severe, moderate, minor) of DDIs;  5Computerized medication 
interaction information system (USA);  SFINX = Swedish, Finnish, Interaction X-referencing database; 7 Database 
Information System constructed by the Department of Health, Executive Yuan, Taiwan. 
 
 
2.6.4.Factors associated with risks of DDIs  
 The number of drugs used (Juurlink et al. 2003, Lindblad et al. 2005, Zhan et al. 2005, Cruciol-




al. 2010, Lin et al. 2011, Teixeira et al. 2012), cardiovascular diseases (Secoli et al. 2010), 
comorbidities (Lindblad et al. 2005, Gagne et al. 2008), and number of prescribers have been 
associated with increased risk of DDIs (Cruciol-Souza and Thomson 2006). There are contradictory 
findings concerning the association of gender (Juurlink et al. 2003, Zhan et al. 2005, Cruciol-Souza 
and Thomson 2006, Johnell and Klarin 2007, Gagne et al. 2008) and age with DDIs (Lindblad et al. 
2005, Malone et al. 2005, Cruciol-Souza and Thomson 2006, Johnell and Klarin 2007, Gagne et al. 
2008, Hosia-Randell et al. 2008, Nobili et al. 2009, Lin et al. 2011).  
Generally, the DDIs leading to hospital admissions occur after administration of drugs with well-
known side effects, e.g. digoxin, warfarin, ACE-inhibitors, and antidiabetic drugs (Juurlink et al. 
2003). The most dependent, institutionalized patients are prone to DDIs due to polypharmacy, 
comorbidities, and physiological changes associated with ageing such as altered pharmacokinetics 
and pharmacodynamics (Liao et al. 2008).  
 
2.6.5.Concomitant use of DAPs and cholinesterase inhibitors (ChEIs) 
 
ChEIs and DAPs are in pharmacological opposition and their concomitant use leads to decreased 
therapeutic effect of both drugs (Sink et al. 2008, Boudreau et al. 2011). DAPs often block 
muscarinic receptors in the brain, resulting in lower acetylcholine levels, whereas ChEIs act to 
increase acetylcholine levels in brain synapses by inhibiting the enzyme acetylcholinesterase, which 
breaks down acetylcholine in the synaptic clefts (Defilippi and Crismon 2003). Thus, concomitant 
use of DAPs may reduce the therapeutic effect of ChEIs (Modi et al. 2009, Palmer et al. 2015).   
Dementia patients treated with ChEIs have an increased risk of subsequently being treated with 
DAPs (Roe et al. 2002, Carnahan et al. 2004, Gill 2005, Johnell and Fastbom 2008, Modi et al. 
2009, Palmer et al. 2015), especially to manage e.g. urinary incontinence (Sink et al. 2008). Urinary 
antispasmodics, antidepressants, antihistamines, and antipsychotics are among the DAPs 
administered most often concomitantly with ChEIs (Roe et al. 2002, Gill et al. 2005, Johnell and 
Fastbom 2008).  Concomitant use of DAPs and ChEIs is often seen in older people in institutional 
settings, where dementia and multiple medical conditions are common (Sink et al. 2008, Modi et al. 
2009). Concomitant use of DAPs and ChEIs has not been associated with a higher risk of nursing 
home placement or death (Boudreau et al. 2011).   
Administration of multiple DAP is common among patients concomitantly receiving ChEIs and 
DAPs (Roe et al. 2002). The prevalence of concomitant use of DAPs and ChEIs has varied from 
 11% to - 47% in nursing home settings and depends on the DAP criteria used and prevalence of 
ChEIs (Table 13). 
Table 13. Epidemiology of concomitant use of DAPs and ChEIs in nursing home populations 





%), age  
Concomitant use 
of DAPs and 
ChEIs (n, %) 
DAPs 
examined 
Factors associated with 
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25% of residents 
used 
concomitantly 
DAPs and ChEIs 
 
ACBS Aggressive behaviour, male 
gender, lower age, and lower 
cognitive impairment  
1Carnahan et al. 2006; 2Anticholinergic Cognitive Burden Scale (Boustani et al. 2008) 
 
2.7.Summary of the literature 
Older people in institutional settings are at special risk for ADRs due to changes in 
pharmacokinetics and pharmacodynamics, comorbidities, polypharmacy, and frequent use of PIDs 
(Jyrkkä et al. 2006, Hosia-Randell et al. 2008).  Long-term use of PPIs is very common among the 
elderly in institutional settings (de Souto Barreto et al. 2013, Vetrano et al. 2013).   
Although PPIs have been shown to be generally safe, their long-term use may be associated with 
adverse events such as gastrointestinal infections (Dial et al. 2005),  -pneumonia (Laheij et al. 
2004), malabsorption of calcium and vitamin B12 (Arkkila 2015), and increased risk of fractures 
(Yang et al. 2006).  Use of PPIs may be associated with adverse side effects such as diarrhoea, 




with PPIs may be due to Clostridium difficile infections or bacterial overgrowth both associated 
with complications (Yearsley et al. 2006, Arkkila 2015).  Previous studies have shown 
contradictory results regarding the association between long-term use of PPIs and mortality, with 
pre-existing illnesses, disabilities, and comorbidities considered as possible predisposing factors 
(Bateman et al. 2003, Maggio et al. 2013a).  There are only three studies exploring the association 
between the use of PPIs and mortality (Bateman et al. 2003, Wilson et al. 2011, Maggio et al. 
2013a).   
Use of DAPs is common among older people in institutional settings (Bergman et al. 2007, 
Kumpula et al. 2011), especially to treat clinical conditions related to dementia (Kolanowski et al. 
2009). Use of DAPs is associated with side-effects possibly affecting cognition, functional 
activities, and quality of life (Ancelin et al. 2006, Landi et al. 2007, Kolanowski et al. 2009). 
However, there are no previous studies exploring the association of use of DAPs with psychological 
well-being. 
A few studies have shown that the concomitant use of ChEIs and DAPs is common among older 
residents in institutional settings (Sink et al. 2008, Modi et al. 2009). The therapeutic efficacy of 
ChEIs may be diminished with concomitant use of DAPs (Modi et al 2009, Palmer et al. 2015).  
The concomitant use of these drugs may be associated with reduced functional abilities, decline in 
cognitive function, behavioural symptoms, and comorbidities (Sink et al. 2008, Modi et al. 2009, 
Palmer et al. 2015). 
Older people are susceptible to adverse events related to DDIs (Mallet et al. 2007).  Factors 
associated with increased risk for DDDIs include polypharmacy and comorbidities (Mallet et al. 
2007). The recognition and management of DDDIs may be challenging among older people due to 
pre-existing vague symptoms that can mask the DDDIs (Seymour and Routledge 1998). The 
prevalence of DDIs is not well documented (Mallet et al. 2007). Examples of drugs leading to DDIs 
are digoxin, warfarin, carbamazepine, and potassium-sparing diuretics (Juurlink et al. 2003, Hosia-
Randell et al. 2008). Institutionalized older people are commonly prescribed a high number of drugs 
due to chronic diseases, and they present altered physiology due to ageing, and thus, are highly 
vulnerable to DDIs (Delafuente 2003).  
 3. Aims of the study 
 
The general aim of this study was to investigate the prevalence and potential risks associated with 
PPIs, DAPs, and DDDIs among older people in institutional settings. Specific aims were as follows: 
1. to assess the prevalence of PPIs and to identify their associated factors and risks among 
nursing home residents (Studies 1 and 2) 
2. to explore the risk of death associated with use of PPIs in three institutionalized populations. 
(Study 2) 
3. to  assess the prevalence of the use of DAPs and their association with psychological well-
being (Study 3) 
4. to determine the concomitant use of DAPs and ChEIs in assisted living facilities (Study 3) 
5. to assess potentially severe DDDIs and risks for mortality among residents in assisted living 







4.  Materials and methods 
4.1.  Study samples 
The data for this study were gathered among institutionalized older people who are known to be 
prone to polypharmacy and adverse drug events. Participants were all living in places where their 
daily needs for help could be fulfilled – in assisted living facilities, nursing homes, acute geriatric 
wards, and long-term hospital wards. The study samples are shown in Figures 1, 2, and 3. 
Study 1 comprised cross-sectional data collected during February 2003 from all nursing homes in 
Helsinki, Finland as part of a nutritional care study project (Muurinen et al. 2003). There were in 
total 2424 residents (1088 residents from 4 public nursing homes and 1336 residents from 16 
private nursing homes). Inclusion criteria for the study were long-term residency, accessibility of 
information concerning demographic factors, medication data available, willingness to participate, 
and age ≥ 65 years. Of all residents, 1987 (response rate 82.0%) were eligible for the study.  
The samples for Study 2 were obtained from three previous studies. The first cohort was a cross-
sectional sample collected in March 2007 as part of a larger project investigating nutritional care in 
assisted living facilities in the cities of Helsinki (n=36) and Espoo (n=33), Finland (Jekkonen et al. 
2007). There were in all 2188 residents, and 1389 (response rate 63.5%) participated. The inclusion 
criteria for the study were long-term residency, accessibility of information concerning 
demographic factors, medication data available, willingness to participate, and age ≥ 65 years 
(Study 2, first cohort). The second cohort of Study 2 included 1444 residents from long-term care 
hospital wards in Helsinki (n=53), Finland, in September 2003, as part of a project investigating 
their nutritional care (Soini et al. 2004). The inclusion criteria for the study were accessibility of 
information concerning demographic factors, medication, mortality, and readiness to participate. Of 
these residents, 1004 were eligible for the study after exclusion of 357 refusals, 35 residents with 
incomplete medication data, and 48 residents without follow-up mortality data (response rate 
69.5%). The third cohort of Study 2 included 425 consecutive patients in acute geriatric wards 
(n=230, Kivelä and Laakso Hospitals in Helsinki) and residents in nursing homes (n=195) in 
Helsinki, Finland, during 1999-2000, primarily assessed for delirium (Pitkälä et al. 2005). The 
exclusion criteria for the study were age ≤70 years and coma. 
 
  
Figure 1. Flow chart of Study 1.  
  





Figure 3. Flow chart of Studies 3 and 4. 
 
In Studies 3 and 4, the data were gathered for all residents in Helsinki and Espoo assisted living 
facilities in 2007. Of the 2188 residents in these facilities, 713 were excluded (608 due to refusal, 
105 due to temporary respite care), leaving 1475 residents (Study 3). In Study 4, 148 participants 
were further excluded due to insufficient availability of medication or mortality data, leaving 1327 
residents eligible for the study. 
4.2. Methods 
4.2.1.Background data 
All data were gathered by trained nursing home staff by using structured questionnaires (Appendix 
1), except in Study 2 (third cohort), in which the information in acute geriatric wards was gathered 
by two geriatricians.  
All demographic data (including age, gender, marital status, education, and place of residence) were 
retrieved from medical records. In addition, education and current medical diagnoses were gathered 
from residents’ medical charts. CCI was computed as described elsewhere.  Briefly, the CCI was 
constructed to predict a one-year mortality for a patient who may have a range of comorbid 
conditions, such as heart disease, dementia, or cancer (a total of 22 conditions). Each condition is 
 assigned a score of 1, 2, 3, or 6, depending on the risk of dying associated with each one. For 
example, stroke and cancer give 2 points, whereas dementia and myocardial infarction give one 
point. The scores are summed to provide a total score. CCI was used to evaluate burden of 
comorbidities (Charlson et al. 1987). 
Mini-Nutritional Assessment (MNA) was used to evaluate residents’ nutritional status (Guigoz et 
al. 2002) in Studies 1, 2 and 4. The MNA scores (range 0 to 30) distinguish older people as 
malnourished (less than 17 points), at risk for malnutrition (17-23.5 points) or as well-nourished 
(>23.5 points). Some MNA items were used to evaluate, for example, residents’ mobility status 
(bed- or chair-bound / able to get out of bed but does not go out / goes out) or fluid intake (less than 
3 cups per day/ 3 to 5 cups per day/ more than 5 cups per day). Their weight and height were 
measured, and body mass index was calculated accordingly (weight in kg/height in m2; kg/m2). If 
the resident was unable to stand, the height was evaluated from knee height (Soini et al. 2004) 
(Appendix 1). 
Memory problems and dependence in activities of daily living (ADL) were assessed by items from 
the Clinical Dementia Rating Scale (CDR) (Hughes et al. 1982) in Studies III and IV. CDR 
“memory class” 1 or higher was used as a cut-off point for significant memory problems (0=No 
memory loss or slight inconsistent forgetfulness/ 0.5= Consistent slight forgetfulness; partial 
recollection of events; "benign" forgetfulness/ 1=Moderate memory loss; more marked for recent 
events; defect interferes with everyday activities/ 2= Severe memory loss; only highly learned 
material retained; new material rapidly lost/ 3= Severe memory loss; only fragments remain). CDR 
“personal care” higher than 1 was used as a cut-off point to define significant need for help in ADL 
(0-0.5= Fully capable of self-care/ 1= Needs prompting/ 2= Requires assistance in dressing, 
hygiene, keeping of personal effects/ 3= Requires much help with personal care; frequent 
incontinence) (Appendix 2). 
Some gastrointestinal symptoms were retrieved from the study questionnaire in Study 2. The 
questionnaire item was “Does the resident have the following symptoms: constipation (yes/no), 
diarrhoea (yes/no), vomiting (yes/no). Furthermore, celiac disease (yes/no) and lactose intolerance 
(yes/no) were inquired about in the questionnaire (Study 2). The presence of delirium was 
determined according to the operationalized DSM-IV criteria (Study 2, third cohort) (Appendix 3). 
The Psychological Well-Being Scale was used to assess the well-being of residents (Studies 3 and 
4) (Routasalo et al.2009). This scale shows good test-retest reliability (Routasalo et al.2009), 
statistically significant prognostic validity (Pitkälä et al. 2004), and good validity for areas relevant 
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in psychological well-being (WHO 2003).  This scale comprises dimensions important in older 
people’s psychological, emotional, and social well-being (WHO 2004). 
 
The Psychological Well-Being Scale is constructed according to responses to six questions. These 
six questions show good test-retest reliability and prognostic validity concerning mortality. These 
questions inquire about life satisfaction (yes/no), feeling needed (yes/no), having plans for the 
future (yes/no), having zest for life (yes/no), feeling depressed (seldom or never/sometimes/ often 
or always), and suffering from loneliness (seldom or never/sometimes/often or always). Responses 
“no” in questions 1-4 and “often or always” in question 5 or 6 yield 0 point. Responses 
“sometimes” in question 5 or 6 yield 0.5 point. Responses “yes” in questions 1-4 and “seldom or 
never” in question 5 or 6 yield 1 point. The Psychological Well-Being Score is then calculated by 
dividing the sum total of points by the number of questions that the participant has answered. A 
score of 1 represents the best and 0 the poorest well-being (Routasalo 2009). Participants were 
invited to evaluate their self-rated health (Study 3), which was categorized as good (healthy/quite 
healthy) or poor (quite unhealthy/unhealthy). 
4.2.2.Medication use 
In all samples, drug use was retrieved from medical records and assessed as the point prevalence on 
the day of assessment. Only drugs and vitamins administered on a regular basis were taken into 
account. Participants were classified as regular users if their medical charts indicated a regular 
sequence of dosage. All drugs were categorized according to the Anatomical Therapeutic Chemical 
classification system (World Health Organization 2010). The total number of regularly used drugs 
was calculated for each resident.  
Proton-pump inhibitors 
This study investigated the use of the following proton-pump inhibitors (PPIs; ATC codes A02BC): 
omeprazole, pantoprazole, esomeprazole, lansoprazole (Studies 1 and 2) and rabeprazole (Study 2).   
To assess the potential indications of PPIs, such as gastro-intestinal (GI) protection for non-
steroidal anti-inflammatory drugs (NSAIDs), drugs causing potential GI-bleeding were also 
categorized. The NSAIDs included all drugs with the ATC code B01AC06 (acetylsalicylic acid, 
including low-dose acetylsalicylic acid  ≤250 mg), and drugs with the ATC code M01A (anti-
inflammatory and antirheumatic drugs), excluding coxibs M01AH (diclofenac, etodolac, ibuprofen, 
indomethacin, ketoprofen, mefenamic acid, nabumetone, naproxen, piroxicam, tolfenamic acid). 
 Only oral formulations of NSAIDs were included in the analyses. Furthermore, use of selective 
serotonin reuptake inhibitors (ATC code N06AB: citalopram, escitalopram, fluoxetine, 
fluvoxamine, paroxetine, sertraline) was assessed for the same reason.  
Furthermore, in Study 1, drugs associated with possible GI side effects, thus confounding the 
adverse effects of PPIs, were also assessed. These drugs included laxatives (bulk laxative ATC code 
A06AC, osmotic agents A06AD, stimulant laxatives A06AB, neuromuscular agents such as 
cisapride, metoclopramide, carbamylcholine, pyridostigmine, distigmine), cholinesterase inhibitors 
(ChEIs; ATC code N06DA), and constipation-inducing-drugs such as iron supplements (ATC code 
B03A), antibiotics (ATC code J01), and metformin (ATC code A10BA02).  
Calcium (ATC code A12A) and vitamin D (ATC code A11CC) were also categorized. In previous 
reports, PPIs were suggested to have an effect on the absorption of calcium and associated with hip 
fractures.  
Drugs with anticholinergic properties (DAPs) 
In Study 3, DAPs were categorized according to the anticholinergic risk scale (Rudolph et al. 2008) 
(Table 14). The Rudolph scale includes commonly used DAPs and classifies them according to 
their potential anticholinergic effects. The drugs having high potential anticholinergic effects 
receive three points, whereas those with moderate anticholinergic effects receive two points and 
those with mild effects one point. The list in its current form accurately identifies the ADRs of these 
drugs with respect to their anticholinergic adverse effects. The Rudolph scale is simple and easy to 
use and allows international comparisons (Rudolph et al. 2008, Salahudeen et al. 2015b). According 
to the original study, higher ARS scores were associated with higher risk of anticholinergic side 
effects (Rudolph et al. 2008).  
Because DAPs may counteract the effects of ChEIs, the cholinesterase inhibitors (donepezil, 
galantamine, rivastigmine; ATC code N06DA) were categorized in the data.  
Drug-drug interactions (DDIs) 
The Swedish, Finnish, Interaction X-referencing database (SFINX), a computerized database 
system (Böttiger et al. 2009), was used to assess severe, D-class drug-drug interactions (DDDIs) 
(Study 4).  
SFINX is a commercial medical DDI database introduced in Finland in 2005 (SFINX 2015). It is 
updated four times a year by Medbase Ltd. in Turku, Finland, the Karolinska Institute Department 
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of Clinical Pharmacology in Stockholm, Sweden and the Stockholm County Council in Stockholm, 
Sweden. Interactions are classified according to their clinical significance (A-D) and documentation 
level (0-4), where A indicates a clinically insignificant interaction and D a clinically significant 
interaction that should be avoided. This study investigates the prevalence of DDDIs among older 
people in residential care facilities in Helsinki and Espoo, Finland (Study 4). 
Table 14. Drugs available in Finland at the time of Study 3 and included in the Anticholinergic Risk 
Scale (Rudolph et al. 2008). 3 points = drugs with high anticholinergic properties, 2 points = drugs 
with moderate anticholinergic properties, 1 point = drugs with low anticholinergic properties. 
3 Points 2 Points  1 Point 
 
Amitriptyline hydrochloride Amantadine hydrochloride Carbidopa-levodopa 
Atropine products Baclofen Entacapone 
Carisoprodol Cetirizine hydrochloride Haloperidol 
Chlorpromazine hydrochloride Clozapine Metoclopramide hydrochloride 
Diphenhydramine 
hydrochloride 
Loperamide hydrochloride Mirtazapine 
Fluphenazine hydrochloride Loratadine Paroxetine hydrochloride 
Hydroxyzine hydrochloride 
and hydroxyzine pamoate 
Nortriptyline hydrochloride Pramipexole dihydrochloride 
Hyoscyamine products Olanzapine Quetiapine fumarate 
Oxybutynin chloride Prochlorperazine maleate Ranitidine hydrochloride 
Perphenazine Tolterodine tartrate Risperidone 
Thioridazine hydrochloride  Selegiline hydrochloride 




Mortality data were obtained from national registers (Studies 2 and 4).  Mortality rates were 
followed for one year in Study 2 and for three years in Study 4.   
 
4.3. Ethical considerations 
All study procedures were planned in accordance with the Helsinki declaration. All studies were 
approved by the Helsinki University Central Hospital Ethics Committee. Informed consent was 




 4.4. Statistical analyses 
The data were coded with either Microsoft ACCESS or Microsoft Excel programs and analyzed 
with the NCSS (Number Cruncher Statistical System) and SPSS 12.0.1. (SPSS Inc., Chicago, IL, 
USA) software programs.  
In all studies, the participants were divided for the analyses according to the use of potentially 
harmful medications (PPIs, DAPs, DDDIs), and users and non-users of the index drugs were 
compared. In Study 1, the participants were also dichotomized into groups having or not having 
diarrhoea, and these two groups were compared. In Study 3, the participants were also divided into 
four groups for the analyses: those using only DAPs, those using DAPs and ChEIs concomitantly, 
those using only ChEIs, and those using none of these. At baseline the groups were compared for 
categorical variables using ?2 tests or Fisher’s exact test. Differences between non-normally 
distributed continuous variables were assessed using Mann-Whitney U-tests when comparing two 
groups and Kruskall-Wallis test when comparing four groups.  
Logistic regression models were used to evaluate the association of the variables (PPIs, DAPs, 
ChEIs) with outcomes (diarrhoea, psychological well-being). In Study 2, the analysis was adjusted 
for age, gender, fluid intake, comorbidities, lactose intolerance, celiac disease, chronic 
inflammatory bowel disease, constipation, use of laxatives, calcium supplements, and SSRIs, when 
assessing the association of PPIs with diarrhoea. In Study 3, the analysis was adjusted for age, 
gender, educational level, comorbidities, Parkinson disease, psychiatric disorder, and use of ChEIs, 
when assessing the association of DAPs with PWB.  
Cox regression analysis was used to explore the prognostic value of PPI use and DDIs for mortality 
in Studies 2 and 4, respectively. The covariates were age, gender, CCI, and use of SSRI and/or 
Aspirin. Cohorts 1 and 2 were further adjusted for malnutrition and cohort III for delirium. Kaplan-
Meier curves were constructed and log-rank tests were performed. 




5.1.Characteristics of samples 
There were four large samples of institutionalized frail older people in these studies. The sample 
sizes ranged from 425 to 1987. The mean ages ranged from 81 to 86, and females comprised the 
majority of participants in all samples. Dementia was common in all samples (range 59% to 74%). 
In assisted living facilities, about 15% of participants were immobile, whereas in the nursing home 
sample about 30% were unable to move independently, and the respective figure in the long-term 
care wards was 86% (Table 15). 
Table 15. Characteristics of participants in study samples.  
 

















Helsinki / Espoo assisted living 
facilities in 2007 
Study 1 2 2 2 3 4 
No. of participants 1987 425 1004 1389 1475 1327 
Mean age, range 84 
 (65 to 105) 
86 
(69 to 104) 
81 
(23 to 104) 
         83 
(55 to 99) 
83 
(55 to 99) 
83 
(55 to 99) 
Females, % (n) 80.7 (1603) 81.6 (347) 75.2 (755) 78.2 (1086) 77.7 (1146) 78.3 (1039) 
Unable to move 
independently, % (n) 
30.3 (602) n.a. 85.9 (862) 14.6 (202) 14.6 (215)  15.0 (199) 
MNA<17points, % (n) 28.4 (565) n.a. 60.0 (602) 13.2 (183) 13.4 (197) 12.7 (169) 
Dementia, % (n) 69.5 (1380) 60.0 (255) 74.3 (746) 59.0 (819) 58.9 (869) 58.9 (781) 
Charlson Comorbidity Index, 
mean, range 
2.1 ( 0 to 8) 2.2 (0 to 7) 2.5 (0 to 9) 2.9 (0 to 8) 2.9 (0 to 8) 2.9 (0 to 8) 
Drugs, mean (range) 
Polypharmacy: 
Patients with 6-9 drugs, % (n) 
Patients with >10 drugs, % (n) 




















8.0 (0 to 21) 
 
49.7 (659) 
33.5 (445)  
 Malnutrition was also common. In assisted living facilities, 13% of residents were malnourished, in 
nursing homes 28%, and in long-term care wards 60%, predisposing them to adverse effects of 
drugs.   Participants suffered from a high number of comorbidities (CCI range 2.1 to 2.9), which 
corresponds to a moderate risk for one-year mortality. Participants were also administered a high 
number of drugs, mean range from 7.1 to 8.4. Of residents, 79-88% had polypharmacy and 24-37% 
excessive polypharmacy.  
5.2.    Proton-pump inhibitors 
5.2.1.Adverse effects associated with PPI use 
In Study 1, the participants were old (mean age 84 years), mostly female (81%), and frail. Of 
participants, 30% were unable to move independently. One in three had suffered from a prior stroke 
(30%), and coronary heart disease was also common in this sample (38%).  
Of assessed residents in study 1 (N=1987), one in five (21.8%) were treated with regular PPIs. No 
differences existed in age, gender, or nutritional status between users and non-users of PPIs. The 
factors associated with PPI regular treatment were poorer functional status (inability to move 
independently) (35.5% vs. 28.9%, p=0.009), higher CCI score [2.3 (1.3) vs. 2.1 (1.2), p<0.001], and 
higher number of medications [10.5 (3.4) vs. 7.2 (3.2), p<0.001]. Use of calcium supplements 
(40.1% vs. 24.9%, p<0.001), vitamin D supplements (37.7% vs. 29.5%, p=0.001), and SSRIs 
(32.8% vs. 24.9%, p=0.001) was also associated with regular PPI treatment. Other factors 
associated with regular PPI use were prior ventricular or duodenal ulcer (15% vs. 3.1%, p<0.001), 
cancer (15.1% vs. 10.3%, p=0.008), coronary heart disease (47.4% vs. 34.9%, p<0.001) and lactose 
intolerance (15.1% vs. 7.8%, p<0.001). PPI users suffered less often from dementia (56.8% vs. 
73%, p=0.001). 
PPI use was associated with diarrhoea (19.7% vs. 12.9%, p<0.001) and frequent vomiting (8.2% vs. 
3.7%, p<0.001). PPI users had more often a prior history of hip fracture (28.5% vs. 19.4%, 
p<0.001) than those without PPI. No significant association was present between low-dose aspirin 
or NSAID administration and regular PPI treatment.  
Among PPI users, those suffering from diarrhoea were older [84.9 years (7.2) vs. 83.5 years (7.7), 
p=0.003], had more comorbidities (2.3 (1.2) vs. 2.1 (1.2), p=0.001], were administered a higher 
number of medications [8.6 (3.6) vs. 7.8 (3.5), p<0.001], and suffered more often from frequent 
vomiting (9.2% vs. 3.7%, p<0.001). Diabetes (21.7% vs. 16.6%, p=0.047), celiac disease (1.5% vs. 
0.3%, p=0.009), lactose intolerance (28.1% vs. 6.4%, p<0.001), prior ventricular or duodenal ulcer 
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(9.0% vs. 4.8%, p=0.007), and coronary heart disease (44.3% vs. 36.1%, p=0.0013) were also 
associated with diarrhoea. Residents suffering from diarrhoea used less often laxatives (46.2% vs. 
56.6%, p=0.001), but were administered more often SSRIs (31.8% vs. 25.9%, p=0.041) than their 
peers without diarrhoea. 
In logistic regression analysis, PPI use showed an independent association with diarrhoea (OR 1.60, 
95% CI 1.20-2.15; p=0.002) even after adjustment for age, gender, fluid intake, CCI, lactose 
intolerance, celiac diasease, chronic inflammatory bowel disease, constipation, use of laxatives, 
calcium supplements, and SSRIs. Other factors associated with diarrhoea were CCI (OR 1.16, 95% 
CI 1.05-1.28; p=0.005) and age (OR 1.02, 95% CI 1.00-1.04; p=0.008).  
5.2.2.PPI use and mortality 
Study 2 contained three cohorts. Of the residents in assisted living facilities (n=1389; the first 
cohort of Study 2), 25% suffered from prior stroke and 13 % had prior myocardial infarction. Of 
residents, 22% were treated regularly with SSRIs, 45% with low-dose Aspirin, and 3% with 
NSAIDs. In addition, 26% were using PPIs.  
Among residents in assisted living, no association existed between 12-month all-cause mortality 
and use of PPIs (20.2% vs. 20.4%, p=0.94).  There was no increased risk of death associated with 
the use of PPIs (HR 1.06; 95% CI 0.77–1.46) in the Cox proportional hazards model adjusted for 
age, gender, CCI, immobility, and use of SSRIs. A positive association emerged between age (83.6 
vs. 82.4, p=0.011), mean number of drugs (8.8 vs. 7.6, p<0.001), use of SSRIs (27.5% vs. 20.6%, 
p=0.007), and immobility (18.0% vs. 13.3%, p=0.030) and use of PPIs. There were no associations 
with use of PPIs and comorbidities or the use of NSAIDs or Aspirin.  
Of residents in long-term care hospital units (n= 1004; the second cohort of Study 2), 38% had had 
a previous stroke, 36% were treated with low-dose Aspirin, 28% were treated with regular SSRIs 
and 3% with regular NSAIDs Of this sample, 23% were administered PPIs. 
In long-term care hospital patients (n = 1004), mortality was higher among PPI-users than non-
users (33.3% vs. 26.6%, p=0.048).  In the Cox proportional hazard model adjusted for age, sex, 
CCI, use of SSRIs, and malnutrition, there was an increased  risk of mortality associated with the 
use of PPIs (HR 1.36; 95% CI 1.04-1.77). PPI-users had a higher mean number of drugs than non-
users (9.3 vs. 6.4, p<0.001), higher use of SSRIs (38.1% vs. 24.7%, p<0.001), and higher level of 
comorbidity evaluated with CCI (2.7 vs. 2.5, p=0.042). PPI-users were diagnosed less with 
dementia (63.1% vs. 80.0 %, p<0.001). PPI users presented more often a previous history of 
 myocardial infarction (16.8% vs. 9.8%, p=0.010) and duodenal/ventricular ulcer (12.6% vs. 2.2%, 
p<0.001). No difference existed between users and non-users of PPIs concerning immobility, 
previous stroke, or use of NSAIDs or low-dose Aspirin.  
Of participants in acute geriatric hospitals and nursing homes (n = 425; the third cohort of Study 2), 
25% suffered from acute delirium. Of the sample, 25% had suffered from previous stroke and 76% 
were dependent in their ADL according to CDR. In this sample, 48% received regular low-dose 
Aspirin, 8% regular NSAIDs, and 27% regular SSRIs. Of the whole sample, 21% were on PPIs. Of 
participants using comcomitantly low-dose Aspirin or NSAID with SSRI (n=67, 15.8%), only six 
(9.0%) were on PPIs. 
In patients in acute geriatric hospitals and nursing homes (n = 425), mortality was higher among 
users than non-users of PPIs (36.3% vs. 21.9%, p=0.005). In the Cox proportional hazard model 
adjusted for age, gender, CCI, delirium, and use of Aspirin and SSRIs, there was an increased risk 
of mortality associated with the use of PPIs  (HR 1.90; 95% CI, 1.23-2.94). Users of PPIs had a 
higher level of comorbidity (2.5 vs. 2.1, p=0.046), were administered a higher number of drugs 
[10.7 vs. 7.8, p<0.001] and were less dependent in ADL activities (62.6% vs. 79.6%, p<0.001) than 
non-users. Compared with non-users, PPI-users were also found to use less Aspirin (34.1% vs. 
52.4%, p=0.002) and SSRIs (15.4% vs. 29.9%, p=0.005), to suffer less from dementia (46.2% vs. 
63.8%, p=0.002), and to present more often with previous history of duodenal/ventricular ulcer 
(11.0% vs. 2.4%, p<0.001). No difference emerged in age, gender, or use of NSAIDs among users 
and non-users of PPIs.  
5.3.Use of DAPs and ChEIs  
Among the participants assessed in assisted living facilities in Study 3 (n=1475), 26% suffered from 
previous stroke, 21% from depression, 10% from other psychiatric disorders, and 5% from 
Parkinson´s disease. Of residents, 81% were dependent in ADL according to CDR “personal care”. 
Of the sample, 59% had a diagnosis of dementia and 52% scored one or more in the CDR 
“memory” item, indicating moderate or severe dementia (Hugher et al. 1982). In this sample, 42% 
were administered DAPs according to the ARS (Rudolph et al. 2008). 
Among the participants in residential care facilities (n = 1475), 41.6% (n = 613) were users of 
DAPs according to ARS. The most commonly used DAPs, with low to moderate anticholinergic 
activity (1-2 points according to Anticholinergic Risk Scale), were mirtazapine (30.3%), risperidone 
(29.4%), quetiapine (16.2%), levodopa (11.4%,) and olanzapine (9.6%). 
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  The participants were divided according to ChEI and DAP drug treatment into 4 groups: 1) 
residents receiving both ChEIs and DAPs (10.7%), 2) residents receiving ChEIs but not DAPs 
(11.7%), 3) residents receiving DAPs but not ChEIs (30.8%), and 4) residents receiving neither 
ChEIs nor DAPs (46.7%) (see Study 3, Table 4).  
The residents receiving DAPs but not ChEIs were the youngest group (mean age 81.5 years), 
whereas those receiving ChEIs but not DAPs were the oldest group (mean age 84.2 years). The 
ChEI users had a higher educational level, lower stages of cognition according to the CDR memory 
class, and more dependence on ADL according to the CDR personal care class than non-users of 
ChEIs. No significant difference emerged regarding gender distribution or mean CCI among the 
four groups studied.   
The residents administered DAPs were more often administered a higher number of drugs (8.8 (SD 
3.4) vs 7.5 (SD 3.3), p<0.001) and were more often treated with ChEIs or memantine (34.6% vs. 
26.9%, p=0.0016). DAP use was associated significantly with lower psychological well-being  
(0.66 [0.25] vs. 0.69 [0.23], p=0.010). Low PWB (score<0.50) was used as a response variable. In 
logistic regression analysis, use of DAPs was associated with low psychological well-being (OR 
1.40, 95% CI 1.00 to 1.94, p=0.048) even after adjustment for covariates (age, sex, education, CCI, 
psychiatric illnesses, Parkinson`s disease, and use of ChEIs). The effect of anticholinergic burden, 
defined by the anticholinergic risk scale (ARS), on psychological well-being was also examined. 
Proportions of poor psychological well-being among those having scores of 0, 1, 2, or 3 or more 
were 14.2%, 19.2%, 25.0%, and 12.0%, respectively (p=0.030 for trend).  
Users of DAPs presented more disabilities (CDR, personal care >1) (85% vs. 78%, p<0.001) than 
non-users of DAPs. No significant difference was present between use of DAPs and CCI. DAP 
users suffered more often from depression (26.4% vs. 16.4%, p<0.001), psychiatric disorders 
(18.4% vs. 4.8%, p<0.001), and Parkinson’s disease (10.0% vs. 1.3%, p<0.001) than non-users. No 
significant difference between users and non-users of DAPs regarding cognition (CDR, memory 
class > 0.5) was seen (54.6% vs. 50.6%, p=0.12).  
Residents with concomitant use of DAPs and ChEIs suffered more from depression (29.9%), and 
had less frequently a previous history of stroke (17.2%) or coronary disease (22.4%) than the other 
groups. 
 
 5.4.Potentially serious drug-drug interactions (DDDI) 
Of participants assessed in Study 4 (n = 1327), one in five had had a prior stroke, and 18% 
presented with diabetes mellitus. Over half of the residents suffered from significant cognitive 
decline according to CDR scale (memory class >0.5) (55%), and 68% were dependent in ADL 
(CDR personal care >1). Of this sample, 6% were exposed to potentially serious DDIs. 
Of the assessed participants in assisted living and having drug data available (n = 1327), 78 (5.9%) 
were found to have DDDIs according to SFINX, with a total of 86 interactions. Eight residents were 
susceptible to two DDDIs (Table 16). 
Compared with other residents, those exposed to DDDIs had been prescribed a higher number of 
drugs (10.8 (SD 3.8) vs. 7.9 (SD 3.7), p<0.001) and more often had rheumatoid or osteoarthritis 
(24.7% vs. 15.4%, p=0.030). DDDIs were not associated with age, gender, marital status, 
education, common medical conditions, functioning, nutrition, or psychological well-being. A 
larger portion of residents with DDDIs suffered from cardiovascular diseases (37.7% vs. 28%, 
p=0.070). 
The most common DDDIs were related to concomitant use of potassium with either amiloride 
(n=12) or spironolactone (n=12). However, 12 residents concomitantly using potassium and 
potassium-sparing diuretics were also administered furosemide. There were 13 DDDIs related to 
the concomitant use of carbamazepine and risperidone (N=5), felodipine (N=2), cyclosporin (N=1), 
quetiapine (N=1), estriol (N=1), oxycodone (N=1), tolterodine (N=1), or lercanidipine (N=1). There 
were 9 participants concomitantly receiving methotrexate and pantoprazole (N=4), omeprazole 
(N=2), esomeprazole (N=2), or lansoprazole (N=1). However, methotrexate was not administered 
in high dosages, thus, not predisposing these patients to DDDIs.The concomitant use of a calcium-
channel and beta-blockers was observed in 10 residents. Only three DDDI cases presented with 
concomitant use of NSAIDs and warfarin. 
There was no significant difference between three-year all-cause mortality among those with and 




 Table 16. Potentially severe drug interactions in residents of assisted living in Helsinki and Espoo, 
Finland. 
Drug Interacting drug Number of 
residents 
exposed  to 




5 Increased risk of bleedings, if combined 
 

























Loss of therapeutic effect of the interacting drug 





Reduced absorption of the interacting drug 




















Increased risk for methotrexate intoxication with high 
doses of methotrexate 
 
Oxycodone Rifampicin 1 Loss of oxycodone efficacy 
Magnesium Norfloxacin 
 
1 Loss of therapeutic effect of norfloxacin 
Periciazine Levodopa, 
cabergoline 
2 Loss of therapeutic effect of both drug and interacting 
drug 
Amlodipine Rifampicin 1 Loss of amlodipin efficacy 
Fenytoin Tamsulosin 1 Loss of therapeutic effect of the interacting drug 
Tramadol Duloxetine 1 Increased risk for serotonin syndrome 
Felodipine Itraconazole 1 Increased felodipine therapeutic effect 
Timolol Acetazolamide 
 
5 Increased risk for dyspnoea and acidosis in patients with 
pulmonary obstruction or emphysema 




In these studies, 21-26% of residents were administered PPIs on a daily basis. Regular PPI use was 
associated with diarrhoea and prior hip fracture, indicating possible side effects. The use of PPIs 
was not associated with mortality among residents in assisted living facilities. However, their use 
was associated with increased mortality in settings where residents experienced higher levels of 
disability and comorbidities (long-term hospitals, geriatric wards, and nursing homes), indicating 
the higher vulnerability of these individuals to adverse events of PPIs. Of residents in assisted living 
facilities, 10.7% were administered ChEIs and DAPs concomitantly. DAP use was associated with 
use of a higher number of drugs, more severe disability, depression, psychiatric disorders, and 
Parkinson´s disease. DAP use was associated with low psychological well-being even after 
adjustment for age, gender, education, comorbidities, and use of ChEIs. Use of PPIs and DAPs was 
associated with polypharmacy.  
Potentially serious DDIs according to SFINX were observed in 5.9% of residents in assisted living 
facilities. Use of higher number of drugs and rheumatoid/osteoarthritis were associated with 
DDDIs. The most frequent DDDIs were related to the concomitant use of potassium with amiloride 
or spironolactone. Carbamazepine was also associated with more frequent DDDIs. No difference in 
mortality was observed between residents exposed to DDDIs and those not exposed to DDDIs. 
6.1. Methodological considerations 
6.1.1. Study populations 
This study consisted of  a large number (N=4891) of older people in the metropolitan area of 
Finland living in various institutional settings such as assisted living facilities, nursing homes, long-
term care wards and acute geriatric wards. They represent a wide range of frail older people with 
polypharmacy, and a high number of comorbidities and disabilities. Thus, they represent the frailest 
part of the older population prone to adverse events related to drug use. The original studies aimed 
to examine all institutionalized residents and the exclusion criteria were thus kept low. The study 
samples had satisfactory response rates ranging from 63% to 82%. The exclusion criteria were age 
younger than 65 years (Studies 1-4; only cohorts 1 and 2 in Study 2) and 70 years (Study 2, cohort 
3), short-term residency, refusal to participate, insufficient information on drug use or demographic 
data, and coma (Study 2, cohort 3). In Studies 2 and 4, exclusion criteria also concerned patients 
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with insufficient information on social security codes. The only limiting factor was obtaining 
informed consent from all residents  and – in cases of dementia – from their closest proxies. Thus, 
the populations may be considered to represent fairly well their respective background populations.  
The data were collected between the years 1999 and 2007. The population in institutional settings 
has undergone a significant change from those times, since the number of nursing home beds has 
been constantly decreasing in the last decade, whereas the number of beds in assisted living 
facilities has significantly increased (Pitkälä et al. 2015). The institutionalized population in Finland 
is significantly older and more disabled today than ten years ago. In addition, they have a higher 
number of comorbidities and dementia is more prevalent. Furthermore, in assisted living facilities 
polypharmacy has increased between 2007 and 2011 (Pitkälä et al. 2015). However, the population 
in assisted living facilities today resembles that of nursing homes in 2003 (Pitkälä et al. 2015).  
The mean age of patients varied from 81 years (Study 2, long-term care wards) to 86 years (study 2, 
geriatric wards and nursing homes). In European nursing homes, the mean age has ranged from 83 
to 86 years (Kersten et al. 2013b, Onder et al. 2012, Haasum et al. 2012), and in the USA the 
respective figure was 84 years (Palmer et al. 2015). In line with previous studies in institutional 
settings, nearly four of five of the participants were females (Kersten et a. 2013b, Onder et al. 2012, 
Haasum et al. 2012, Palmer et al. 2015). The proportion of malnourished participants varied from 
13% (Study 2, assisted living facilities) to 60% (Study 2, long-term care hospital wards), which is 
similar to previous studies (Guigoz 2006). The CCI varied from 2.1 (Study 1, nursing homes) to 2.9 
(Study 2, assisted living facilities, Studies 3 and 4), which is in line with previous studies from 
institutional settings and indicates a high number of comorbid conditions (Onder et al. 2012). 
Consistent with previous studies, the mean number of drugs ranged from 7.1 (study 2, long-term 
care hospital wards) to 8.4 (study 2, geriatric wards and nursing homes) (Haasum et al. 2012). The 
prevalence of dementia varied from 59% (study 2, assisted living facilities, studies 3 and 4) to 74% 
(study 2, long-term care wards). In an inter-European study, the prevalence of cognitive decline was 
69% (Onder et al. 2012).  
6.1.2. Study design and data collection 
All of the studies here used a cross-sectional design with follow-up of mortality data. The drug use 
and other characteristics were assessed as a point prevalence at baseline. Thus, it is not known how 
the drug use changed during the follow-up period, which is a limitation of the studies. 
 The data were collected by trained registered nurses who knew the residents from their wards well. 
All nurses received at least half a day of training for data collection and assessments. The 
demographic data, current diagnoses, and drug lists were retrieved from medical records, ensuring 
the reliability of data. Thus, data on current drug use were comprehensive.  Mortality data were 
retrieved from central registers, and it was 100% complete among those who had the correct social 
security code.  
Furthermore, the studies used the same questionnaire throughout the years enabling comparisons 
between studies. The questionnaires were embedded with well-validated scales such as MNA 
(Guigoz et al. 2002), CCI (Charlson et al. 1987), CDR (Hughes et al. 1982), and the Psychological 
Well-Being Scale (Routasalo et al. 2009).  
6.1.3. Strengths of the study 
The main strength of this study is the large representative samples of frail older people in 
institutional care with well-characterized cohorts (assisted living facilities, nursing homes, long-
term care hospitals, acute geriatric wards). Clinical data on demographic factors were collected by 
well-trained nurses familiar with the residents, increasing the reliability of the results. Medical 
diagnoses and use of medications were gathered from medical records and mortality data from 
central registers, which are reliable and accurate in Finland. The drugs were classified with ATC 
codes, an international classification system that allows comparisons (World Health Organization 
2015). Structured questionnaires were retrieved from validated measures (CDR, MNA, 
psychological well-being, CCI). To minimize data coding errors, a researcher compared the 
participants´ medication lists in the questionnaire with the electronic version of the list.  
6.1.4. Limitations of the study 
This study had a cross-sectional design. Thus, it is not possible to draw any definite conclusions 
concerning causal relationships or trends between the factors associated with mortality or 
psychological well-being and drug use.  Factors restricting the interpretation of the findings 
included unavailability of prescription sequence, limited number of variables, and limited 
information on specific medical conditions and aetiologies. The original studies did not include 
information on variables such as Clostridium difficile infections, pneumonias, B-12 vitamin 
deficiency, or oesopheageal reflux disease, which would have been important confounders to 
explore in the PPI studies. Diarrhoea was only inquired about with a yes/no question, thus limiting 
the interpretation of the relationship between symptoms and use of PPIs. Similarly, the DAP study 
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did not include variables affecting psychological well-being such as mood, social relationships, or 
social activities. Unfortunately, the typical AEs of DAPs, such as cognitive decline or falls, were 
not assessed in our study. One additional limitation is the possibility of potential confounding 
factors among older people with multiple morbidities. As usually seen in observational studies, the 
associations observed here may have been due to residual confounding. 
Only residents with regular drug administration were considered as drug users. Drugs used on an as 
needed basis were not included here. This may have influenced the results concerning drug 
prevalences, but ensures the reliability of the results. There is no standardized, reliable, and 
practical method to assess anticholinergic burden in clinical practice (Lampela et al. 2013).The 
rating of anticholinergic activity for medicines in various rating scales is inconsistent. The same 
drug is rated with varying degrees for anticholinergic activities according to different lists 
(Salahudeen et al. 2015a). Drug lists vary according to different criteria (Viipuri 2016).  The DAP 
classification used in this study (ARS, Rudolph et al. 2008) may be criticized. There are a number 
of DAP classifications available in the literature (see Table 7). The ARS  includes 49 drugs as 
DAPs, thus representing a medium-sized list. Some of the drugs on the ARS list are not associated 
with central adverse effects, and other drugs on the list do not present potentially anticholinergic 
properties (Rudolph et al. 2008). In Finland, 32 drugs are available according to the ARS list. 
However, the ARS is one of the most used DAP lists, allowing international comparisons. 
It might have been interesting to explore the mortality causes for the samples. However, these data 
were not available.  
One limitation with SFINX is that it only considers interactions between two drugs. Thus, in a 
population prone to polypharmacy, the true prevalence of potentially serious interactions is 
probably much higher than the figures presented here. Furthermore, another limitation of SFINX is 
that it does not usually include information concerning pharmacodynamic interactions in older 
patients.   
  
6.2. Proton-pump inhibitors 
6.2.1. Adverse effects associated with PPI use 
About one-fifth of nursing home residents received PPIs regularly. The prevalence of use of PPIs in 
nursing homes in Helsinki was lower to that reported in many recent studies, in which figures have 
 ranged from 37.2% to 79.7% (de Souto Barreto et al. 2013, Patterson et al. 2013, Vetrano et al. 
2013, Pitkälä et al. 2014).  Thus, the use of PPIs seems to have increased during the past decade. 
This may be due to the guidelines recommending the use of PPIs not only for anti-ulcer treatment 
but also for gastrointestinal protection with concomitant use of NSAIDs or anti-platelet treatment 
(Bhatt et al. 2008).  According to the Fimea and Kela statistics, PPIs as an individual drug class are 
among those drugs with the highest costs to their users and to society (Fimea and Kela 2016). In 
2015, there were 638 943 users receiving financial compensation for PPIs and more than 41 million 
euros were spent on PPIs in Finland. The number of users of PPIs has more than tripled from 2003 
to 2015 (Fimea and Kela 2016) 
Differences in gender or nutrition were not associated with use of PPIs. In line with previous 
studies, PPI use was associated with poorer functional status (Corsonello et al. 2014), increased 
number of comorbidities, higher number of medications, use of calcium supplements, SSRI use, 
and previous history of peptic ulcer or coronary heart disease (de Souto Barreto et al. 2013). 
Consistent with de Souto Barreto´s study, PPI use was lower in residents with dementia.   
In some earlier studies, PPIs were administered to reduce the risk of gastrointestinal bleeding 
related to use of NSAIDs and low-dose Aspirin (de Souto Barreto 2013).  In the present study, users 
of NSAIDs and Aspirin were not more often administered PPIs, except in cohort 3 of Study 2 
(patients in nursing home and acute geriatric wards), in which the users of low-dose Aspirin were 
more often on PPIs. Furthermore, no consistent relationship between use of PPIs and prior ulcer 
diagnoses was seen in residents in assisted living facilities, possibly indicating PPI use without 
clear therapeutic indications. Among SSRI users, the use of PPIs was significantly higher in all 
cohorts. SSRI users are considered to be at risk for GI-bleeding, especially when they 
concomitantly use NSAIDs (Böttiger et al. 2009). 
In this study, use of PPIs was associated with prior hip fracture. Previous studies have reported an 
association between PPI use and increased risk of fractures among older people with risk factors for 
osteoporosis, possibly due to malabsorption of calcium (Masclee et al. 2014, Arkkila 2015).  In the 
present study, PPI users more frequently received calcium and vitamin D supplementation, 
probably for secondary prevention of fractures. 
In multivariate logistic regression analysis, the use of PPIs along with CCI and age were 
independently associated with diarrhoea. About half of PPI users with diarrhoea were administered 
laxatives. This may be inappropriate. However, some of these patients may suffer intermittently 
from constipation and diarrhoea. Diarrhoea was logically associated with lactose intolerance, celiac 
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disease, and use of SSRIs, but not with use of ChEIs. The latter group of drugs is considered to 
have gastrointestinal side effects (Nordberg and Svensson 1998). 
The association between use of PPIs and symptoms of diarrhoea could be attributed to an increased 
risk of Clostridium difficile infection. Long-term acid suppression may cause small bowel bacterial 
overgrowth, which is further enhanced by age, antibiotic exposure, and prior hospitalization as risk 
factors for C. difficile infection (Laheij et al. 2004, Kwok et al. 2012, Masclee et al. 2014, Zarowitz 
et al. 2015). Unfortunately, in this study it was not possible to get information regarding possible 
aetiologies of diarrhoea in the population.  
There are a few studies investigating CDI prevalence in nursing home residents (Simor et al. 2002, 
Laffan et al. 2006, Zarowitz et al. 2015).  Predisposing factors to CDI in this population include,  
underlying diseases, such as diabetes and heart disease, and treatment with PPI, as reported by 
Zarowitz et al. (2015). In line with this study, residents using PPI and suffering from diarrhoea 
suffered more from diabetes and heart disease.  
Residents in institutional care facilities, prone to recurrent episodes of hospitalizations, are often 
prescribed PPIs for routine prophylaxis. Use of PPIs is continued without a specific indication after 
discharge (Amaral et al. 2010). In this population, diarrhoea may reduce the quality of life, 
therefore deserving special attention. The benefits and possible risks associated with long-term PPI 
use in frail older people should be evaluated on a regular basis, avoiding unnecessary long-term 
treatment without clear therapeutic purposes.  
6.2.2.PPI use and mortality 
Use of PPIs was associated with increased mortality in cohorts of frail older people with high levels 
of comorbidities (long-term care hospitals, nursing homes, and acute geriatric wards). Among 
residents with better function in ADL-activities in assisted living facilities, no excess mortality 
associated with PPI use was observed.  
There are few studies investigating the association of PPIs with mortality risk among older people. 
According to an Italian study, use of PPIs in an older population discharged from hospitals was 
associated with increased mortality risk in previously hospitalized older people. Predictive factors 
for mortality were age, hypoalbuminaemia, being dependent in ADL-activities, and comorbidity 
(Maggio et al.2013a). However, in an Australian study, use of PPIs was not associated with 
mortality among residents in intermediate-level residential aged-care facilities (Wilson et al. 2011). 
 There may be several reasons for the association between PPIs and mortality. It might be accounted 
for by confounding by indication. However, the analyses were adjusted for CCI. Previous studies 
have reported an association between use of PPIs, bacterial overgrowth, C. difficile infections 
(Laheij et al. 2004), pneumonia (Yearsley et al. 2006), hip fractures (Yang et al. 2006), 
cardiovascular adverse outcomes (Masclee et al. 2014), and gastrointestinal cancer (Arkkila 2015). 
In line with Wilson and colleagues (2011), in the present study PPI use among residents in assisted 
living was not associated with increased mortality risk. Differences in risk of increased mortality 
among the cohorts could be explained by the residents in assisted living being less frail, presenting 
with better nutritional status, and having less disability than patients in long-term care hospitals, 
nursing homes, or acute geriatric wards, who would be more vulnerable to complications such as 
infections, hip fractures, and strokes. However, the association between PPIs and mortality could be 
due to residual confounding, and further studies are needed to confirm the finding in the frailest 
populations. 
6.3.Concomitant use of ChEIs and DAPs 
In our study sample, DAPs were commonly used among these frail elderly residents in residential 
care facilities; 41.6% of those in this study were receiving these drugs, which falls between the 
figures of 2.5% and 48% reported previously (Johnell and Fastbom 2008, Landi et al. 2014).  The 
prevalence of DAP use has varied widely (Carnahan et al. 2004, Gill et al. 2005, Johnell and 
Fastbom 2008, Sink et al. 2008, Modi et al. 2009, Landi et al. 2014) depending on the patient 
population as well as the definition of  DAPs. In the present study, DAP users suffered more from 
medical conditions requiring DAP treatment (depression, psychiatric disorders, Parkinson’s 
disease). 
Among the residents, 15.7% were administered ChEIs. The ChEI users were more often cognitively 
impaired and disabled, but had better subjective health. In accord with previous studies, there were 
significantly more users of DAPs among the users of ChEIs than among the non-users (Carnahan et 
al. 2004, Gill et al. 2005, Johnell and Fastbom 2008, Sink et al. 2008, Modi et al. 2009). DAPs may 
be used to treat the adverse effects of ChEIs, such as urinary incontinence and gastrointestinal 
problems, resulting in a prescribing cascade in which misattribution of an ADE leads to 
inappropriate use of a second drug. In general, patients with dementia are more prone to receive 
DAPs than patients without dementia. The concurrent use of DAPs and ChEIs is not clinically 
indicated because they antagonize each other and DAPs further impair cognition among patients 
with dementia (Defilippi and Crismon 2003, Johnell and Fastbom 2008).  
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Anticholinergic drugs may impair cognition and also have several other adverse effects in older 
people (Ancelin et al. 2006, Rudolph et al. 2008, Uusvaara et al. 2009). Studies investigating the 
association of use of ChEIs and DAPs with psychological well-being have been scarce.  
In multivariate logistic regression analysis, after adjusting for age, sex, education, CCI, psychiatric 
illnesses, Parkinson’s disease, and use of ChEIs, DAPs was associated with poor psychological 
well-being. Use of DAPs exposes patients to various adverse effects, which may in turn explain the 
poor psychological well-being of their users. DAPs may also be markers of underlying disease (e.g. 
urinary incontinence, depression, Parkinson’s disease), which is the true risk factor for poor 
psychological well-being (Miu et al. 2010).  
In the present study, the effect of anticholinergic burden according to the ARS scale (Rudolph et al. 
2008) was evaluated, and higher burden was associated with lower psychological well-being. 
Although the original Rudolph list includes drugs without significant anticholinergic properties, it 
does not include some common DAPs. Despite the fact that many drugs on the original Rudolph list 
are not available in Finland, the scale is simple, easy to use, and allows international comparisons. 
A limitation of this study is that the burden of various DAPs (dosage or potency) could not be 
measured reliably. Exploring anticholinergic burden is difficult in older people for many reasons 
(e.g. variability in blood-brain barrier and anticholinergic tolerance between patients, unavailability 
of information about anticholinergic burden and SAA of some drugs). In addition, the detailed 
mechanism of DAPs affecting psychological well-being could not be evaluated and adjustment for 
the severity of medical conditions could not be performed, which could be due to residual 
confounding.  
6.4. Drug-drug interactions  
About 6% of residents in assisted living facilities were predisposed to potentially severe drug-drug 
interactions (DDDIs). Those participants vulnerable to DDDIs were treated with a higher number of 
drugs and were more likely to suffer from rheumatoid arthritis or osteoarthritis. There was also a 
trend with respect to cardiovascular diseases. 
Almost half of the DDDIs detected in this study were associated with risk of loss of therapeutic 
effect of the interacting drugs. About one fifth of DDDIs was associated with an increased risk for 
hyperkalemia. One of ten DDDIs was associated with increased risks for cardio-depressive effect. 
The most frequent DDDIs were potassium with potassium-sparing diuretics, carbamazepine with 
various drugs, and calcium-channel blockers with beta-blockers. The DDDI of methotrexate with 
 proton-pump inhibitors cannot be confirmed since the risk of DDDI between these drugs is highest 
among patients receiving methotrexate in high doses for cancer. The indications for methotrexate 
could not be confirmed. The patients in this study were likely to receive methotrexate mostly for 
treatment of auto-immune diseases such as rheumatoid arthritis. DDDIs were not associated with 
risk of higher mortality.  
In addition to polypharmacy, comorbidities and decreased nutritional status may increase the risk 
for DDIs in older people (Mallet et al. 2007). In the present study, with respect to potentially severe 
DDIs (DDDIs), common medical conditions and nutritional status were not associated with 
increased risk for DDDIs.  
In previous studies, the range of DDDIs has varied from 0.7% to 16% between different 
populations, countries, and settings (Johnell and Klarin 2007, Hosia-Randell et al. 2008, Nobili et 
al. 2009, Teixeira et al. 2012). In the present study, the prevalence of DDDIs (5.9%) compared 
quite well with that observed in earlier studies, particularly when the same criteria (SFINX) were 
used (Johnell and Klarin 2007, Hosia-Randell et al. 2008). However, the prevalence rates are not 
directly comparable since SFINX has been regularly updated. 
In this study, dementia was not associated with increased risk for DDDIs, contrary to a previous 
study conducted in nursing homes in Finland (Hosia-Randell et al. 2008).  In line with earlier 
findings, there was an association between a higher number of drugs and an increased risk of 
DDDIs (Bjerrum et al. 2003, Zhan et al. 2005, Cruciol-Souza et al. 2006, Johnell and Klarin 2007, 
Hosia-Randell et al. 2008, Nobili et al. 2009, Secoli et al. 2010, Lin et al. 2011). Only a few 
previous studies have assessed adverse outcomes of DDDIs, and they have suggested an association 
between DDDIs and hospitalizations (Juurlink et al. 2003, Moura et al. 2009). Unfortunately, it was 
not possible to study hospitalizations. However, no difference with respect to DDDIs was observed 
for 1-year or 3-year mortality. 
In line with another Finnish study, the most common DDDIs were related to concomitant use of 
potassium with potassium-sparing diuretics and concomitant use of carbamazepine with other drugs 
(Hosia-Randell et al. 2008).  However, 12 residents concomitantly using potassium and potassium-
sparing diuretics were also administered furosemide, which may lower the risk of hyperkalemia. 
Only three DDDI cases caused by concomitant use of NSAIDs and warfarin were found. 
In a Swedish study investigating older people in six European countries, the most common DDDIs 
were associated with a combination of bromide- and B2-agonists (29% of total DDDIs), potassium 
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and potassium-sparing agents (18% of total DDDIs), and antithrombotic agents combined with 
NSAIDs or acetylsalicylic acid (18% of total DDDIs) (Björkman et al. 2002).  
Although DDDIs are seldom life-threatening, they should be avoided. DDDIs are associated with 
loss of therapeutic effect of the interacting drug, increased risk of hyperkalemia, cardio-depressive 
effects, increased bleeding risk, and as suggested by a few previous studies – risk of hospitalizations 
(Juurlink et al. 2003, Moura et al. 2009).  Physicians in charge of older people`s care in institutional 
settings should place a major emphasis on drug lists and check for possible serious interactions 
using the available databases. Special care should, however, be taken when drugs with narrow 
therapeutic indices are administered (Delafuente 2003). The impaired physiological functions of 
older patients augment additive DDIs (Seymour and Routledge 1998) and it should be borne in 
mind that the altered pharmacokinetics and pharmacodynamics of older people increase risks of 
DDIs (Mallet et al. 2007.  
 
  
 7. Conclusions 
The use of PPIs and DAPs is common among institutionalized residents. Use of PPIs was 
associated with diarrhoea and prior hip fracture in older residents in nursing homes.  PPIs were also 
associated with increased all-cause mortality in older people in long-term care hospitals, acute 
geriatric wards, and nursing homes. In assisted living facilities, PPIs were not associated with 
increased mortality. 
The use of DAPs according to the ARS was very high, with four of ten patients on DAPs. The use 
of DAPs was associated with low psychological well-being. Concomitant use of DAPs and ChEIs 
was common among older adults in assisted living facilities.  
About 6% of older people in residential care facilities were exposed to DDDIs. The exposure was 




8. Implications for future studies 
 
Further investigations are needed to improve the recommendations concerning PPI indications, 
duration, and discontinuation of therapy among frail older people in institutional care settings. 
Prospective intervention trials and larger observational studies should investigate the possible risks 
between PPI use and adverse effects in this population segment.  
Future research should aim to improve knowledge of DAP use among the elderly and clarify these 
risks. Physicians need to consider how DAP use affects the overall risk and well-being of each 
patient. 
Another area requiring research is the clinical applications of computerized database systems for 
DDDIs among older people in institutional care living facilities.   
It is important for clinicians to regularly evaluate the medications of older patients in institutional 
care settings. Clinicians should if possible avoid long-term use of PPIs and DAPs unless their 
benefits clearly exceed their risks. Clinicians should regularly use SFINX-PHARAO databases and 
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 11. Appendices 
Appendix 1. ASUKKAAN RAVITSEMUSTILAN ARVIOINNIN TUTKIMUSLOMAKE 
Kirjaa tiedot asianomaiseen kohtaan tai merkitse rasti 
 
Lomakkeen täyttöpäivämäärä: ____________ 
 
Asukkaan sukunimi, etunimi _________________________________________  
Asukkaan sosiaaliturvatunnus _______________________  
Talon nimi: ____________________________________________________  
Talon tutkimusnumero (ohjeesta): ___________ 
Ryhmäkodin/osaston nimi:________________________________________ 
Ryhmäkodin/osaston tutkimusnumero (ohjeesta):______________ 
Asukas on pitkäaikaisasukas ___ tai arviointi- ja kuntoutusjakson asiakas____ (rasti oikeaan kohtaan) 
Asukas asuu (merkitse rasti) 
□ 1 Yhden hengen huoneessa osastolla/ryhmäkodissa □ 2 Kahden hengen huoneessa osastolla/ryhmäkodissa □ 3 Useamman hengen huoneessa osastolla/ryhmäkodissa □ 4 Yksin erillisessä palvelutaloasunnossa □ 5 Erillisessä palvelutaloasunnossa toisen henkilön kanssa □ 6 Muu asumismuoto tai huonejärjestely, mikä? ___________ 
 
Asukkaan pituus ___________ cm (katso ohje MNA-testin käyttöoppaasta kysymys 6.) 
 
Paino nyt (kk sisällä punnittu) ____________ kg 
Paino keväällä 2011 (noin 6 kk aiemmin) _________ kg Tietoa ei ole____ (laita rasti). 
 
Kauanko hoitojakso on kestänyt tässä ryhmäkodissa/osastolla/palveluasunnossa? 
____vuotta ____ kuukautta ______ päivää 
Seuraavissa kysymyksissä ympyröi yksi vastausvaihtoehdoista ja kirjaa ympyröimäsi numero 
kysymyksen oikealla puolella olevaan ruutuun. 
 
MNA SEULONTA 
1. Onko ravinnonsaanti vähentynyt viimeisen kolmen kuukauden aikana ruokahaluttomuuden, 
ruoansulatusongelmien, puremis- tai nielemisvaikeuksien takia? 
0 =   Kyllä, ravinnonsaanti on vähentynyt huomattavasti 
1 = Kyllä, ravinnonsaanti on vähentynyt hieman 
2 = Ei muutoksia   





2. Painonpudotus kolmen viime kuukauden aikana? 
0 =    Painonpudotus yli 3 kg 
1 = Ei tiedä 
2 = Painonpudotus 1-3 kg 
3 = Ei painonpudotusta   
 
3. Liikkuminen? 
0 =    Vuode- tai pyörätuolipotilas 
1 = Pääsee ylös sängystä, mutta ei käy ulkona 
2 = Liikkuu ulkona  
    
4. Onko viimeisen kolmen kuukauden aikana ollut psyykkistä stressiä tai akuutti sairaus? 
0 =    Kyllä 
1 =    Ei 
 
5. Neuropsykologiset ongelmat? 
0 =    Dementia tai masennus 
1 = Lievä dementia, depressio tai neuropsykologinen ongelma 
2 = Ei ongelmia 
 
6. Painoindeksi eli BMI (=paino / (pituus)2 kg/m2) 
0 =    BMI on alle 19 
1 = BMI on 19 tai yli, mutta alle 21 
2 = BMI on 21 tai yli, mutta alle 23 
3 = BMI on 23 tai enemmän 
 
Pisteet yhteensä (kohdat 1-6)  
MNA ARVIOINTI 
7. Asuuko haastateltava kotona (kaikille vastataan 0 = Ei) 
1 = Kyllä  
0 = Ei 
 
8. Onko päivittäisessä käytössä enemmän kuin 3 reseptilääkettä? 
0 = Kyllä 
1 = Ei 
 
9. Painehaavaumia tai muita haavoja iholla? 
                 0 = Kyllä 
                 1 = Ei 
 
10. Päivittäiset lämpimät ateriat (sisältää puurot ja vellit)? 
0 = 1 ateria 
1 = 2 ateriaa 
2 = 3 ateriaa 
 
11. Sisältääkö ruokavalio vähintään 
Ei  Kyllä 
? Yhden annoksen maitovalmisteita 
(maito, juusto, piimä, viili)                                       ____ __ 
? Kaksi annosta tai enemmän kananmunia 
viikossa (myös ruuissa, esim. laatikot)                     ____ __ 
 ? Lihaa, kalaa tai linnun lihaa joka päivä                      ____       __ 
         0.0 = Jos 0 tai 1 kyllä –vastausta 
 0.5= Jos 2 kyllä -vastausta 
1.0 = Jos 3 kyllä –vastausta 
 
12. Kuuluuko päivittäiseen ruokavalioon kaksi tai useampia annoksia hedelmiä tai kasviksia? 
0 = Ei 
1 = Kyllä 
 
13. Päivittäinen nesteen juonti? 
0 = Alle 3 lasillista 
0.5 = 3-5 lasillista 
1 = Enemmän kuin 5 lasillista 
14. Ruokailu 
0 = Tarvitsee paljon apua tai on syötettävä 
1 = Syö itse, mutta tarvitsee hieman apua 
2 = Syö itse ongelmitta 
 
15. Oma näkemys ravitsemustilasta 
0 = Vaikea virhe- tai aliravitsemus 
1 = Ei tiedä tai lievä virhe- tai aliravitsemus 
2 = Ei ravitsemuksellisia ongelmia 
 
16. Oma näkemys terveydentilasta verrattuna muihin samanikäisiin 
0 = Ei yhtä hyvä 
 0.5 = Ei tiedä 
1 = Yhtä hyvä 
2 = Parempi 
 
17. Olkavarren keskikohdan ympärysmitta (OVY cm) 
0 = OVY on alle 21 cm 
0.5 = OVY on 21-22 cm 
1.0 = OVY on yli 22 cm 
 
18. Pohkeen ympärysmitta (PYM cm) 
1 = PYM on alle 31 cm 
2 = PYM on 31 cm tai enemmän 
 
 
Pisteet yhteensä (kohdat 7-18) 







Kysymyksien vastausvaihtoehdoista ympyröidään sopivin numero (vain yksi) tai kirjoitetaan puuttuva tieto. 
19. Ikä: _______ vuotta 
20. Sukupuoli? 
1 = Nainen 
2 = Mies 
21. Siviilisääty? 
1 = Naimaton 
2 = Leski 
3 = Eronnut 
4 = Avio- tai avoliitossa 
22. Koulutus? 
1 = Kansakoulu tai vähemmän 
2 = Keskikoulu, ammattikoulu, lukio, muu ammattitutkinto 
3 = Korkeakoulu 
 
23. Syökö asukas yleensä pääateriansa yksin 
1 = Ei 
2 = Kyllä 
 
24. Missä asukas syö yleensä pääaterian/pääateriat 
1 = Talon ruokasalissa 
2 = Ryhmäkodin ruokasalissa 
3 = Ruoka viedään palvelutalossa asukkaan kotiin 
4 = Ruoka tulee kotiateriapalvelusta asukkaan kotiin 
5 = Asukas hoitaa itse ateriansa 
6 = Muu, mikä____________________ 
 
25. Asukkaan mahdollisuus valita annoksen koko ja ruokalaji 
1 = Ruoka on valmiiksi annosteltuina asukkaalle 
2 = Asukas voi itse tai avustettuna annostella ruokansa, ei vaihtoehtoja pääruokalajista 
3 = Asukas voi itse tai avustettuna annostella ruokansa, ainakin kaksi vaihtoehtoa 
pääruokalajista 
 
26. Millainen on asukkaan ruoan rakenne? 
1 = Nestemäinen 
2 = Sosemainen 
3 = Pehmeä 
4 = Kiinteä (normaali) 
 
27. Kuinka paljon asukas syö tavallisesti pääaterioilla? 
1 = vähän 
2 = melko vähän 
3 = normaalisti 
4 = melko paljon 
5 = paljon 
 
28. Syökö asukas välipaloja? 
1 = Ei 




 29. Käyttääkö asukas täydennysravintovalmisteita (esim. Nutridrink, Resource)? 
1 = Ei 
2 = Kyllä 
30. Käyttääkö asukas tehostettua ruokavaliota (energia- ja/tai proteiinitiheä ruokavalio)? 
1 = Ei 
2 = Kyllä 
 
31. Käyttääkö asukas kalsiumvalmistetta? 
1 = Ei 
2 = Kyllä 
 
31. Käyttääkö asukas D-vitamiinivalmistetta 
1 = Ei 
2 = Kyllä 
 
32. Seurataanko asukkaan painoa säännöllisesti?  
1 = Ei koskaan 
2 = Kerran vuodessa tai harvemmin 
3 = Kahdesti - kuudesti vuodessa 
4 = Yli kuusi kertaa vuodessa 
 
33. Onko asukkaalla seuraavia ruokailuun ja suuhun sekä ruoansulatuselimistöön liittyviä ongelmia? (voi 
valita useita vaihtoehtoja)  Ei Kyllä 
1 = Puremisongelmia 1 2 
2 = Kuiva suu 1 2 
3 = Kipua suussa 1 2 
4 = Nielemisongelmia 1 2 
5 = Ummetusta 1 2 
6 = Ripulia 1 2 
7 = Oksentelua 1 2 
 8 = Muita ongelmia, mitä _________________ 1 2 
 
34. Mikä on asukkaan hampaiston tila? 
1 = Hampaaton, ei proteesia 
2 = Kokoproteesi sekä ylä- että alaleuassa 
3 = Hampaaton, mutta joko ylä- tai alaleuan kokoproteesi ja/tai muita osaproteeseja 
4 = Omia hampaita ja yksi tai useampia proteeseja 
5 = Vain omia hampaita 
 
35. Peseekö asukas hampaansa/puhdistaa proteesinsa päivittäin (itse tai avustettuna)? 
1 = Ei 
2 = Kyllä 
 
36. Koska hammaslääkäri tai suuhygienisti on tarkastanut asukkaan hampaat/suun viimeksi? 
1 = alle vuosi 
2 = yhdestä kolmeen vuoteen 
3 = yli kolme vuotta sitten 
4 =  
 
37. Onko asukkaalla seuraavia sairauksia tai onko hän sairastanut jonkin niistä aikaisemmin? 
                    Ei  Kyllä 
1 = Diabetes (sokeritauti) 1 2 
2 = Sepelvaltimotauti 1 2 
3 = Sydänveritulppa eli sydäninfarkti 1 2 
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4 = Aivohalvaus tai aivoverenkiertohäiriöitä 1 2 
5 = Dementia 1 2 
6 = Depressio 1 2 
7 = Muu psykiatrinen sairaus 1 2 
8 = Parkinsonin tauti 1 2 
9 = MS, ALS, muu neurologinen sairaus 1 2 
10 =  Nivelkulumat, reuma 1 2 
11 =  Krooninen keuhkoputkentulehdus (COPD), astma tai muu keuhkosairaus 1 2 
12 =  Maha- tai pohjukaissuolen haavauma 1 2 
13 =  Muu krooninen suolistosairaus 1 2 
? Jos on, mikä _________________ 
14 =  Lonkkamurtuma 1 2 
15 =  Syöpä 1 2 
? Jos on, mikä _________________ 
16 =  Pitkäaikainen tulehdus 1 2 
? Jos on, mikä _________________ 
17 =  Jokin muu pitkäaikainen sairaus 1 2 
? Jos on, mikä _________________ 
Kysytään asukkaalta itseltään: 
 
38. Oletteko tyytyväinen elämäänne? 
1. en 
2. kyllä 
3. asukas ei pysty vastaamaan 
 
39. Tunnetteko itsenne tarpeelliseksi? 
1. en  
2. kyllä  
3. asukas ei pysty vastaamaan 
 
40. Onko Teillä tulevaisuudensuunnitelmia? 
1. ei 
2. kyllä 
3. asukas ei pysty vastaamaan 
 
41. Onko Teillä elämänhalua? 
1. ei 
2. kyllä 
3. asukas ei pysty vastaamaan. 
 
42. Oletteko masentunut? (jos asukas ei kykene vastaamaan, hoitajan arvio) 
1 = harvoin tai ei koskaan 
2 = toisinaan 
3 = usein tai aina 
 
43. Kärsittekö yksinäisyydestä? (jos asukas ei kykene vastaamaan, hoitajan arvio) 
1 = harvoin tai ei koskaan 
2 = toisinaan 
3 = usein tai aina 
 
44. Millaiseksi arvioitte oman terveydentilanne tällä hetkellä? 
1 = Pidän itseäni terveenä 
2 = Pidän itseäni melko terveenä  
3 = Pidän itseäni sairaana 




 Hoitajan arvio asukkaan tilanteesta: 
 
45. Millainen on asukkaan muisti (kognitiiviset toiminnat)? 
1 = Ei muistin huonontumista tai pientä muistamattomuutta toisinaan 
2 = Lievää jatkuvaa muistamattomuutta, tapahtumien osittaista muistamista, ”hyvänlaatuista” 
muistamattomuutta 
3 = kohtalaista muistin huonontumista, selvempänä koskien viimeaikaisia tapahtumia, 
vaikuttaa jokapäiväisiin toimintoihin 
4 = Vaikea muistihäiriö, vain hyvin opittu aines säilynyt, uusi aines unohtuu pian 
5 = Vaikea muistihäiriö, vain pirstaleita säilynyt 
 
46. Miten asukas huolehtii päivittäisistä toiminnoistaan (itsestä huolehtiminen) 
1 = Täysin kykenevä huolehtimaan itsestään 
2 = Tarvitsee kehotuksia ja muistutuksia 
3 = Tarvitsee apua pukeutumisessa, henkilökohtaisessa hygieniassa ja henkilökohtaisten 
tavaroidensa hoidossa 
4 = Tarvitsee paljon apua itsestään huolehtimisessa, usein inkontinentti (virtsan tai ulosteen 
pidätyskyvyttömyys) 
 
47. Pystyykö asukas vaivatta liikkumaan sisällä? 
1 = Kyllä  
2 = Ei, hän tarvitsee kepin tai rollaattorin 
3 = Ei, hän tarvitsee toisen henkilön apua 
4 = Ei, hän ei pysty kävelemään 
5 =  
 
48. Pystyykö asukas vaivatta liikkumaan ulkona? 
1 = Kyllä  
2 = Ei, hän tarvitsee kepin tai rollaattorin 
3 = Ei, hän tarvitsee toisen henkilön apua 
4 = Ei, hän ei pysty kävelemään 
 
49. Näkeekö asukas lukea? 
         1 = Ei 
         2 = Kyllä 
 
50. Kuuleeko hän tavallista puhetta?  
         1 = Ei 
         2 = Kyllä 
 
51. Tiedot taustatietolomakkeeseen antoi 
1 = asukas pääosin itse 




52. Tulosta tai kopioi asukkaan voimassa oleva lääkelista ja niittaa se tähän 
kyselylomakkeeseen liitteeksi. 
 
Tarkista vielä, että kaikki kohdat tulivat täytettyä. Kiitos! 
Lomakkeet kootaan talossa ja palautetaan vanhusten palvelujen vastuualueelle ___31_/_10___2007 





















 Appendix 3. Delirium tutkimuksen kyselylomake 
Potilaan perustiedot: (pyydä yhteystiedot: osoite, puh.nro, tai käytä TARRAA) 
Täydennä tai rengasta: 
1. Potilaan nimi ________________________________ Tutkija: ________________ 
2. Potilaan sotu:  __________ - ________ 
3. Potilaan numero :  ____________ 
4. Tutkimuspäivä: ______________ / klo:      ___________________ 
5. Tutkimuspaikka: __________________________ 
1. geriatrinen akuuttiosasto 
2. kuntoutusosasto   
3. vanhainkoti  
4. psykogeriatrinen osasto  
6. Tutkimusmaa    1. Suomi 2. Ruotsi 3. Englanti 
7. Potilaan koulutustaso 1. Vähemmän kuin kansakoulu  
2. Kansakoulu   
3. Keskikoulu  
4. Lukio    
5. Korkeakoulu   
8. Missä työssä potilas on ollut eniten elämänsä aikana 
1. Maanviljelys, karjanhoito, metsätyö, emäntä 
2. Tehdas, kaivos, rakennus tms työ 
3. Toimistotyö, palvelutyö, henkinen työ 
4. Kotirouva, perheenemäntä 
5. muu, mikä?_________________ 
9. Siviilisääty: 1. Naimisissa tai avoliitossa 
2. Naimaton 
3. Asumuserossa tai eronnut 
4. Leski 
10 .Missä potilas asuu:1. Kotona 
2. Pysyvästi kodinomaisissa olosuhteissa, missä: __________________  
3. Pysyvästi vanhainkodissa, missä: ____________________ 
 4. Pysyvästi sairasosastolla, missä : ___________________ 
11. Tupakointi:  1. Ei ollenkaan 
2. alle 10 tupakkaa /vrk 
3. Yli 10 tupakkaa/vrk 
12. Alkoholin käyttö 1. Ei ollenkaan 
2. harvemmin kuin kerran viikossa  
3. Kerran viikossa tai useammin 
13.Potilaan perussairauksien diagnoosit:1. ______________________  2.________________ 
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3. ______________________ 4. ______________________ 5. ________________________ 
6. ______________________ 7. ______________________ 8. ________________________ 
muita:______________________________________________________________________ 
14. Potilaan käyttämä lääkitys: 1. ______________________  2. ____________________ 
3. ______________________ 4. ______________________ 5. ________________________ 
6. ______________________ 7. ______________________ 8. ________________________ 
muita:______________________________________________________________________ 
___________________________________________________________________________ 
15. RR _________ / ___________   16.  Pulssi __________ /min 
 16. Sairaalaan tulon syy: _______________________________________ 
KYSYMYSKAAVAKE  
Ohje kaavakkeen täyttäjälle:  
Voit keskustella potilaan kanssa aluksi täysin vapaamuotoisesti, jotta hän tuntisi olonsa mukavaksi. 
Potilaalle tulee kertoa, mistä tutkimuksessa on kyse (oheinen potilastiedote). Lisäksi voit sanoa esim: 
"Tutkimme iäkkäillä sairaalapotilailla yleisinä ilmeneviä sekavuusoireyhtymän oireita, jonka vuoksi tulemme 
haastattelussa testaamaan muistia, keskittymistä, päättelykykyä sekä teidän itsenne kokemia oireita 
sairaalassaoloaikana / viime aikoina vanhainkodissa. Osa kysymyksistä on helppoja, osa hieman vaikeampia, 
eikä teidän tarvitse huolestua, mikäli kaikkiin ei löydy vastausta." 
Kun vastaat kysymyskaavakkeen tutkijan täydettävään osaan, tulee sinun osissa:  3. Havainnoinnin häiriöt 
6. Uni 7. Psykomotoriikan aktiivisuus (osin)  10. Alku ja kesto 11. Vaihtelu 12. Sundowning 13. Tunteet 
14. Etiologia 15. Dementia  - ottaa huomioon potilaan oireet ainakin viimeisten viikkojen ajalta. Saat siis 
käyttää potilaspapereita, tietoja omaisilta tai potilasta hoitavilta apunasi.  
Sen sijaan osiot: 2. Tajunnantaso ja tarkkaavaisuus 3. Abstrakti ajattelu ja yleinen käsityskyky 5. Puhe 8. 
orientaatio, 9. muisti, 16. muut oireet sinun tulisi päätellä potilaasta saamasi vaikutelman perusteella. 
Täytä oheinen KYLLÄ / EI / En tiedä -lista  seuraavasti: mikäli potilas vastaa oikein tai hyvin lähelle oikeaa 
vastausta, täytä KYLLÄ. Samoin mikäli näkemyksesi väittämästä tai kysymyksen vastauksesta on 
myönteinen tai lähellä sitä, vastaa KYLLÄ. Mikäli potilas vastaa väärin, tai hänellä ei ole ko oiretta tai 
potilaan status ei vastaa väitettä, vastaa EI. Mikäli olet täysin epävarma, vastaa "en tiedä".  
OSA 1. Potilaan haastattelu: 
Jos potilas vastaa oikein tai lähelle oikea vastaus, ruksaa KYLLÄ, muutoin EI. Pyri välttämään vaihtoehtoa 
"en tiedä". Kysymyksiin 1.8 – 1.19 sekä 1.45 – 1.47 suoraan  potilaan mielipide/vastaus. 
 
 
                           
                   
 kyllä ei en tiedä 
1.1. Mikä teidän nimenne on (etu- ja sukunimi)?    
1.2.Kuinka vanha te olette?    
1.3. Miksi olette joutunut sairaalaan (tietääkö potilas?)    
1.4. Oletteko naimisissa?    
1.5. Onko teillä perhettä?    
1.6. Kuinka monta lasta teillä on?    
1.7. Mitä olette tehnyt aikaisemmin ammatiksenne?    
    
1.8. Oletteko tunteneet itsessänne outoa sekavuutta viime päivinä?    
1.9. Onko teillä ollut ongelmia nukkumisen kanssa viime päivinä?    
1.10. Onko teillä ollut vaikeuksia nukahtaa viime päivinä?    
1.11. Onko teillä ollut päiväaikaista väsymystä?    
1.12. Onko teillä ollut kipuja tai meteliä, jotka ovat  vaikeuttaneet nukkumista?    
1.13. Onko teillä ollut ikäviä painajaisia viime päivinä?    
1.14. Onko teillä ollut vaikeuksia muistaa asioita viime päivinä?    
    
1.15. Oletteko nähnyt viime päivinä ihmisiä, asioita tai  esineitä joita ei oikeasti 
ole olemassa? 
   
1.16. Oletteko viime päivinä kuullut ääniä tai puhetta joiden todellisuutta 
epäilette? 
   
1.17. Oletteko kokenut näitä asioita täällä sairaalassa ollessa vai myös aiemmin 
kotona? 
   
1.18.Onko teillä ollut outoa kokemusta että esineet liikkuvat, ovat liian pieniä 
tai suuria?. 
   
1.19. Entä onko oma kehonne muoto tai koko tuntunut oudolta?    
    
1.21. Mikä vuosi nyt on?     
1.23. Mikä vuodenaika?  (kevät, kesä, syksy, talvi)    
1.20. Monesko päivä tänään on? (+/- yksi päivä)    
1.24. Mikä viikonpäivä nyt on?    
1.22. Mikä kuukausi?    
1.25. Paljonko kello on? (suurinpiirtein, +/- kaksi tuntia)    
1.25.1 Missä maasa me olemme?    
1.26. Tiedättekö mikä tämä paikka on?    
1.26.1 Missä kerroksessa me olemme?    
1.27. Tietääkö potilas olevansa sairaalassa/vanhainkodissa, vaikka ei 
muistaisikaan sen nimeä ? 
   
1.28. Minä vuonna olette syntynyt?    
1.29. Mikä on teidän osoitteenne (tai puhelinnumeronne)?    
1.30. Muistatteko äitinne tyttönimen?    
1.31. Kuka on Suomen presidentti tällä hetkellä?    
1.32. Kuka oli edellinen presidentti?    
1.33. Seuraavassa pyydän teitä painamaan mieleenne kolme pientä sanaa, 
jotka teidän tulisi painaa mieleenne. Heti kun olen sanonut ne, voitteko toistaa 
ne perässäni: PAITA, RUSKEA, VILKAS. (montako oikein: __________) 
   
1.34. Seuraavassa keskittymistä mittaavassa tehtävässä pyytäisin Teitä 
luettelemaan sanan PUTKI kirjaimet lopusta alkuun. (vaihtoehtoisesti 1.37) 
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1.35. Voisitteko nimetä viikonpäivät takaperin     
1.36.Muistatteko ne kolme pientä sanaa, jotka aiemmin  toistitte 
perässäni?(kuinka monta meni oikein: _____) 
   
1.37 Voisitteko vähentää luvusta 100    7? Ja edelleen miinus 7? Ja edelleen 
miinus 7? Jne.  Kuinka monta meni oikein (nollaan saakka): _____________ 
   
1.37.1 Vähentäkää luvusta 20   3.  Ja edelleen 3, jne (nollaan saakka): Oikein 
________ 
   
1.37.1 Nyt luen teille lauseen. Pyytäisin teitä toistamaan sen: OPPILAS RATKAISI 
MONIMUTKAISEN TEHTÄVÄN 
   
1.37.2.1  Seuraavassa annan teille paperin ja pyydän teitä tekemään sille jotain. 
Annetaan paperi: ottakaa paperi oikeaan käteenne      (ottaa paperin oikeaan 
käteen) 
   
1.37.2.2.  taittakaa se keskeltä kahtia                            (taittaa sen)    
1.37.2.3. ja laittakaa se polvienne päälle                     (laittaa polviensa päälle    
1.37.3. Nyt näytän teille tekstin. Pyytäisin teitä lukemaan sen ääneen ja 
noudattamaan kehotusta (viimeinen sivu) 
   
1.37.4. Tässä on kynä ja paperia. Kirjoittaisitteko jonkin itse keksimänne 
lauseen. 
   
1.37.5. Voisitteko piirtää tämän alapuolelle samanlaisen kuvion (viimeinen sivu)    
1.37.6. Digit span etuperin: pt toistaa ______ numeroa    
1.37.7. Digit span takaperin: pt toistaa ______ numeroa    
1.38 Mitä tekisitte, jos löytäisitte kadulta kirjekuoren, jossa on osoite ja 
leimaamaton postimerkki päällä? 
   
1.39. Miksi pitää pysyä erossa huonosta seurasta?    
1.40 Voitteko selittää, miksi junassa on veturi?    
1.41. Miksi maksetaan veroja?    
1.42. Mitä tarkoittaa sananlasku "On taottava kun rauta on kuumaa"?    
1.43. Mitä tarkoittaa sananlasku "Tyhjät tynnyrit kolisevat eniten"?    
1.44.Mitä tekisitte, jos eksyisitte metsään päiväsaikaan?    
1.45. Oletteko tunteneet itsenne masentuneeksi viime aikoina?(kysy erikseen 
kysymyksen 13.1. kaikki oireet potilaalta) 
   
1.46. Oletteko tunteneet itsenne ahdistuneeksi tai hermostuneeksi viime 
aikoina? (kysy erikseen kysymyksen 13.3 kaikki oireet potilaalta) 
   
1.47. Oletteko pelännyt viime aikoina?    
1.48. Tunnistaako potilas rannekellon JA kynän?    
1.49.Pystyykö potilas kooperoimaan testauksessa ?    
1.50.Kieltäytyykö potilas testistä kesken testauksen?    
 
 OSA 2.  Tutkijan täydennettävä:  
2. Tajunnantaso ja tarkkaavaisuus                          
TÄYTÄ HAASTATTELUSSA SAAMASI VAIKUTELMAN PERUSTEELLA             
 kyllä ei en tiedä 
2.1.1. Onko potilaalla tietoisuuden hämärtymistä /"sumenemista" (heikentynyt 
tietoisuus ympäristöstä)?  
   
VALITSE SEURAAVISTA  2.1.2 – 2.1.7 VAIN YKSI VAIHTOEHTO:    
2.1.2. Onko potilaalla muuta tajunnantason häiriötä?    
2.1.3. Onko potilaan tajunnataso normaali (valpas)?    
2.1.4. Onko potilaan tajunnataso ylivalpas (säpsähtelevä)?    
2.1.5. Onko potilas unelias (helposti herätettävissä)?    
2.1.6. Onko potilas erittäin unelias (vaikeasti heätettävissä)?               
    
2.2.1. Onko potilalla alentunut kyky kohdistaa tarkkaavaisuuttaan (esim 
keskustelun aloituksessa haastattelijan kanssa)? 
   
2.2.2. Onko potilaalla alentunut kyky keskittyä  (esim ongelmia tavatessaan 
sana ”PUTKI” lopusta alkuun 1.34 tai laskiessaan 1.37 tai  1.37.1)? 
   
2.2.3. Onko potilaalla alentunut kyky ylläpitää tarkkaavaisuuttaan (esim 
luetellessaan viikonpäiviä takaperin)? 
   
2.2.4. Onko potilaalla vaikeutta siirtää huomiotaan (esim. kyselyn aihepiirin 
vaihtuessa uuteen)? 
   
2.2.5. Jääkö potilas herkästi keskustelun aikana tuijottelemaan kaukaisuuteen 
kykenemättä seuraamaan ympäristönsä tapahtumia? 
   
2.2.6. Onko potilalla toistuvia ajatuksia/pakkomielteitä, jotka estävät häntä 
reagoimasta asianmukaisesti ympäristöön (esim. etsii kadonnutta 
omaisuuttaan tai on aikeissa lähteä jonnekin)? 
   
2.2.7. Onko potilaan tarkkaavaisuudessa vaihtelua (esim. vastaus alkaa 
asianmukaisesti, mutta hiipuu kesken lauseen)? 
   
2.2.8. Onko kysymyksen toisto tai asiaan palauttaminen tarpeen enemmän kuin 
kerran? 
   
2.2.9. Puhuuko potilas asiaankuulumattomia (esim vaihtaa puheenaihetta 
yllättävästi tai kertoo asiaankuulumattoman tarinan)? 
   
2.2.10. Onko tarkkaamattomuuteen mahdollisesti syynä vaikea kipu, heikotus, 
masennus, kiihtymys...? 
   
 
3. Abstrakti ajattelu ja ymmärys                           
TÄYTÄ HAASTATTELUSSA SAAMASI VAIKUTELMAN PERUSTEELLA             
 kyllä ei en tiedä 
3.1. Onko potilaalla kyky johdonmukaiseen päättelyyn? (esim. vastaa oikein 
kysymyksiin 1.40 TAI 1.41)  
   
3.2. Onko potilaalla kyky abstraktiin ajatteluun? (esim. kykenee vastaamaan 
oikein ainakin yhteen kysymyksistä 1.42. tai 1.43)  
   
3.3. Onko potilaalla arvostelukykyä? (esim. vastaa oikein yhteen kysymyksistä 
1.38 tai 1.39)  
   
3.4. Onko potilaalla kyky suunnitelmalliseen toimintaan? (esim. vastaa oikein 
kysymykseen 1.44) 
   
3.5. Kyseleekö potilas epäasianmukaisia kysymyksiä?    
3.6. Voikomatalan henkisen suorituskyvyn selittää vähäisellä koulutuksella tai 
aikaisemmalla henkisellä vajaakykyisyydellä? 
   
 
4. Havainnoinnin häiriö                               
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TÄYTÄ OTTAEN HUOMIOON POTILAAN OIREET VIIKKOJEN AJALTA             
 kyllä ei en tiedä 
4.1. Onko potilaalla väärintulkintoja , aistihairahduksia(=aistiärsykkeen 
väärintulkinta) tai aistiharhoja (= sisäisiä todellisilta tuntuvia aistimuksia, esim 
näkö tai kuuloharha)? 
   
4.3. Onko potilaalla muita havainnoinnin häiriöitä? Mitä? 
______________________ 
   
4.4. Onko potilaalla harhaluuloja (virhepäätelmiä ulkoisesta todellisuudesta)?    
4.5. Onko potilas nähnyt sellaista (esim. esineitä, asioita, ihmisiä) joita ei 
oikeasti ole? (näköharhoja) 
   
4.6. Onko potilas nähnyt esineitä tai muita objekteja liian pienenä, suurena tai 
useana? 
   
4.7. Onko potilas tunnistanut näkemänsä esineet väärin (esim. virtsannut 
roskakoriin tai syönyt kukkia tai kysymys 1.48)? 
   
4.8. Onko potilas kuullut puhetta tai muita ääniä, joita ei ole olemassa 
(mahdollista olemassaolevaa korvien soimista ei oteta huomioon) 
(kuuloharhoja) ? 
   
4.9. Onko potilas tulkinnut kuulemiaan ääniä väärin (esim. luullut huutavaa 
huonetoveriaan itkeväksi lapseksi)? 
   
4.10. Onko potilaalla tuntoaistimuksia (joku koskettaa, satuttaa, ryömii iholla) 
joita ei voi selittää? 
   
4.11. Onko potilaalla tunne liikkumisestaan (esim putoamisesta) ollessaan 
paikoillaan? 
   
4.12. Onko potilaalla vainoharhaisia ajatuksia (esim. myrkytetyksi tai 
ryöstetyksi tulemisesta tai jonkin pahan tapahtumisesta kotonaan)? 
   
4.13. Onko potilaalla delusionaalista väärintulkintaa (esim. uskoo 
tutkijan/hoitajan olevan hänen puolisonsa)? 
   
4.14. Onko potilaalla merkittävästi heikentynyt kuulo (vaikeus kuulla kovaa 
puhetta korvan vierestä - mahdollisen kuulolaitteensakaan avulla)? 
   
4.15. Onko potilaan näkö merkittävästi heikentynyt (kyvyttömyyys lukea 
apuvälineidenkään avulla)?  
   
 
5. Puhe                                
TÄYTÄ HAASTATTELUSSA SAAMASI VAIKUTELMAN PERUSTEELLA             
 kyllä ei en tiedä 
5.1. Onko potilas kyvytön puhumaan? (ei puhu lainkaan)    
5.2. Onko potilaan puhe hajanaista? (esim. toistuvaa syrjähtelyä puhutusta 
asiasta tai epäjohdonmukaisuutta) 
   
5.3. Onko potilaan puhe epätarkoituksenmukaista? (esim. sopimatonta tai 
aihepiiriin kuulumatonta) 
   
5.4. Onko potilaan puhe harhailevaa? (esim .toistuvaa rönsyilyä aihepiiristä 
toiseen) 
   
5.5. Onko potilaalla elimellinen puhehäiriö (dysfasia tai dysartria, esim. 
aivohalvauksen jälkitilana)? 
   
5.6. Onko potilaalla muu puheen häiriö? Mikä? _________________    
5.7. Onko potilaan puhe epätavallisen nopeutunutta?    
5.8. Onko potilaan puhe epätavallisen hidastunutta?    
5.9. Onko potilas epätavallisen toistelevaa (esim. juuttuu vastaukseen 
uudelleen ja uudelleen)? 
   
5.10.Onko potilaan puhe epätavallisen äänekästä?    
 5.11. Puhuuko tai laulaako potilas itsekseen? OTA HUOMIOON OIRE 
VIIMEISTEN VIIKKOJEN AJALTA 
   
5.12. Käyttääkö potilas asiaan liittymättömiä sanoja tai fraaseja ?     
5.13. Onko potilaalla järjestäytymätöntä ajattelua , joka ilmenee harhailevana, 
epätarkoituksenmukaisena tai epäjohdonmukaisena puheena?  
   
 
6. Uni                             
TÄYTÄ OTTAEN HUOMIOON POTILAAN OIREET VIIKKOJEN AJALTA             
 kyllä ei en tiedä 
6.1. Onko potilaalla unettomuutta?    
6.2. Onko potilaalla päiväaikaista väsymystä?     
6.3. Onko potilaalla uni-valverytmin häiriö?    
    
6.5. Kärsiikö potilas täydellisestä unen puutteesta?    
6.6. Onko potilas valveilla enemmän kuin 3 tuntia yössä (klo 24 - 06)?    
    
6.8. Nukkuuko potilas enemmän kuin 3 tuntia päivisin (klo 9 - 20)?    
6.9. Onko potilaalla ilmeinen syy uni-valverytmin häiriöön (esim.kipu, huutava 
huonetoveri, ym.)? 
   
6.10. Nukahteleeko potilas ennakoimattomasti ( esim. kesken lauseen, 
ruokailun tai WC-käynnin)? 
   
6.11. Onko potilaan uni-valverytmi käänteinen (nukkuu suurimman osan päivää 
ja valvoo suurimman osan yötä)? 
   
6.12. Kärsiikö potilas häiritsevistä unista tai painajaisista?    
6.13. Onko potilaalla vaikeutta erottaa unet todellisuudesta ( esim. unilla on 
taipumus jatkua heräämisen jälkeen harhanäkyinä)? 
   
 
7. Psykomotorinen aktiivisuus                              
TÄYTÄ OTTAEN HUOMIOON POTILAAN OIREET VIIKKOJEN AJALTA                     
 kyllä ei en tiedä 
7.1. Onko potilaalla lisääntynyt psykomotorinen aktiivisuus(esim. puuhailee 
puhuessaan, yrittää lähteä jonnekin, kipeää laitojen yli, kiskoo letkuja ja 
katetreita, repii vuodevaatteita, riisuutuu ym.)?  
   
7.2. Onko potilaalla vähentynyt psykomotorinen aktiivisuus (esim. 
liikkumattomuus, taipumus olla paikoillaan)? 
   
7.3. Onko potilaan reaktioaika pidentynyt (kestääkö epätavallisen kauan ennen 
kuin potilas seuraa ohjeita tai vastaa kysymyksiin)? VAIKUTELMA 
HAASTATTELUSSA 
   
7.4. Onko osoitettavissa autonomisen, erityisesti sympaattisen, hermoston 
aktivoitumista (nopea pulssi, laajentuneet pupillit, punakat kasvot, hikoilevat 
kämmenet)? VAIKUTELMA HAASTATTELUSSA 
   
7.5. Kärsiikö potilas uutena oireena virtsa-tai ulosteinkontinenssista?    
7.7. Onko potilas helposti säpsähtelevä tai pelokas? VAIKUTELMA 
HAASTATTELUSSA 
   
7.8. Vaihteleeko potilaan psykomotorinen aktiivisuus ennakoimattomasti 
hitaudesta/uneliaisuudesta kiihtynykseen? 
   
7.9. Onko potilasta jouduttu sitomaan lepositeisiin viimeisen viikon aikana? 
(Sänkyyn tai esim G-tuoliin pöydän avulla) 
   
8. Orientaatio 
                             
TÄYTÄ HAASTATTELUSSA SAAMASI VAIKUTELMAN PERUSTEELLA             
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 kyllä ei en tiedä 
8.1. Onko potilas orientoitunut aikaan? (kysymykset 1.21 - 1.24 kaikki oikein, 
yksi virhe sallitaan) 
   
8.2. Onko potilas orientoitunut paikkaan? (kysymykset 1.26 TAI 1.27 oikein)    




9. Muisti                              
TÄYTÄ HAASTATTELUSSA SAAMASI VAIKUTELMAN PERUSTEELLA                
 kyllä ei en tiedä 
9.1. Onko potilaalla vaikeutta välittömässä mieleenpalauttamisessa (esim. 
kysymys 1.33)?  
   
9.2. Onko potilaalla vaikeutta muistaa viimeaikaisia tapahtumia (esim 
sairaalaan tulon syy, jonkin merkittävä tapahtuma viime viikoilta)?  
   
9.3. Onko potilaalla vaikeutta muistaa varhaisia asioita (esim. kysymys 1.6,1.7 
tai 1.32)?  
   
9.4. Onko potilaalla vaikeutta pitää mielessään juuri puhuttuja asioita (kysymys 
1.36)?  
   
9.5. Onko potilaalla vaikeutta muistaa juuri tapahtuneita asioita ( esim. 
sairaalassa olonsa syy, omaisten vierailut, päiväohjelma, ateriat, ym., kts 
kysymys 1.3 )? 
   
9.6. Onko potilaalla vaikeutta muistaa oma henkilöhistoriansa (esim. siviilisääty, 
lasten lukumäärä, aiempi ammatti, ym., esim. kysymys 1.5-1.7 )?  
   
9.7. Johtuuko muistinmenetys edeltävästä dementiasta?     
9.8. Onko Alzheimerin taudista selvää näyttöä?  (pään CT)    
9.9.  Verisuoniperäisestä eli ns. vaskulaaridementiasta? (  - " -  )    
9.10. Sekatyyppisestä dementiasta?  ( - " - )    
9.11. Lewyn kappale dementiasta?  ( - " -)    
9.12. Muusta dementoivasta sairaudesta? Mistä?: _________________    
9.13. Onko potilaan muistia testattu ennen häiriötä? (Testi, päivämäärä, 
tulos?______________). 
   
9.14. Onko potilaan muistia testattu häiriön aikana? (Testi, päivämäärä, 
tulos?______________). 
   
9.15. Mikä on oma vaikutelmasi: Onko potilaalla muistihäiriö?    
9.16. Onko potilaalla mielestäsi sekavuusoireyhtymä eli delirium?    
9.17. Mikä on vaikutelmasi: onko potilaalla tilapäisiä sekavuusoireita?    
 
10. Oireiden alku ja kesto                 
                                 
MIKÄLI POTILAS ON MIELESTÄSI SEKAVA TAI HÄNELLÄ ESIINTYY                               
JOITAKIN EM. 2. – 7. KYSYMYSRYHMIEN OIREITA, TÄYTÄ SEURAAVA 
KYSYMYKSISSÄ TARKOITETAAN SEKAVUUTEEN LIITTYVIÄ TILAPÄISIÄ 
UUSIA OIREITA  ( ESIM VUOSIA JATKUNEITA DEMENTIAN MUISTIOIREITA 
EI OTETA HUOMIOON, ELLEI UUTTA ÄKILLISTÄ MUUTOSTA OLE TAPAHTUNUT 
 kyllä ei en tiedä 
10.1. Ovatko häiriön kliiniset oireet (sekavuus) kehittyneet lyhyen ajan kuluessa 
(yleensä tuntien, päivien aikana)? 
   
10.2. Onko häiriö kestänyt vähemmän kuin 6 kuukautta?    
10.5. Ovatko kliiniset piirteet kehittyneet muutaman viikon kuluessa?    
10.6. Ovatko kliiniset piirteet kestäneet yli kaksi viikkoa?    
 10.7. Onko häiriö kestänyt yli 6 kuukutta?    
10.9. Mitä käytit tietolähteenä vastatessasi näihin kysymyksiin (10.1.-10.9.)? 
(potilas itse, omainen, henkilökunta, potilasasiakirjat?)(alleviivaa oikea 
vaihtoehto) 
   
 
11. Oireiden vaihtelevuus                               
MIKÄLI POTILAS ON MIELESTÄSI SEKAVA TAI HÄNELLÄ ESIINTYY                          
JOITAKIN EM. 2. – 7. KYSYMYSRYHMIEN OIREITA, TÄYTÄ SEURAAVA 
 kyllä ei en tiedä 
11.1. Vaihtelevatko kysymysryhmien 2. – 9.  kliiniset oireet (onko niillä 
taipumus lisääntyä tai vähentyä voimakkuudeltaan) minuuttien kuluessa (esim. 
keskustelun aikana)? Tuntien kuluessa, päivän kuluessa, viikkojen 
kuluessa?(alleviivaa oikea vaihtoehto) 
   
12. Oireiden ajankohta                                         
MIKÄLI POTILAS ON MIELESTÄSI SEKAVA TAI HÄNELLÄ ESIINTYY                          
JOITAKIN EM. 2. – 7. KYSYMYSRYHMIEN OIREITA, TÄYTÄ SEURAAVA 
 kyllä ei en tiedä 
12.1.Mihin vuorokauden aikaan kliiniset oireet (kysymysryhmien 2. – 9.)  ovat 
pahimmillaan? Yöaikaan? 
   
12.2. illalla?    
12.3. aamulla?    
12.4. päiväsaikaan?    
12.5. Milloin potilaan sekavuusoireet ovat ilmenneet viimeisen vuodokauden 
aikana (alleviivaa oikeat): a. aamulla b. päivällä c. illalla d. yöllä 
   
13. Tunneoireet                             
TÄYTÄ OTTAEN HUOMIOON POTILAAN OIREET VIIKKOJEN AJALTA             
 kyllä ei en tiedä 
13.1. Onko potilaalla kliinisesti masennus/masentunutta mielialaa esim. 
alakuloisuutta, kiinnostuksen puutetta, epätavallista itkuisuutta, kuoleman 
toiveita, tarpeettomuuden tunteita, apatiaa, arvottomuuden tunteita, 
itsesyytöksiä tai somaattisia depression oireita)? (Alleviivaa potilaan oireet). 
Muita, Mitä: ____________ 
   
13.2. Onko potilaalle tehty jokin depressiotesti?  (Testi, päivämäärä, 
tulos?_____________________________________________) 
   
13.3. Onko potilaalla ahdistustata (esim.pelkoja, keskittymisvaikeutta, 
motorista levottomuutta, epätavallista kyvyttömyyttä odottamiseen, 
hermostuneisuutta tai ahdistuksen somaattisia ilmentymiä kuten 
rintatuntemusta, vapinaa, hikoilua, punakkuutta, ym.)? (Alleviivaa potilaan 
oireet). Muita, mitä: _______________ 
   
13.4. Onko potilaalla pelkoa (esim pelko olevansa korkeassa paikassa tai 
pimeässä/ suljetussa tilassa, epätavallisen voimakasta uskomusta jonkin pahan 
tapahtumisesta itselleen/muille)? Mitä: ___________________________ 
   
13.5 Onko potilaalla ärtyisyyttä (epätavallista närkästystä kosketukseta, 
puheesta, ym.)? 
   
13.6.Onko potilaalla  euforiaa (esim. epätavallista hyväntuulisuutta, hymyä ja 
naurua, vastoinkäymisten kieltämistä)? 
   
13.7. Onko potilaalla apaattisuutta (esim. epätavallisen heikkoja 
tunnereaktioita, välinpitämättömyyttä vastoinkäymisiä kohtaan)? 
   
13.8. Onko potilaalla ihmettelevää hämmennystä (esim. yllättymistä, 
epätietoisuutta, kiusaantuneisuutta)? 
   
13.9. Onko potilaalla joku muu ilmeinen tunne-elämän häiriö?    
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Mikä?_______________    
13.10. Onko potilaalla selvä vaikeus pidätellä tunteitaan (esim. raivoa, 
epäsopivaa naureskelua tai itkua)? 
   
13.11. Onko potilaalla tilanteeseen selvästi sopimattomia mielialan vaihteluita 
(esim. tunteiden nopeaa muuttumista)?  
   
13.14.Onko potilas ollut aggressiivinen tai väkivaltainen?    
13.15. Onko potilas huutanut vihaisesti?    
13.16. Onko potilaalla ollut pyrkimystä harhailla tai karata osastolta?    
13.17, Onko potilas herkästi kiihtyvä?    
13.18. Onko potilas levoton?    
    
 
 
14. Aiheuttaja                                
MIKÄLI POTILAS ON MIELESTÄSI SEKAVA TAI HÄNELLÄ ESIINTYY                               
JOITAKIN EM. 2. – 7. KYSYMYSRYHMIEN OIREITA, TÄYTÄ SEURAAVA 
(14.1 –14.3 ovat vaihtoehtoja toisilleen) 
 kyllä ei en tiedä 
14.1 .Onko potilaalla selvä osoitettavissa oleva orgaaninen syy/syyt, joka on 
aiheuttanut häiriön (sekavuuden)? 
   
14.2. Onko potilaalla todennäköinen orgaaninen syy/syyt, joka on aiheuttanut 
häiriön? 
   
14.3. Onko potilaalla mahdollinen orgaaninen syy/syyt, joka on aiheuttanut 
häiriön? 
   







   
14.5. Oliko häiriön syy/syyt mahdollista määrittää yksinomaan potilaan kliinisen 
tutkimuksen perusteella? 
   
14.6. Mitä muita lähteitä oli käytössäsi selvittäessäsi häiriön syytä/syitä 
(omainen, henkilökunta, potilasasiakirjat, kliininen tutkimus, laboratoriokokeet, 
röntgentutkimukset, muita, mitä:_____________________)? (alleviivaa oikeat 
vaihtoehdot) 
   
14.7. Onko potilaalle tehty häiriön aikana EEG-tutkimus? 
Tulos?______________________________) 
   
14.8. Onko näyttöä määritettävissä olevasta lääketieteellisestä sairaudesta tai 
häiriöstä (somaattisesta?) (spesific medical condition)? 
   
14.9. Onko näyttöä lääkeaineen/nautintoaineen haittavaikutuksesta joka 
aiheuttaa sekavuuden tai sen  liikakäytöstä (substance intoxication)? 
   
14.10. Onko näyttöä lääkeaineen/nautintoaineen äkillisestä lopettamisesta 
(substance withdrawl)? 
   
14.11. Onko näyttöä muista aiheuttajista?    
14.12. Onko näyttöä aistitoimintojen virikkeettömyydestä (sensorinen 
deprivaatio)? 
   
 
15. Dementia                            
TÄYTÄ SEN PERUSTEELLA MIKÄ ON OLLUT POTILAAN KOGNITIIVNEN                          
 SUORITUSKYKY SAIRAUTTA /SEKAVUUSTILAA EDELTÄVÄSTI TAI 
VIIMEISTÄÄN KAKSI KUUKAUTTA SITTEN                
 kyllä ei en tiedä 
15.1. Onko potilaalla aiempi dementia?    
15.2. Perustuuko sen diagnoosi neurolgin/geriatrin/psykiatrin arvioon?    
15.3. Onko potilaalle tehty pään tietokonekuvaus? 
Tulos:_________________________________ 
Milloin:_________________________________ 
   
15.4.Ovatko omaiset tai hoitajat havainneet potilaan muistin tai henkisen 
suorituskyvyn heikentyneen jo ennen tätä sairastumisjaksoa?  
   
15.5.Onko potilaalla ollut apraxiaa? (vaikeutta hallita liikkeitään)    
15.6. Onko potilaalla ollut agnosiaa? (vaikeutta tunnistaa/nimetä esineitä 
normaaleista aisteista huolimatta)? 
   
15.7. Onko potilaalla ollut vaikeutta suorittaa suunnitelmallista, lopputulokseen 
tähtäävää toimintaa (esim. suunnitella, organisoida, analysoida, ajatella 
abstraktioita)? 
   
15.8. Onko muistin heikkous ja 15.5 - 15.7. aiheuttanut merkittävää puutetta 
sosiaalisessa kanssakäymisessä ja onko häiriö pitkällä aikavälillä lisääntynyt 
aiemmasta tasostaan? 
   
15.9. Onko tämä häiriö alkanut hiipivästi ja onko henkisen suorituskyky hitaasti 
heikkenemässä? 
   
15.10. Onko potilaalla mitään seuraavista diagnooseista: aivoverenkierron 
häiriö, Parkinsonin tauti, Huntingtonin tauti, subduraalihematoma, 
normaalipaineinen hydrokephalus tai aivokasvain? Mikä: 
_____________________ 
   
15.11. Onko potilaalla mitään seuraavista dementian aiheuttajista: 
kilpirauhasen vajaatoiminta, B12-vitamiinin tai foolihapon tai niasiinin puute, 
hyperkalsemia,  neurosyphilis or HIV-infektio?  Mikä :_____________________ 
   
15.12. Onko häiriön syy joku kemiallinen tekijä (esim. alkoholi)?    
15.13. Onko häiriö mahdolisesti depression tai skitsofrenian aiheuttama? 
Alleviivaa 
   
 
16. Muut oireet                            
TÄYTÄ HAASTATTELUSSA SAAMASI VAIKUTELMAN PERUSTEELLA                
 kyllä ei en tiedä 
16.1. Onko potilaalla vapinaa?    
16.2. Tunnistaako potilas olevansa sairas?    
16.3.  Onko potilaan persoonallisuudessa tapahtunut äkillinen muutos 
viimeisen kuukauden aikana? (AIEMPI TILANNE) 
   
 
17. CDR –luokitus  
TÄYTÄ LUOKITUS SILLÄ PERUSTEELLA MIKÄ HÄNEN SUORITUSKYKYNSÄ ON OLLUT PARI KUUKAUTTA 
SITTEN / ENNEN NYKYISTÄ SAIRASTUMISJAKSOA 
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